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Abstract 
The process of translation initiation in mammalian systems is complex and not fully 
understood.  It is regulated by an intricate network of signalling pathways and is a significant 
energetic burden to the cell.  Although models of initiation are available for yeast, to date, 
such models do not include the regulation of this process, nor do they exist for mammalian 
systems.   Existing literature was used to reconstruct the process of translation initiation and 
the regulatory signalling networks in the Petri Net formalism within the software Snoopy.  
The final version of the model was altered to incorporate the effects of Murine Norovirus.  
The model was converted to a binary form and the software QSSPN was used to run 
Gillespie algorithm-based stochastic simulations.  The predictive power of the model was 
established by incorporating commonly used chemical inhibitors.  Using the Matthews’ 
Correlation Coefficient, a quantitative measure of predictive power was established by 
comparing the model behaviour to the effects of each inhibitor recorded in existing 
literature.  A qualitative model containing 584 reactions was constructed.  The predictive 
power of the model was raised to MCC = 0.4558 through a series of refinements.  Two 
predicted behaviours, an increase in eIF4E phosphorylation and a reduction of AKT 
phosphorylation both in response to Rapamycin, were validated with the Immunoblotting 
techniques, Western Blotting and Human Phospho-MAPK Arrays, in the murine 
monocyte/macrophage RAW 264.7 cell line.  The model incorporating the effects of Murine 
Norovirus infection generated five testable predictions.  Of these, four were verified with 
the Human Phospho-MAPK Arrays.   The model presented here demonstrates the value of 
generating large-scale models using the binary model formalism and performing simulations 
with QSSPN.  The model of the regulation of translation initiation has shown that it is 
capable of generating experimentally verifiable predictions.  Furthermore, the incorporation 
of viral effects demonstrates that the model has a range of potential future uses. 
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List of Models and Variants 
 
Case Study Model - 
  Comment 
Petri Net Component Count This model contained only molecular interactions relating to 
eIF4E phosphorylation and availability.  This information was 
taken from existing literature on mammalian translation 
initiation and the signalling pathways regulating this process.  
The interactions in this model were extracted from the large-
scale model (see Final Version of the Binary Model) 
Place/Molecular Species 70 
Transitions/Reaction 65 
Edges 132 
Read Edges 50 
Inhibitor Edges 43 
 
Final Version of the Binary Model -  
  Comment 
Petri Net Component Count This model contained information from existing literature on 
mammalian translation initiation and the signalling pathways 
regulating this process.  Additionally, this model contained the 
model of ERK1/2 activation created by Schilling et al. (2009) 
and, which was treated as a binary model during the course of 
this project. 
Place/Molecular Species 511 
Transitions/Reaction 582 
Edges 1236 
Read Edges 515 
Inhibitor Edges 545 
 
Metabolic Model -  
  Comment 
Petri Net Component Count This version of the Final model included information on the 
regulation of metabolism by the mTORC1 signalling pathway.  
In this regard, enzymes expression was added along with any 
post-translational modifications dependent upon mTORC1.  
Furthermore, these enzymes were also linked to the 
corresponding reactions in the FBA GSMN model of a RAW 
264.7 murine macrophage cell line.  This model was simulated 
with the Asynchronous method and the ODE method.  This was 
used in Chapter 5 – Integration of the Translational Control 
Model with a Genome Scale Metabolic Network of a RAW 
264.7 Cell. 
Place/Molecular Species 699 
Transitions/Reaction 781 
Edges 1576 
Read Edges 656 
Inhibitor Edges 706 
 
 
 
 
 
xxix 
 
Junin Virus Model -  
  Comment 
Petri Net Component Count Used in Chapter 4 – Modelling the Effects of Viral Infection, 
this variant of the Final model included extra Petri Net 
components to model the translational effects of JUNV 
infection and the effects viral factors have upon cellular 
signalling pathway components. 
Place/Molecular Species 539 
Transitions/Reaction 611 
Edges 1301 
Read Edges 532 
Inhibitor Edges 557 
 
 
Murine Norovirus Model -  
  Comment 
Petri Net Component Count Used in Chapter 4 – Modelling the Effects of Viral Infection, 
this variant of the Final model was used to model MNV 
infection.  Various Petri Net components were added to model 
the effects MNV has upon cellular signalling components.  
Furthermore, the alterations MNV induces in the cellular 
translational machinery were included.  Such changes to the 
model were based upon existing literature, such as Royall et al. 
(2015). 
Place/Molecular Species 533 
Transitions/Reaction 604 
Edges 1287 
Read Edges 521 
Inhibitor Edges 542 
 
 
Andes Virus Model -  
  Comment 
Petri Net Component Count Used in Chapter 4 – Modelling the Effects of Viral Infection, 
this variant of the Final model concerned the effects of ANDV 
infection.  It was necessary to include additional Petri Net 
components to model how viral translation is carried out.  
Furthermore, the effects of ANDV on signalling factors was 
included. 
Place/Molecular Species 540 
Transitions/Reaction 606 
Edges 1292 
Read Edges 529 
Inhibitor Edges 554 
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Section 1.1 – Cellular Translation Initiation 
The process of translation initiation was central to the model produced during the course of 
this project.  As a consequence of this, a complete understanding of this process is 
necessary.   
The ability to synthesise nascent proteins is fundamental for all organisms.  Translation is 
the cytoplasmic process of forming complex polypeptides from amino acids using 
messenger RNA (mRNA) transcripts to convey information encoded by genes within the 
nucleus (Brenner et al., 1961).  The process of translation can be divided into three key 
stages: initiation, elongation and termination.  A number of key signalling pathways act to 
regulate these stages; of which initiation is the most tightly regulated.  The importance of 
this ‘energetically demanding process’ (Laxman et al., 2013) is highlighted by the presence 
of over 30,000 protein encoding regions in the human and mouse genomes (Lander et al., 
2001; Waterston et al., 2002).  Each of these genes, would in theory, need to be expressed 
and translated.  The process of translation, particularly in higher eukaryotic and mammalian 
systems, is complex and not fully understood.  The currently accepted view of translation 
initiation is shown in Figure 1.1a. 
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Figure 1.1a – Overview of Mammalian Translation Initiation.  Adapted from Jackson et al. (2010), 
this illustration gives a complete overview of the currently accepted mechanism of translation 
initiation in mammalian cells.  
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As can be seen in Figure 1.1a, the process of translation can be regarded as cyclic.  The end 
product of the termination stage is a Post-Termination Ribosomal Complex (Post-TC).  
Recycling of this complex must occur to allow the loading of various eukaryotic initiation 
factors (eIFs) onto the small 40 Svedberg (40S) ribosomal subunit to form the 43S complex 
(Jackson et al., 2010).  Prior to translation, mature mRNA is exported from the nucleus.  
Such mRNA contains a 5’ methylguanosine cap and 3’ poly(A) tail with both 5’ and 3’ 
untranslated regions and an open reading frame (Sahin et al., 2014).  Once the mRNA, and 
associated eIFs, are loaded onto the the 43S complex, scanning of the mRNA to find a start 
codon sequence within the 5’ region of the mRNA begins.  This scanning process requires 
the unwinding of the mRNA by the action of a helicase.  Once this has been found, the 48S 
complex is formed and this complex is committed to initiating translation at this site (Ibid).  
The formation of the 80S ribosome, capable of carrying out translation, occurs through the 
joining of the large, 60S ribosomal subunit (Jackson et al., 2010).   
Section 1.1.1 – Post-Termination Ribosomal Complex Recycling 
The first stage of initiation is the recycling of Post-TCs.  These are formed by the release of 
the nascent polypeptide and the action of the eukaryotic Release Factors (eRF) 1 and 2 
(Alkalaeva et al., 2006).  Although only eIF3 displayed any inherent activity towards carrying 
out Post-TC recycling, and the subsequent formation of the 40S and 60S subunits, eIF1 and 
eIF1A were required for efficient removal of deactetylated tRNA and mRNA (Pisarev et al., 
2007).  The release of the nascent polypeptide from the 80S ribosome is mediated by the 
actions of eRF1 and eRF3 (Alkalaeva et al., 2006) both of which are retained on the Post-TC 
(Pisarev et al., 2007).  However, it is possible that the retained eRF1 plays a later role in the 
recycling of the Post-TC (Pisarev et al., 2010).  The ATP-Binding Cassette, ABCE1, has been 
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shown to mediate recycling of Post-TCs in a manner that requires the presence of eRF1 
(Ibid).   
Section 1.1.2 – Ternary Complex Formation 
The Ternary Complex (TC) consists of an amino-acetylated tRNA charged with a Methionine 
residue (Meti-tRNA) and eIF2 bound to Guanosine Diphosphate (GDP) and an inorganic 
phosphate group (Algire et al., 2005).  Prior to a new round of translation initiation, the GDP 
molecule is exchanged for a Guanosine Trisphosphate (GTP) molecule through the 
conserved action of eIF2B in both yeast and mammals (Cigan et al., 1993; Williams et al., 
2001).   
Given that eIF2 has around a 400-fold greater affinity for GDP than GTP (Panniers et al., 
1988), eIF2B can only catalyse this exchange if GTP is in excess relative to GDP ((Dholakia & 
Wahba, 1989; Oldfield & Proud, 1992; Nika et al., 2000 (As cited by Williams et al., 2001)).  
eIF2B functions in the formation of the TC by promoting the release of eIF2 from the 
complex with eIF5 (Jennings et al., 2013).  The context of this complex between eIF2 and 
eIF5 will be discussed in Section 1.1.5 – 60S Subunit Joining.  Of the five eIF2B subunits, the 
ε-subunit is required for the exchange of GDP for GTP (Fabian et al., 1997). 
eIF2 consists of α, β and γ subunits (Hashem et al., 2013).  The γ-subunit of eIF2 may be 
responsible for interacting with both the Meti-tRNA and the 40S ribosomal subunit (Shin et 
al., 2011).  The γ-subunit of eIF2 links the TC to the small ribosomal subunit through eIF3 
within the 43S Complex (Chaudhuri et al., 1997; Chaudhuri et al., 1999).  The eIF2 β-subunit 
mediates an interaction between eIF2 and eIF2B (Kimabll et al., 1998).  The ability of eIF2B 
to exchange GDP for GTP is partially dependent upon phosphorylation of eIF2β by Protein 
Kinase A (Ibid).  This interaction between eIF2β and eIF2B appears to be altered under 
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conditions in which eIF2α is phosphorylated (Kimball et al., 1998; Krishnamoorthy et al., 
2001).  The role of the α-subunit of eIF2, and the mechanism by which it is capable of 
inhibiting translation initiation, will be discussed in Section 1.2.4 – Phosphorylation of 
Eukaryotic Initiation Factor 2α. 
Section 1.1.3 – eIF4F Components & mRNA Circularisation 
The eIF4F complex is comprised of eIF4A, eIF4E and eIF4G and mediates the interaction 
between the mRNA and the assembling ribosome.  The components of the eIF4F complex 
anchor mRNA to the 43S complex and allow mRNA scanning.  eIF4F carries out the function 
of binding mRNA through the cap binding protein, eIF4E, and the unwinding of mRNA during 
scanning by the helicase, eIF4A (Jackson et al., 2010).   
eIF4G is a scaffold protein of around 200kDa (Yan et al., 1992; Hernández et al., 1998).  Two 
functional isoforms of eIF4G, designated eIF4GI and eIF4GII, are found in human cells (Gradi 
et al., 1998) and display 46% similarity at the amino acid level with with some regions of the 
middle domain being completely conserved (Ibid).   These two isoforms may be required for 
targeting specific mRNAs for preferential expression under certain environmental conditions 
(Gradi et al., 1998).   
eIF4G recruits mRNA to the 48S complex through an interaction with eIF3 (Korneeva et al., 
2000; LeFebvre et al., 2006; Villa et al., 2013).  In addition to multiple initiation factors, 
eIF4G can interact with several additional proteins, including the Mitogen-Activated Protein 
Kinase (MAPK)-Interacting Kinase (MNK) 1 (Pyronnet et al., 1999) and a protein required for 
the translation of histone mRNAs, Stem Loop Binding Protein (SLBP)-Interacting Protein 1 
(Cakmakci et al., 2007). 
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A second component of the eIF4F complex is primarily responsible for scanning mRNA in 
order to identify start codon sequences. This component is the DEAD (Asp-Glu-Ala-Asp)-Box 
RNA helicase, eIF4A (Rogers Jr. et al., 1999; Rogers Jr. et al., 2001a).  The helicase activity of 
eIF4A is dependent upon ATP binding (Ray et al., 1985; Abramson et al., 1987; Blum et al., 
1992).  However, binding of either ATP or mRNA to eIF4A, in the first instance, does not 
preclude the other from interacting with the helicase (Lorsch & Herschlag, 1998a).  The 
conformational changes in eIF4A occurring upon an interaction with either ATP or mRNA 
result in an increase in affinity for the other (Lorsch & Herschlag, 1998b).  Furthermore, ADP 
binding results in lower affinity binding to mRNA suggesting that a succession of ATP 
hydrolysis events enable further mRNA unwinding (Ibid). 
Two additional initiation factors, namely eIF4B (Abramson et al., 1987) and eIF4H (Richter et 
al., 1999; Rogers Jr. et al., 2001b; Rozovsky et al., 2008) are required to achieve optimal 
eIF4A activity.  While a combination of both factors has been shown to increase the activity 
of eIF4A by around 30% (Richter-Cook et al., 1998), the effects of eIF4B and eIF4H are not 
simply additive with the increase being more dependent upon eIF4B (Özeş et al., 2011).  
eIF4B, together with eIF4G, couples the unwinding of mRNA to ATP hydrolysis by 
maintaining eIF4A in a state in which both ATP and mRNA are bound (Andreou & 
Klostermeier, 2014).  Furthermore, the amount of ATP required for unwinding mRNA is 
markedly reduced in the presence of eIF4B (Harms et al., 2014).  
The final component of eIF4F is the 5’ cap binding protein, eIF4E.  This protein acts to 
anchor the 5’ end of mRNA to the eIF4F complex and the 43S complex.  As discussed later in 
Section 1.2.1 – eIF4E-Binding Proteins & The mTORC1 Signalling Pathway, eIF4E availability 
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is tightly regulated by the 4E-Binding Proteins (4E-BPs) which function to sequester eIF4E 
and prevent an interaction with eIF4G (Marcotrigiano et al., 1999). 
The mRNA 3’ Poly(A) tail interacts with the Poly(A) Binding Protein (PABP) (Sachs et al., 1986 
(as cited by Tarun Jr. & Sachs, 1996); Görlach et al., 1994).   PABP has also been shown to 
interact with human and yeast eIF4G via the the N-terminal domain (Tarun Jr. & Sachs, 
1996; Imataka et al., 1998; Kessler & Sachs, 1998; Wakiyama et al., 2000).  Given these 
interactions, it has been postulated that the mRNA, linked by eIF4E and PABP, and bridged 
by eIF4G, at the 5’ and 3’ ends, respectively, becomes circularised (Wells et al., 1998).   
Section 1.1.4 – Start Codon Recognition 
The start codon refers to an AUG (Adenosine-Uracil-Guanosine) nucleotide sequence found 
within the 5’ region of mRNA.  Kozak (1987) established that in addition to this AUG 
sequence, several other nucleotides, both upstream and downstream, are required to 
ensure that this sequence is decoded by the 48S complex, only when it occurs in an 
appropriate context.  The optimal and conserved context consists of the sequence: AXXaugG 
where X represents any nucleotide (Kozak, 1987; Kozak, 1997; Rogozin et al., 2001). 
In addition, alternative initiation sequences, such as CUG (Cytosine-Uracil-Guanosine), are 
commonly used.  It has been shown that the use of ‘Kozak Sequences’ as initiation sites 
maybe a low as a third of initiation sequences (Lee et al., 2012).   
Following the eIF4A-mediated scanning, recognition of the mRNA start codon can occur.  
This stage of translation initiation has not been well studied in mammalian systems and, as a 
consequence, much of the summary here relies on work conducted in yeast.  eIF1 and eIF1A 
both act to ensure the recognition of a start codon (Saini et al., 2010) by maintaining the 
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ability of the 48S complex to scan through mRNA for the start codon (Passmore et al., 2007; 
Hussain et al., 2014).  When a start codon is recognised, eIF1 is displaced from the codon-
anti-codon binding site and this converts the 48S complex to a state where scanning is no 
longer possible (Hussain et al., 2014).   
Consistent with this view, in mammalian systems eIF1, eIF1A and eIF5 interact through the 
C-terminal domain of eIF5 and N-terminal domain of eIF1A (Luna et al., 2013).  This 
interaction prevents eIF5 from accessing eIF2 in advance of start codon recognition.  Once 
the Meti-tRNA and start codon interact, this interaction between eIF1A and eIF5 is 
prevented and scanning ceases, allowing eIF1 to dissociate (Ibid).   
Section 1.1.5 – 60S Subunit Joining 
Upon recognition of the start codon, eIF5, a GTPase-Activating Protein (Paulin et al., 2001), 
mediates eIF2-driven GTP hydrolysis to release the tRNA.  It has been proposed that eIF5 
interacts with eIF2β which allows the release of the inorganic phosphate molecule from eIF2 
(Luna et al., 2013).  eIF5B subsequently mediates the 60S subunit joining through a second 
GTP hydrolysis (Pestova et al., 2000) and may be dependent upon eIF1A (Acker et al., 2006), 
while the bound eIFs are released (Unbehaun et al., 2004).   
To prevent re-association of the 40S and 60S subunits after recycling, eIF6 acts by binding to 
the 60S subunit (Valenzuela et al., 1982; Raychaudhuri et al., 1984; Si et al., 1997; Wood et 
al., 1999).  The ability of eIF6 to prevent the formation of the 80S complex is regulated by 
PKC β-mediated phosphorylation (Ceci et al., 2003).  The yeast Elongation Factor-Like 1 
protein may also regulate the interaction between eIF6 and the 60S subunit (Senger et al., 
2001).  
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Section 1.2 – Key Points of Regulation & Upstream 
Signalling Pathways 
The regulation of initiation occurs through the coordinated and complex activity of a 
number of cellular signalling pathways, including the Mitogen-Activated Protein Kinase 
(MAPK) pathways (Extracellular Signal-Regulated Kinase (ERK) 1/2, p38, c-Jun N-Terminal 
Kinase (JNK1) and ERK5), the Phosphoinositide-3-Kinase (PI3K) and the mammalian Target of 
Rapamycin Complex 1 (mTORC1) pathways, as shown in Figure 1.2a. 
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Figure 1.2a – Position of Translation Initiation within the Signalling Network.  The cellular 
signalling network is intimately involved with the regulation of translation initiation and while 
the initiation phase of translation is key to the synthesis of nascent proteins it is only a small part 
of the model produced during the course of this project, as shown by the area within the red 
box.  This signalling network must interact with the translational machinery at key points in 
order to regulate the process of initiation.  The aim of this project was to produce a qualitative 
model of this system in which translation initiation is regulated by a signalling network. 
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In order to accurately model the regulation of the initiation phase of translation it is 
necessary to understand the points at which these signalling pathways converge on the 
translational machinery.  Furthermore, the mechanisms by which translation initiation is 
affected by these pathways must also be known in order to correctly model this process.  A 
further level of complexity is added by the large degree of cross-talk and feedback 
mechanisms existing in and between these pathways resulting in complex interaction 
networks.  This section will therefore focus upon introducing the key signalling pathways 
and how they affect the translational machinery.     
Section 1.2.1 – eIF4E-Binding Proteins & The mTORC1 Signalling Pathway 
As introduced in Section 1.1.3 – eIF4F Components & mRNA Circularisation, the activity of 
a key initiation factor, eIF4E, is regulated by the phosphorylation of 4E-BP1, which is 
controlled by the mammalian Target of Rapamycin (mTOR) Complex 1 (mTORC1).   
Two discrete mTOR complexes are found in mammalian cells, each with distinct biological 
functions (Laplante & Sabatini, 2009).  mTORC1 is composed of mTOR, Regulatory-
Associated Protein of mTOR (RAPTOR), DEP-Containing mTOR-Interacting Protein (DEPTOR), 
mammalian Lethal with Sec13 Protein 8 (mLST8), and the Proline-Rich AKT1 Substrate of 
40kDa (PRAS40) (Ibid).  By comparison, mTOR Complex 2 (mTORC2) contains mTOR, the 
Rapamycin-Insensitive Companion of mTOR (Rictor), mammalian Stress-Activated Protein 
Kinase Interacting Protein (mSIN1), DEPTOR and mLST8 (Leplante & Sabatini, 2009).  The 
activation on mTORC1 is not fully understood but several discrete mechanisms have been 
observed. 
Upstream of mTORC1 lies the Phosphoinosite 3-Kinase (PI3K) pathway component Protein 
Kinase B (AKT1) (summarised in Figure 1.2.1a).  This Ser/Thr kinase is a member of the AGC 
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(Protein Kinase A, Cyclic Guanosine Monophosphate-Dependent Protein Kinase and Protein 
Kinase C) kinase family and expressed in three isoforms: AKT1, AKT2 & AKT3 (Hanks & 
Hunter, 1995; Scheid & Woodgett, 2001; Zinda et al., 2001).  AKT1 is phosphorylated and 
activated in response to several stimuli, including insulin (Alessi et al., 1996; Kulik et al., 
1997; Hermann et al., 2000), by 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) 
(Alessi et al., 1997b) and mTORC2 (Hresko & Mueckler, 2005; Sarboassov et al., 2005; 
Guertin et al., 2006; Ikenoue et al., 2008).  Feedback mechanism within this pathway are 
discussed in Section 3.1.3 – Interplay Between mTORC1 & AKT1. 
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Figure 1.2.1a – Schematic of the mTORC1 Pathway & the Downstream Components Regulating 
Translation Initiation.  Upon binding of Insulin to the Insulin Receptor, the Insulin Receptor Substrate 
1 (IRS-1) becomes phosphorylated (Gual et al., 2005).  Downstream of IRS-1 is Phosphatidylinositol 3-
Kinase (PI3K) (Shaw, 2001; Khamzina et al., 2003).  Downstream of PI3K lies the 3-Phosphoinositide-
Dependent Protein Kinase (PDK1) and Protein Kinase B (AKT1) (Cantley, 2002; Hemmings & Restuccia, 
2015).  A further signalling component downstream of PI3K is the Mammalian Target of Rapamycin 
Complex (mTORC) 2 (Liu et al., 2015).  The activation of AKT1 requires phosphorylation by both PDK1 
and mTORC2 (Alessi et al., 1997b; Hresko & Mueckler, 2005; Sarbassov et al., 2005).  Once activated, 
AKT1 serves to activate, via several mechanisms, mTORC1 (discussed later in this Section).  
Downstream of mTORC1, two proteins involved in the regulation of translation initiation are 
phosphorylated, p70 Ribosomal S6 Kinase 1 (S6K1) (Seufferlein & Rozengurt, 1996; Burnett et al., 
1998) and eIF4E-Binding Protein 1 (4E-BP1) (Beretta et al., 1996; von Manteuffel et al., 1996).  
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The first mechanism of mTORC1 activation involves the phosphorylation, and inhibition of 
the protein Tuberin (TSC2) by AKT1 (Inoki et al., 2002; Potter et al., 2002; Cai et al., 2006) 
and several other key signalling components including, ERK1/2 (Arvisais et al., 2006; Winter 
et al., 2011), the p90 Ribosomal S6 Protein Kinase (RSK1) (Roux et al., 2004) and the p38 
substrate MAPK-Activated Protein Kinase-2 (MK2) (Li et al., 2003).  TSC2, along with 
Hamartin (TSC1), composes the Tuberous Sclerosis Complex (Carbonara et al., 1994; Green 
et al., 1994 (as cited by Tee et al., 2003)).  In the unphosphorylated state, TSC2 interacts 
with the GTPase protein, Ras-Homologue Enriched in Brain (Rheb) and the hydrolysis of 
Rheb-bound GTP occurs, which maintains mTORC1 in an inactive state (Garami et al., 2003; 
Inoki et al., 2003; Zhang et al., 2003).  However, once phosphorylated, the GTPase Activating 
Protein (GAP) activity of TSC2 is inhibited and the ability of Rheb to hydrolyse bound GTP is 
diminished (Inoki et al., 2002; Potter et al., 2002).   
AKT1 further activates mTORC1 through the phosphorylation of PRAS40 (Kovacina et al., 
2003; Nascimento et al., 2006; Vander Haar et al., 2007) (as shown in Figure 1.2.1b).  
PRAS40 interacts, via RAPTOR, with mTORC1 with PRAS40 preventing mTORC1 substrates 
interacting with RAPTOR (Sancak et al., 2007; Wang et al., 2007c).  Such inhibition is 
prevented by AKT1-mediated phosphorylation of PRAS40 (Sancak et al., 2007).   
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Figure 1.2.1b – Summary of the Role of AKT1 in the Activation of mTORC1.  AKT1 is known to mediate 
the activation of mTORC1 through two distinct, complementary mechanisms.  The first is the 
phosphorylation of the Tuberin (TSC2) component of the Tuberous Sclerosis Complex 1/2 complex. 
AKT1-dependent TSC2 phosphorylation is believed to occur on multiple Serine residues (Inoki et al., 
2002).  The result of this phosphorylation is suppression of the GTPase Activating Protein (GAP) activity 
of TSC1/2 toward Ras-Homologue Enriched in Brain (Rheb) (Garami et al., 2003).  This results in the 
activation of mTORC1 via a mechanism that is not clearly defined.  The second mechanism concerns 
the direct phosphorylation of Proline-Rich AKT Substrate 40kDa (PRAS40) (Kovacina et al., 2003).  In 
the unphosphorylated form, PRAS40 prevents substrate recognition by the Regulatory-Associated 
Protein of mTOR (RAPTOR) (Wang et al., 2007a).  Once PRAS40 is phosphorylated the mammalian 
Target of Rapamycin (mTOR) Complex 1 (mTORC1) becomes activated as RAPTOR is free to interact 
with mTORC1 substrates, such as 4E-BP1 and S6K1.  The two mechanisms are believed to act in a 
synergistic manner (Sancak et al., 2007). 
 Page 17 
 
 A further mechanism requires the localisation of mTORC1 to the lysosome (Sancak et al., 
2008).  This localisation is mediated through the actions of four small heterodimeric GTPase 
proteins, termed RagA through to RagD, and a five protein complex, termed Ragulator, 
which serves as a Guanine Nucleotide Exchange Factor (GEF) for the Rag GTPases (Sancak et 
al., 2008; Sancak et al., 2010; Bar-Peled et al., 2012).  The GATOR1 complex opposes the GEF 
activity of the Ragulator complex by providing Rag-directed GAP activity (Bar-Peled et al., 
2013).  The activation of mTORC1 by the Ragulator complex requires amino acids and the 
lysosomal vacuolar H+/ATPase (Zoncu et al., 2011; Bar-Peled et al., 2012; Jewell et al., 2015).  
This mechanism of activation is further complicated by the fact that different amino acids 
activate mTORC1 through different Rag proteins and that additional proteins are required to 
allow Rag GTPases to respond to specific amino acids (Jewell et al., 2015; Resamen et al., 
2015; Wang et al., 2015).    
Both mechanisms of activation serve to allow mTORC1 to respond to a diverse array of 
stimuli and may in fact work to complement each other.  In support of this idea, it is worth 
noting that Rheb is localised to the lysosomal membrane (Saito et al., 2005 (as cited by 
Groenewald & Zwartkruis, 2013)). 
In a tissue-specific manner, vertebrates encode three proteins that sequester eIF4E from an 
interaction with eIF4G: 4E-BP1, 4E-BP2 and 4E-BP3 (Marcotrigiano et al., 1999; Graber et al., 
2013).  The sequence to which eIF4E interacts with 4E-BP1, or eIF4G, is Tyr-x-x-x-x-Leu-h (in 
which x represents any amino acid whilst h denotes a hydrophobic residue) (Marcotrigiano 
et al., 1999; Niedzwiecka et al., 2002).  Interactions with 4E-BP1 prevent an interaction 
between eIF4E and the mRNA cap structure (Tomoo et al., 2005; Volpon et al., 2006).  
Hypophosphorylated 4E-BP1 interacts with eIF4E, as shown in Figure 1.2.1c.  Once 
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phosphorylated, by the RAPTOR subunit (Hara et al., 2002; Schalm et al., 2003) of mTORC1 
(Beretta et al., 1996; von Manteuffel et al., 1996; Burnett et al., 1998; Gingras et al., 1998; 
Marcotrigiano et al., 1999), 4E-BP1 dissociates from eIF4E and allows the eIF4F complex to 
form.  Multiple resides on 4E-BP1, Thr-37, Thr-46, Thr-70 and Ser-65, are targetted for 
phosphorylation (Gingras et al., 2001) with phosphorylation of positions 37 and 46 occuring 
first (Gingras et al., 1999). 
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Figure 1.2.1c – Regulation of Translation Initiation by the Sequestration of eIF4F Components.  The 
eIF4F complex consists of the scaffold protein, eIF4G, the cap binding protein eIF4E and the mRNA 
helicase, eIF4A.  The availability of eIF4E and eIF4A are tightly regulated by interactions with the 
binding proteins 4E-BP1 and Programmed Cell Death 4 (PDCD4), respectively.  Once sequestered, 
these initiation factors are unable to interact with eIF4G to form the eIF4F complex.  Consequently, 
the 43S complex is then unable to form.  However, the activity of these binding proteins is tightly 
regulated by the mTORC1 and PI3K signalling pathways.  Once these pathways are activated, 4E-BP1 
becomes phosphorylated by mTORC1 (Beretta et al., 1996) and PDCD4 is phosphorylated by AKT1 
(Palamarchuk et al., 2005) and S6K1 (Dorrello et al., 2006).  These post-translational modifications 
have an inhibitory effect on the interactions with either eIF4E or eIF4A (as shown by the red round-
headed arrows) and, thus, these factors are free to form the eIF4F complex. 
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Unlike the regulation of 4E-BP1, the interaction between eIF4E and 4E-BP2 is only partially 
regulated by mTORC1-dependent phosphorylation.  4E-BP2, within the brain of mammals, 
interacts with RAPTOR at higher affinity when two Asparagine residues, not conserved in 4E-
BP1 or 4E-BP3 at positions 99 and 102, are deamidated (Bidinosti et al., 2010).  The 
regulation of 4E-BP3 is not fully understood (Kleijn et al., 2002). 
Additionally, truncation of 4E-BP1 (Tee & Proud, 2002; Constantinou et al., 2008; Dennis et 
al., 2011) and 4E-BP2 (Wollenhaupt et al., 2012), at the N-terminal phosphorylation sites, 
results in sequestration of eIF4E.  Such truncation promotes the long-term, stable repression 
of translation and occurs primarily during cellular stress (Constantinou et al., 2008). 
The availability of eIF4A is similarly regulated by the binding protein, Programmed Cell 
Death 4 (PDCD4) (Yang et al., 2003; Zakowicz et al., 2005; Suzuki et al., 2008).  As with 4E-
BP1, the phosphorylation of PDCD4 serves to negatively regulate the PDCD4-eIF4A 
interaction (Palamarchuk et al., 2005; Dorrello et al., 2006). 
Section 1.2.2 – eIF4E Phosphorylation and The Role of ERK1/2 & p38 
eIF4E phosphorylation occurs in response to multiple stimuli, including oxidative stress (Rao, 
2000; Duncan et al., 2003; Duncan et al., 2005) and viral infection (Mizutani et al., 2004), 
and may contribute to the transformation process (Topisirovic et al., 2004; Bianchini et al., 
2008; Furic et al., 2010; Robichaud et al., 2015).  Whilst the relevance of eIF4E 
phosphorylation has been hard to elucidate (Minich et al., 1994; Scheper et al.¸2001; 
Zuberek et al., 2003), recent work has shown it mediates a change in gene expression during 
cellular stress responses (Andersson & Sundler, 2006; Herdy et al., 2012; Royall et al., 2015). 
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Extracellular Signal-Regulated Kinase (ERK) 1 (44kDa) and ERK2 (42kDa) are two of the most 
canonical signalling components in the cell and are responsible for the phosphorylation of 
over 160 proteins with a variety of cellular functions (Cobb et al., 1994; Ferrer et al., 2001; 
Yoon & Seger, 2006 (as cited by Zampieri et al., 2007).  ERK1/2 are situated downstream of 
MAPK/ERK Kinase (MEK) 1/2 and Raf-1 (Crews et al., 1992; MacDonald et al., 1993), as 
shown in Figure 1.2.2a.  These two protein kinases are activated by dual phosphorylation of 
sites Thr-183 and Tyr-185 (Payne et al., 1991; Robbins et al., 1993; Canagarajah et al., 1997). 
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Figure 1.2.2a – Signalling Cascade Resulting in the Activation of ERK1/2.  Extracellular 
Signal-Regulated Kinase 1/2 (ERK1/2) is a substrate of MAPK/ERK Kinase 1/2 (MEK1/2).  In 
order to phosphorylate MEK1/2, RAS, when bound to Guanosine Trisphosphate (GTP), 
phosphorylates Raf-1 (MacDonald et al., 1993; Jelinek et al., 1996).  The activation of this 
pathway occurs in response to a wide variety of environmental stimuli through cell 
surface receptors, including the Erythropoietin Receptor (EpoR) (Guillard et al., 2003; 
Miyake et al., 2013) and the Epidermal Growth Factor Receptor (EGFR) (Correa-Meyer et 
al., 2002; Pastore et al., 2005). 
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Several of the 160 ERK1/2 substrates have important functions in the regulation of 
translation intiation, as outlined in Figure 1.2.2b.  These include the phosphorylation of 
RSK1 (Gavin & Nebreda, 1999) and the phosphorylation, and activation, of the mTORC1 
component, RAPTOR (Carríere et al., 2010).   
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Figure 1.2.2b – Effects of ERK1/2 Signalling on Translation Initiation.  Once activated, ERK1/2 
induces several stimulatory effects on translation initiation.  The phosphorylation of the mTORC1 
component Raptor brings about the full activation of the mTORC1 pathway, resulting in the 
phosphorylation of 4E-BP1.  Translation is also enhanced by ERK1/2 through the RSK1-mediated 
phosphorylation of helicase accessory factor, eIF4B and through the suppression of 4E-BP1 
expression. The other main mechanism by which ERK1/2 can affect translation is through the 
phosphorylation of eIF4E via the ERK1/2 substrate, MNK2.  The phosphorylation of eIF4E is 
viewed as allowing the selective translation of specific mRNAs. Through these pathways, ERK1/2 
can be seen as a central regulator of translation initiation.  
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Four isoforms of p38 (α, β, γ and δ) are expressed in a tissue-specific manner in mammals 
and share between 45% and 75% amino acid sequence homology (Jiang et al., 1996; 
Mertens et al., 1996; Goedert et al., 1997; Hu et al., 1999; Korb et al., 2006; Cuenda & 
Rousseau, 2007).  Three kinases have been implicated in the activation of p38: Mitogen-
Activated Protein Kinase Kinase (MKK) 3 (Derijard et al., 1995; Raingeaud et al., 1996; 
Makeeva et al., 2006), MKK4 (Winston et al., 1997; Ganiatsas et al., 1998; Blüher et al., 
2009) and MKK6 (Raingeaud et al., 1996; Bode et al., 2001; Brancho et al., 2003).  It is 
believed that MKK3 is the main kinase responsible for activation of p38 (Galan-Moya et al., 
2011).  Furthermore, MKK4 is only responsible for phosphorylating p38 in vitro (Winston et 
al., 1997; Ganiatsas et al., 1998; Blüher et al., 2009). 
The activation of p38 produces considerable effects on the cell and a number of substrates 
have been identified as being downstream of this kinase, including MK2 (Alessi et al., 1996; 
Zu et al., 1996; Krump et al., 1997), Cyclic AMP-Dependent Transcription Factor (ATF-2) 
(Raingeaud et al., 1995; Waas et al., 2001; Ouwens et al., 2002) and Mitogen- and Stress-
Activated Kinase 1 (MSK1) (Deak et al., 1998; McCoy et al., 2005; van der Heide et al., 2011).  
Downstream of MK2, p38 plays a role in the regulation of translation, as shown in Figure 
1.2.2c, by the phosphorylation of Tristetraprolin (TTP) which has a considerable affect on 
mRNA stability by negatively regulating the degradation of mRNAs containing Adenosine 
and Uridine-Rich Elements (Clement et al., 2011; Tiedje et al., 2012). 
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Figure 1.2.2c – The Activation of p38α & The Effects of this Kinase on Translation and Gene Expression.  The 
activation of p38α occurs in response to cellular stresses, such as Lipopolysaccharide (LPS) treatment.  The 
main cellular kinase responsible for the activation of this MAPK is MAPK Kinase 3 (MKK3) (Galan-Moya et al., 
2011).  Upstream of MKK3 lies several kinases, including Transforming Growth Factor-β
1
-Activated Kinase 1 
(TAK1) (Kim et al., 2007a; Xin et al., 2010).  Other kinases also shown to be responsible for MKK3 
phosphorylation include Mixed Lineage Kinase 3 (Tibbles et al., 1996; Abi Saab et al., 2012; Zhou et al., 2014), 
MAPK Kinase Kinase (MEKK) 3 (Uhlik et al., 2003) and MEKK4 (Abell et al., 2007).  Once phosphorylated by 
MKK3, p38α is capable of not only mediating a change in gene expression, through Cyclic AMP-Dependent 
Transcription Factor (ATF-2) phosphorylation, but it plays a key role in controlling translation.  The first such 
role involves the phosphorylation of MAPK-Interacting Kinase (MNK) 1.  This kinase mediates an increase in 
eIF4E phosphorylation.  The second role in controlling translation is found in regulating the stability of specific 
mRNA.  This occurs through the p38α substrate, MK2.  Once active, MK2 phosphorylates Tristetraprolin (TTP) 
and the degradation of mRNAs containing Adenosine and Uridine Rich Elements. 
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Despite p38 and ERK1/2 having different roles in the regulation of translation initiation, 
both kinases share roles in regulating the expression of 4E-BP1 and the phosphorylation of 
eIF4E.  Both p38 and ERK1/2 have been shown to negatively regulate 4E-BP1 expression 
through the phosphorylation of Elk-1 (GIlle et al., 1996; Cruzalegui et al., 1999; Guha et al., 
2001; Rolli-Derkinderen et al., 2003).   
Both MNK1 and MNK2 have been shown to phosphorylate eIF4E at position Ser-209 
(Scheper et al., 2001; Ueda et al., 2004).  The activity of MNK2 is constitutive and maintains 
the phosphorylation (Ueda et al., 2004), whilst MNK1 activity is inducible (Scheper et al., 
2001).  These two kinases are regulated by the ERK1/2 and p38 mitogen activated protein 
kinases cascades (Fukunaga & Hunter, 1997; Waskiewicz et al., 1997).  MNK1 is regulated by 
p38 whilst ERK1/2 is solely responsible for MNK2 phosphorylation (Fukunaga & Hunter, 
1997; Waskiewicz et al., 1997).  The ability of MNK1 to phosphorylate eIF4E is not 
exclusively dependent upon p38.  It must first interact with eIF4G, within the 43S complex, 
and requires the phosphorylation of eIF4G at position Ser-1186 by Protein Kinase C (PKC) α 
(Dobrikov et al., 2011; Walsh & Mohr, 2014). 
Section 1.2.3 – Ribosomal Protein S6 Kinases  
The activities of the kinases responsible for the phosphorylation of the ribosomal S6 protein 
are a good example of convergence of biological activity.  The two classes of enzyme 
responsible for this have been termed the p70 Ribosomal S6 Kinases (S6K1) (Shima et al., 
1998) and RSK1 (Erikson & Maller, 1985).  Both of these kinases are also able to 
phosphorylate eIF4B (Shahbazian et al., 2006; van Gorp et al., 2009), thereby enhancing the 
activity of eIF4A.  Despite these similarities, both S6K1 and RSK1 have distinct cellular 
functions.  The S6K1 acts to negatively regulate mammalian Target of Rapamycin Complex 2 
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(Julien et al., 2010) and provide negative feedback to Insulin receptor signalling (Tremblay et 
al., 2007).  RSK1 can act to stimulate mTORC1 via suppression of Tuberous Sclerosis 
Complex function (Roux et al., 2004). 
RSK1 is activated by ERK1/2 (Gavin & Nebreda, 1999), ERK5 (Ranganathan et al., 2006) and 
the PDK1 (Jensen et al., 1999), as shown in Figure 1.2.3a.  Interestingly there is some 
evidence that RSK1 is able to phosphorylate ERK5, suggesting that dual regulation may exist 
here (Le et al., 2013).  The regulation of S6K1 is more straight-forward requiring dual 
phosphorylation.  Both mTORC1 (Seufferlein & Rozengurt, 1996; Burnett et al., 1998) and 
PDK1 (Alessi et al., 1997a) are required for activation of this kinase by phosphorylating Ser-
412 (Isotani et al., 1999) and Thr-252 (Alessi et al., 1997a). 
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Figure 1.2.3a – Overview of Pathways Resulting in the Activation of the Ribosomal S6 Protein 
Kinases.  The activation of the p70 Ribosomal S6 Kinase (S6K1) and p90 Ribosomal S6 Kinase 
(RSK1) involves phosphorylation (Magnuson et al., 2012).  While 3-Phosphoinositide-Dependent 
Protein Kinase (PDK1) can phosphorylate both RSK1 and S6K1 (Alessi et al., 1997a; Jensen et al., 
1999), RSK1 can also be activated by Extracellular-Signal Regulated Kinase (ERK) 1/2 (Gavin & 
Nebreda, 1999).  However, in order to fully activate S6K1, an additional mTORC1-dependent 
phosphorylation is also required (Seufferlein & Rozengurt, 1996; Burnett et al., 1998).  In terms of 
biological function, RSK1 and Protein Kinase B (AKT1) both function in the phosphorylation of 
Tuberous Sclerosis Complex (TSC) 2 protein (Inoki et al., 2002; Potter et al., 2002; Roux et al., 
2004) to bring about Mammalian Target of Rapamycin Complex 1 (mTORC1).  Both S6K1 and 
RSK1 function to phosphorylate eukaryotic Initiation Factor 4B (not shown here) (Shahbazian et 
al., 2006; van Gorp et al., 2009). 
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Section 1.2.4 – Phosphorylation of Eukaryotic Initiation Factor 2α 
Eukaryotic initiation factor 2α (eIF2α) phosphorylation occurs in response to a variety of 
cellular stresses, including viral infection (Connor & Lyles, 2005; McInerney et al., 2005; 
Krähling et al., 2009; Elbahesh et al., 2011; Welnowska et al., 2011), amino acid starvation 
(Thiaville et al., 2008; Jiménez-Díaz et al., 2013) and hypoxia (Koumenis et al., 2002; Owen 
et al., 2005; Zhu et al., 2009; Liu et al., 2010).  Phosphorylation of the Serine residue at 
position 51 (Rhoads, 1999) (Ser-51) is an efficient mechanism of inhibiting translation as this 
interaction inhibits the ability of eIF2B to exchange GDP for GTP (Krishna et al., 1997; 
Ramaiah et al., 1994; Kimball et al., 1998; Sudhakar et al., 2000), thus preventing a new 
round of translation initiation occurring.   
While different mechanisms have been proposed in yeast and mammalian cells, the 
phosphorylation of eIF2α leads to a situation in which the interaction between the β- and γ-
subunits of eIF2 and eIF2B, that allows the exchange of GDP for GTP, to be removed 
(Kimball et al., 1998; Krishnamoorthy et al., 2001).  
This mechanism of inhibiting translation is mediated by four kinases capable of 
phosphorylating eIF2α: Double-Stranded RNA-Dependent Protein Kinase (PKR) (Romano et 
al., 1995; Romano et al., 1998; Ung et al., 2001; Vattem et al., 2001), Double-Stranded RNA-
Activated Protein Kinase-Like ER Kinase (PERK) (Shi et al., 1998; Harding et al., 1999; Sood et 
al., 2000; Kouroku et al., 2007), Haem-Regulated eIF2α Kinase (HRI) (Crosby et al., 1994; Han 
et al., 2001; Liu et al., 2008) and General Control Nonderepressing 2 (GCN2) (Dever et al., 
1992; Ramirez et al., 1992; Dever et al., 1993; Berlanga et al., 1999; Hao et al., 2005; Maurin 
et al., 2005).  The stresses that result in the phosphorylation of eIF2α are shown in Figure 
1.2.4a. 
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Figure 1.2.4a – Cellular Stresses Leading to the Inhibition of Translation through the 
Phosphorylation of eIF2α.  The phosphorylation of eIF2α is a powerful mechanism by 
which cellular translation can be inhibited.  Four cellular kinases have been shown to 
phosphorylate this initiation factor on Ser-51.  This phosphorylation occurs in response 
to a wide variety of cellular stresses.  It is worth noting that stresses resulting in the 
activation of HRI and PERK are both considered to be Endoplasmic Reticulum Stresses. 
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Section 1.2.5 – Emerging Roles for JNK1 in the Regulation of Translation 
Initiation 
JNK is expressed from three gene: jnk1, jnk2 and jnk3.  Ten isoforms of JNK can be expressed 
from alternative splicing of these genes (Davis, 2000).  While JNK1 and JNK2 are expressed 
ubiquitously, JNK3 expression is typically expressed in the brain and testes (Ibid).  JNK1 is 
canonically associated with stress responses and apoptosis (Dérijard et al., 1994; Minden et 
al., 1994; Paraskevas et al., 1999; Te et al., 2015).  Whilst not traditionally associated with 
the control of translation initiation, several emerging roles have recently began to emerge. 
There is some confusion of the role of JNK1 in the phosphorylation of eIF4E.  Despite earlier 
work revealing no role for JNK1 in the phosphorylation of this initiation factor (Fukunaga & 
Hunter, 1997), later work demonstrated that eIF4E phosphorylation was inhibited by 
inhibition of JNK1 (Gandin et al., 2010; Jiang et al., 2010).  It is not clear how this regulation 
occurs as both expression of eIF4E has shown to be reduced by JNK1 inhibition (Jiang et al., 
2010) and the eIF4E kinases, MNK1 and MNK2, have been shown to be inhibited by the 
JNK1 chemical inhibitor, SP600125 (Bain et al., 2007).   
The second role for JNK1 in the regulation of translation is found in regulating eIF2α 
phosphorylation.  Dual phosphorylated JNK1 acts as a kinase for Protein Phosphatase 1.  
Such inhibitory phosphorylation prevents the dephosphorylation of eIF2α (Monick et al., 
2006).  ERK1/2 prevents eIF2α phosphorylation by maintaining JNK1 inactivity (Ibid). 
 
 
 Page 33 
 
Section 1.3 – Overview of Viruses Modelled in this Project 
and Viral Strategies to Alter Host Cell Translation Initiation  
Viruses are obligate intracellular parasites and as such usurp the host translation machinery.  
To this end, viruses have evolved several strategies to divert this machinery from translating 
cellular to viral mRNA, and some of these rely on manipulating the signalling pathways that 
regulate translation.  A major part of this project was to adapt the model of cellular 
translational regulation to investigate the effects viruses have upon, the not only 
translational machinery but also, the regulatory signalling network.  Given this aim, it is 
essential to understand the commonly used strategies by which viruses commandeer the 
cellular translation initiation machinery and the points within signalling pathways which 
they affect in order to inhibit host protein synthesis and carry out processes essential for 
viral replication.  Moreover, as a major part of this project involved modelling the effects of 
viral infection upon cellular translational regulation, an introduction into the three viruses 
with effects incorporated into the model is necessary: Junin Virus (JUNV), Murine Norovirus 
(MNV) and Andes Virus (ANDV). 
Section 1.3.1 – General Features & Epidemiology of Viruses Incorporated into 
the Model 
This section describes the general feature of the three viral families incorporated into the 
model in Chapter 4 - Modelling the Effect of Viral Infection and provides a brief 
introduction to the epidemiology and genome of the three viruses in question.  In the case 
of MNV, the overview of the epidemiology will focus primarily upon the medically important 
Human Norovirus (HuNV) as MNV infection, at the organism level, is largely asymptomatic.  
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The incorporation of the effects these viruses induced in the cellular translational and 
signalling machinery into the model served to increase the value of the project. 
Section 1.3.1.1 – Arenaviruses & Junin Virus 
The Arenaviridae family contains 22 enveloped, ambisense RNA viruses (Emonet et al., 
2009; Emonet et al., 2011) with a broad geographical distribution including: North America 
(Bear Canyon Virus, Whitewater Arroya Virus and Catarina Virus), the Caribbean (Tacaribe 
Virus) and South America (Junin Virus (JUNV), Pichindé Virus and Machupo Virus) (Cajimat et 
al., 2007; Cajimat et al., 2013).  Phylogenetic analysis of the New World Arenaviruses reveals 
three clades (A, B and C) (Bowen et al., 1997; Archer & Rico-Hesse, 2002).  Clade B viruses, 
such as JUNV, Machupo, Guanarito and Sabiá viruses are responsible for distinct 
haemorrhagic fevers (Delgado et al., 2008). 
The genome of these cytoplasmic viruses is composed of two segments: the Large segment 
(7.3kb) and Small segment (3.5kb) (de la Torre, 2009; Emonet et al., 2011).  The Large 
segment encodes the 200kDa L protein, an RNA-dependent RNA polymerase (RdRp), and 
the 11kDa Z protein, a Zinc Finger protein.  The Small segment encodes the 75kDa viral 
protein precursor, GPC protein and the 63kDa Nucleoprotein (de la Torre, 2009).  Two stem 
loop structures are found on each segment in the intergenic regions of the JUNV genome 
(Ghiringhelli et al., 1991 (as cited by Palacios et al., 2010)). 
JUNV is responsible for Argenitine Haemorrhagic Fever (AHF) (Arribalzaga, 1955; Parodi et 
al., 1958 (as cited by Peters, 2006)).  The fatality rate for untreated AHF lies between 10% 
and 30% (Maizegui et al., 1975; Harrison et al., 1999).  Around 70% of cases are diagnosed 
by muscle weakness, redness of the eyes, presyncope and subcutaneous rupturing of 
capillaries (Schwarz et al., 1970 (as cited by Harrison et al., 1999)).  Other symptoms include 
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hypotension, lymphadenopathy, irritability and tremors in the hand and tongue (Enria et al., 
2008).  Nearly a third of cases go on to develop haemorrhage and severe neurological 
complications, including convulsions and coma (Ibid).  A combination of leukopenia and 
thromobocytopenia characterise this disease (Harrison et al., 1999). 
New World Arenaviruses are zoonotic infections (Charrell & de Lamballerie, 2010).  
Serological investigations have revealed that predominant rodent species infected with 
JUNV are Calomys musculinus and Calomys laucha, however several other rodent species 
and mammals may also act as hosts (Mills et al., 1991; Mills et al., 1992; Mills et al., 1994). 
Section 1.3.1.2 - Caliciviruses & Murine Norovirus 
The Caliciviridae family contains five genera (Norovirus, Sapovirus, Lagovirus, Vesivirus and 
Nebovirus (ICTV Website, 2012)) of positive-sense, single-stranded RNA viruses (Pesavento 
et al., 2008).  The name of this family is derived from the Chalice, or Calyx, shaped 
indentations covering the viral surface (Madely, 1979).  The genomes of these viruses 
contain between two and four open reading frames (Alhatlani et al., 2015) with fairly 
conserved lengths of between 7.4kb and 7.7kb (Meyers et al., 1991; Carter et al., 1992; 
Rasschaert et al., 1994; Ward et al., 2007).  As HuNV cannot be cultivated (Duizer et al., 
2004; Leung et al., 2010), several other viruses, including MNV, are used as surrogates 
(Esseili et al., 2015).   
The first open reading frame encodes the non-structural polyprotein (Alhatlani et al., 2015).  
The proteins derived from this polyprotein, in FCV, are p5.6, p32, p39 (2C-Like Nucleoside 
Trisphosphatase (NTPase)), p30, p13 (VPg) and p76 (Polymerase-Protease fusion) 
(Sosnovtseva et al., 1999; Sosnovtsev et al., 2002).  In contrast with FCV, MNV requires 
distinct RdRp and protease proteins (Wei et al., 2001; Sosnovtsev et al., 2006).  The second 
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and third open reading frames encode the capsid proteins (Neill et al., 1991).  The fourth 
open+ reading frame of MNV encodes the virulence factor VF1, believed to regulate host 
cell apoptosis (McFadden et al., 2011).   
Two complimentary modes of transmission, foodbourne (Fankhauser et al., 2002; 
Widdowson et al., 2005) and person-to-person (Gunn et al., 1980; Green et al., 2002; 
Isakbaeva et al., 2005), help to ensure disease dissemination.  Initial cases of HuNV occur 
through the consumption of contaiminated water or shellfish (Saitoh et al., 2007; Lowther et 
al., 2012; Pérez-Sautu et al., 2012).  Then similar to FCV dissemination (Pedersen et al., 
2000; Schorr-Evans et al., 2003; Hurley et al., 2004; Clay et al., 2006), the person-to-person 
spread of HuNV occurs through ingestion or inhalation of HuNV-containing fomites (Repp & 
Keene, 2012). 
Most cases of HuNV do not require medical intervention, causing acute, self-limiting 
diarrhoea and vomiting lasting up to five days (Rockx et al., 2002; Lopman et al., 2004; Glass 
et al., 2009).  It is, however, the second leading cause of viral gastroenteritis requiring 
medical intervention, behind Rotavirus (Medici et al., 2006; Tran et al., 2010; Lorrot et al., 
2011; Payne et al., 2013; Lu et al., 2015), and causes considerable morbidity and mortality in 
people over 65 years (Harris et al., 2008; Trividi et al., 2012) and is responsible for 
hospitalising over 23,000 children, under five years, annually in the United States of America 
alone (Patel et al., 2008).  Despite being behind Rotavirus, HuNV places an extra 
CAD4,000,000 burden on healthcare costs in Canada alone (Morton et al., 2015) and a 
multi-million pound burden on the National Health Service in the United Kingdom (Danial et 
al., 2011). 
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Section 1.3.1.3 – Hantaviruses & Andes Virus 
The Hantaviruses, of the Bunyaviridae family, have a genome of segmented, negative-sense 
single-stranded RNA and cause either Haemorrhagic Fever with Renal Syndrome or 
Hantavirus Cardiopulmonary Syndrome (HCPS) (Plyusnin et al., 1996; Jonsson et al., 2010; 
Vaheri et al., 2013).  The genome segments of Andes Virus (ANDV) are termed Large (6.6kb), 
Medium (3.7kb) and Small (1.9kb) (Meissner et al., 2002) and mainly encode the 
Nucleoprotein, Glycoprotein Precursor (GPC) and the RdRp (Tischler et al., 2003; Vera-
Otarola et al., 2012). 
Numerous Hantaviruses cause HCPS, including ANDV (López et al., 1996; López et al., 1997), 
Sin Nombre Virus (SNV) (Elliott et al., 1994) and several others (Morzunov et al., 1995; Khan 
et al., 1996; Johnson et al., 1997; Torrez-Martinez et al., 1998; Johnson et al., 1999; Vincent 
et al., 2000).  In constrast to the strictly zoonotic SNV (Calisher et al., 2007), ANDV is also 
transmissible through person-to-person contact (Enría et al., 1996; Padula et al., 1998; 
Martinez et al., 2005; Lázaro et al., 2007; Martinez-Valdebenito et al., 2014) with infected 
excretions (Castillo et al., 2007; Godoy et al., 2009).  The host reservoir of ANDV appears to 
be members of the Oligoryzomys genus (Toro et al., 1998; Gonzalez Della Valle et al., 2002; 
Medina et al., 2009 (as cited by Torres-Pérez et al., 2010); Andreo et al., 2011).  During 
ANDV infection, the host does not display symptoms, in contrast to SNV infection (Calisher 
et al., 2005). 
ANDV infection has a fatality rate of around 35% and most commonly occurs in men, 
representing an occupational risk, with many cases being labourers in the logging or farming 
industries (Castillo et al., 2001; Unidad de Vigilancia, Dpto. de Epidemiología, Gobierno de 
Chile, 2014).  The initial picture of ANDV infection is reminiscent of influenza.  As the disease 
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progresses, a cough develops and hypotension, tachycardia and tachypnea are noted 
(Castillo et al., 2001).  The majority go on to develop bleeding and renal damage or, in 
severe cases, haemorrhage and renal failure (Castillo et al., 2001).  Extracorporeal 
Membrane Oxygenation has increased survival rates of HCPS in SNV infection (Dietl et al., 
2008; Wernly et al., 2011 (as cited by McNulty et al., 2013)). 
Section 1.3.2 – General Overview of Viral Effects on Translational Regulation 
While the effects specific viruses have upon the cellular translational machinery and the 
signalling network were incorporated into the model, it is worth noting that many other 
strategies are also used by other viruses.  These strategies can be broadly classified as 
belonging to one of several general approaches.  This section describes these strategies, and 
the effect each has upon the translational machinery, and aims to put the specific examples 
incorporated into the model into a broader context. 
Section 1.3.2.1 – Internal Ribosome Entry Site (IRES)-Mediated Translation & 
Host mRNA Degradation 
 Cap-dependent translation is used by the majority of cellular mRNAs and requires the 5’ cap 
to interact with eIF4E (Altmann et al., 1987; Carberry et al., 1989; Goss et al., 1990).  In 
constrast, RNA secondary structures within the 5’ Untranslated Regions of viruses, termed 
Internal Ribosome Entry Sites (IRES) elements, can drive internal recruitment of the 
ribosome to engage in cap-independent translation (Kanamori & Nakashima, 2001; 
Nishiyama et al., 2003; Thurner et al., 2004; Willcocks et al., 2011).  These elements are 
found in the Picornaviridae (Jang et al., 1988; Pelletier & Sonenberg, 1988; Liu et al., 
1999)9*  Flaviviridae (Tsukiyama-Kohara et al., 1992; Rijnbrand et al., 1997; Fletcher & 
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Jackson, 2002) and Retroviruses (Ohlmann et al., 2000; Brasey et al., 2003; Herbreteau et 
al., 2005; Camerini et al., 2008; Weill et al., 2010; Amorim et al., 2014) and allow viral 
translation to continue during infection when host translation is diminished.  The IRES 
elements of these different virus types can be, broadly, classified based upon the 
requirements for cellular factors (Kieft, 2008).   
Whilst several viral families encode the enzymes responsible for encoding 5’ cap structures 
(Decroly et al., 2008; Selisko et al., 2010), others do not and require cellular cap structures 
to carry out viral replication.  These viral families include the Bunyaviridae (Kormelink et al., 
1992; Garcin et al., 1995), Arenaviridae (Raju et al., 1990; Morin et al., 2010) and the 
Orthomyxoviridae (Plotch et al., 1981; Dias et al., 2009).  These viruses conduct cap-
snatching to promote viral transcription, rather than translation, (Lelke et al., 2010; Reguera 
et al., 2010; Lehmann et al., 2014), while suppressing the innate interferon response of the 
cell (Marcus et al., 2005; Qi et al., 2010) and more generally the translational capabilities of 
the host.   
Host mRNA degradation is also mediated by targeting the RNA binding proteins that affect 
mRNA stability.  Members of the Alphavirus family sequester the mRNA stabilising protein, 
HuR, to the 3’ end of the viral genome (Sokoloski et al., 2010; Barnhart et al., 2013).  This 
serves to not only promote the degradation of mRNAs requiring HuR, but given the large-
number of HuR binding sites in intron sequences (Lebedeva et al., 2011; Mukherjee et al., 
2011), this also affects the alternative splicing of mRNAs. 
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Section 1.3.2.2 - VPg Proteins 
Cap-dependent translation does not specifically require the presence of a 5’ 
methylguanosine cap and can occur if a cap analogue is present.  The VPg protein of the 
Caliciviridae family is a good example. 
The viral protein, VPg, is covalently linked to the 5’ region of the viral genome (Schaffer et 
al., 1980) and acts as a 5’ cap analogue (Chaudhry et al., 2006).  Whilst the presence of this 
protein is not unique to the Caliciviridae, with VPg proteins being found in viral families 
including the Astroviridae (Jiang et al., 1993; Fuentes et al., 2012), Picornaviridae (Flanegan 
et al., 1977; Weitz et al., 1986) and Potyviridae (Riechmann et al., 1989; Puustinen et al., 
2002), the size and exact function of this protein is fairly unique.  The VPg function differs 
from that of the Picornaviruses.  Whilst the Caliciviral VPg is required for viral protein 
synthesis (Daughenbaugh et al., 2003; Goodfellow et al., 2005), the VPg of the Picornaviridae 
functions only for viral genome replication (Flanegan et al., 1977; Morasco et al., 2003; 
Murray & Barton, 2003; Liu et al., 2007). 
Much like that of the Potyviridae (Léonard et al., 2004; Hébrard et al., 2010), the Caliciviral 
VPg (Daughenbaugh et al., 2003; Daughenbaugh et al., 2006; Hosmillo et al., 2014) is 
responsible for the interactions with a number of cellular factors vital for the initiation of 
translation.  However, unlike that of the Potyviridae, the VPg of the Caliciviridae does not 
interact with the PABP (Léonard et al., 2004; Beauchemin & Laliberté, 2007).   
Several interactions between VPg and eIF3 and eIF4E are known to occur in Norwalk Virus 
(Daughenbaugh et al., 2003) and Feline Calicivirus (FCV) (Goodfellow et al., 2005).  
Differences in the requirements of eIFs exist between Caliciviruses, but overall, imply a 
mechanism by which the VPg protein is able to join the eIF4F complex to the 43S complex to 
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enable cap-dependent translation (Chaudhry et al., 2006).  More information regarding 
interactions between the VPg and initiation factors is given in Section 4.2.2 – Murine 
Norovirus Model.  
Section 1.3.2.3 - Host Factor Degradation & Viral Mimics of Host Factors  
Viral infection subjects the host cell to pronounced stress and requires the cell to respond 
with changes in gene expression.  However, viruses are also capable of manipulating this 
change to confer an advantage (Villas-Bôas et al., 2009; Royall et al., 2015).  An obvious viral 
target is the cellular translational machinery with mechanisms including the degradation of 
host initiation factors and signalling components and the mimicry of host factors. 
To control eIF2 activity, several viruses, including Vaccinia Virus and members of the 
Ranavirus genera, encode functional proteins mimicking eIF2α, termed K3L (Essbauer et al., 
2001) and vIF2α (Yu et al., 1999; Grayfer et al., 2015), respectively.  K3L inhibits the 
phosphorylation of eIF2α via an interaction between the protein and PKR (Kawagishi-
Kobayashi et al., 1997).  vIF2α, however, targets the homologue of PKR in fish for 
degradation (Jancovich & Jacobs, 2011).  PKR is also degraded during infection with the 
virulent Phleboviruses, such as Rift Valley Fever Virus (Habjan et al., 2009; Ikegami et al., 
2009; Kalveram & Ikegami, 2013; Lihoradova et al., 2013). 
Section 1.3.2.4 - Alteration to Cell Signalling Pathways 
In addition to the degradation of host factors, a commonly used strategy to alter the ability 
of the host to synthesise proteins is to interfere with the normal functioning of cellular 
signalling pathways that control translational activity (as described in Section 1.2 – Key 
Points of Regulation & Upstream Signalling Pathways).   
 Page 42 
 
Given that mTORC1 has a central role in regulating translation initiation, numerous viruses 
target this pathway for activation, including: ANDV (McNulty et al., 2013), Human 
Cytomegalovirus (HCMV) (a β-Herpesvirus) (Bai et al., 2015) and Influenza A Virus (an 
Orthomyxovirus) (Denisova et al., 2014).   
The mechanism by which mTORC1 is activated appears to be dependent upon the family of 
virus that is infecting the cell.  HCMV (Moorman et al., 2008) and Herpes Simplex Virus 1 
(HSV-1) (Chuluunbaatar et al., 2010) both affect the activation of mTORC1 at the level of 
TSC2 activity.  The HSV-1 protein, Us3, phosphorylates TSC2 at the site normally targeted by 
cellular kinases, Thr-1462 (Chuluunbaatar et al., 2010).  The HCMV viral protein, pUL38, was 
able to interact with TSC2 in such a way that mTORC1 activity was increased with this 
interaction mimicking the phosphorylation of TSC2 (Moorman et al., 2008).   
Section 1.4 – Background to Systems Biology Techniques 
Literature reviewed in previous parts of this chapter show that translation is a fundamental 
process in the cell.  It consumes approximately 30% of the ATP produced during oxidative 
phosphorylation (Buttgereit & Brand, 1995).  Furthermore, this literature shows that 
translation initiation is regulated by a vast, interconnected network of molecular 
components which coordinate protein synthesis with other cellular processes in response to 
a diverse array of environmental cues.  Due to the number of components and interactions, 
it is not possible to understand how the system functions by following individual scientific 
articles describing individual interactions.  Since the beginning of this century, the Systems 
Biology field has robustly argued that cellular behaviour at the molecular level can only be 
fully understood if it is studied as a whole and that computational and mathematical 
modelling tools are indispensable in this process (Di Ventura et al., 2006; Chuang et al., 
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2010).  The challenges of modelling biological systems relate to unprecedented complexity 
and the difficulty in obtaining quantitative data have led to the development of an armoury 
of computational systems biology techniques aimed at representing the system in different 
levels of detail.  This being said, these approaches have not yet been fully integrated into 
one generally accepted methodology, with the choice of method depending upon the aim 
and hypothesis of individual projects. 
Throughout the course of this project, several systems biology techniques were used to 
construct the computational model representing literature on the molecular interactions 
network regulating translation initiation in mammalian cells.  The following sections provide 
the background information to these methods.  The first three sections describe the three 
fundamental, most commonly used approaches of computational systems biology: Exact 
Stochastic Simulations with the Gillespie algorithm, Ordinary Differential Equations (ODEs) 
and Flux Balance Analysis (FBA).  Following these sections, Petri Nets will be introduced as a 
qualitative simulation approach and a unifying framework for representing qualitative Exact 
Stochastic and ODE models.  Finally, Quasi-Steady State Petri Nets (QSSPN) will be 
introduced as an attempt to integrate Petri Nets with FBA.  In the final section, the general 
terminology of Petri Nets will be translated to a vernacular more familiar to biologists. 
Section 1.4.1 – Exact Stochastic Simulations with the Gillespie Algorithm 
The Gillespie algorithm for Exact Stochastic Simulations was initially developed to account 
for inherent, random noise in systems of coupled chemical reactions, resulting from the fact 
that individual reactions occur due to random collisions between molecules.  In laboratory 
experiments, reactions are carried out in large volumes involving large numbers of 
molecules.  A consequence of this is deterministic behaviour due to the averaging of 
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random effects.  However, in the small volumes of living cells there may be reactions 
involving just a few molecules (e.g. the binding of 10 molecules per cell of the LacR 
transcription factor to the lactose operon) (Krebs et al., 2013).  In this case, the considerable 
random noise in the outcome of individual reactions is expected and leads to the 
heterogeneity of cellular behaviours.  Indeed, early simulations of prokaryotic gene 
expression with the GIllesipe algorithm (McAdams & Arkin, 1997; Kierzek et al.¸ 2001) 
predicted fundamental stochastic phenomena in gene expression.  These were later 
experimentally demonstrated (Ozbudak et al., 2002; Elowitz et al., 2002).   
The Gillespie algorithm is described in detail below as it is the workhorse of this project and 
used in the majority of the simulations reported here.  However, the purpose of using this 
algorithm is different than in the majority of computational systems biology projects.  The 
Gillespie algorithm is not used to perform quantitative simulations nor is it used to study 
random heterogeneity in the number of molecules in individual cells.  Rather, it is used to 
randomly sample alternative sequences of molecular events, linking signalling network 
inputs and molecular effector outputs in a qualitative model of the molecular system 
regulating mammalian translation initiation.  This important distinction will be revisited in 
Section 1.4.4 – The Petri Net Formalism, where the Qualitative Petri Net approach will be 
introduced in detail.   
The Gillespie algorithm was initiatally formulated to model the dynamics of systems of 
coupled chemical reactions (Gillespie, 1977).  This method is frequently referred to as an 
exact stochastic simulation because it proceeds by generating individual reaction events 
occurring at exact times.  At each iteration two questions are answered: i. Which of these 
reactions will next occur? ii. What is the waiting time for the next reaction to occur? 
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In order to answer these questions, Gillespie (1977) applied a Monte Carlo approach (Ulam 
et al., 1947; Metropolis & Ulam, 1949).  A pseudo-random number generator was used to 
create two numbers (𝑟1 and 𝑟2).  These numbers are, in turn, used to calculate two 
additional variables, 𝜏 and 𝜇, respectively.  The equations below (Equation 1.4.1a and 
Equation 1.4.1b), from Gillespie (1977), describe the calculations used to ascribe values to 𝜏 
and 𝜇: 
𝜏 = (1 𝛼0⁄ )𝑙𝑛(
1
𝑟1⁄ ) 
The value of 𝜇 is an integer value that satisfies the following statement: 
∑ 𝛼𝜈 < 𝑟2𝛼0  ≤
𝜇 − 1
𝜈 = 1
 ∑ 𝛼𝜈
𝜇
𝜈=1
 
In both calculations, the value of 𝛼0 is equal to the sum of the propensity functions 
describing all the reactions in the system.  A propensity function for reaction 𝜇 can be 
described as the product of the number of molecules of various substances involved in 
reaction 𝜇 (ℎ𝜇) and the stochastic rate constant for the reaction 𝜇 (𝑐𝜇), as shown below 
(Equation 1.4.1c): 
𝑎𝜇 = ℎ𝜇𝑐𝜇  
In short, the answer to the question of which reaction will occur next, can be viewed as 
being a probability (Gillespie, 1977).  The probability of instigating reaction 𝜇 will depend 
upon the size of the propensity function for the reaction,  𝑎𝜇, as a fraction of the sum of all 
propensity functions (𝛼0).  As the propensity function of a particular reaction increases, the 
ratio of this to 𝛼0 also increases.  Consequently, it becomes more probable that this reaction 
will occur.  The selection of a propensity function can be exemplified with a pie chart.  As 
Equation 1.4.1a 
Equation 1.4.1c 
Equation 1.4.1b 
 Page 46 
 
shown in Figure 1.4.1a, the probability of randomly selecting a reaction is proportional to 
the size of the area that this function occupies.   
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Figure 1.4.1a – Schematic View of Propensity Functions.  The value of 𝛼0 would be 
described as the sum of all the propensity functions (α
1
 to α
5
) (Gillespie, 1977).  The 
larger the propensity function for a particular reaction, the more likely it is to occur.  
As α
3
 has the largest propensity function, and so the highest fraction of α
0
, it is most 
likely to occur.  Conversely, as α
5
 makes up the smallest fraction of α
0
, the reaction 
with propensity function α5 would occur least.   
α
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α
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α
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The value of 𝜏 describes the time interval taken for the next reaction to occur (Ibid) and 
provides an answer to the second question given above.  In other words, at 𝑡𝑛 = 𝑡𝑛−1 +  𝜏 , 
reaction 𝜇 will occur.  The probability of time interval 𝜏 occurring can be described using an 
exponential decay (Gillespie, 1977), and it is theoretically possible for the waiting time to 
increase to infinity.  However, the probability of this infinite waiting time interval becomes 
infinitesimally small.  The following equation (Equation 1.4.1d) (Ibid) shows how the 
Gillespie algorithm calculates the probability of a waiting time interval, 𝜏, for reaction 𝜇: 
𝑃(𝜏, 𝜇) =  𝛼𝜇𝑒
−𝛼0𝜏 
Once the identity of the next reaction and associated waiting time are determined, the state 
of the system is updated by executing one elementary reaction event occurring at an exact 
time.  Thus, if reaction 𝜇 is: 
𝐴 + 2𝐵 → 𝐶 
In Equation 1.4.1e, the number of molecules of 𝐴 will be decreased by one, the number of 
molecules of 𝐵 will decrease by two and the number of molecules of 𝐶 will increase by one.  
The simulation time is then increased by adding the waiting time, 𝜏, to the current 
simulation time.  This way of updating the system can be described as asynchronous: in a 
given iteration of the simulation, only one event is executed and only the species 
participating in this event are updated.   
The direct method of Gillespie (1977) described above, is computationally time consuming.  
At every iteration, two random numbers must be generated.  Gibson and Bruck (2000) have 
proposed a method, termed the Next Reaction Method, which is equivalent to the Gillespie 
algorithm where only one random number per iteration needs to be generated, and where 
Equation 1.4.1d 
Equation 1.4.1e 
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the search for the next reaction is optimised.  While very sophisticated, this method would 
still be very computationally expensive if the number of molecules were very large.   
To address this problem, the approximate stochastic techniques have also been developed, 
including the τ-Leap method (Gillepsie, 2001).  In this method, the discrete timestep is 
introduced.  In each iteration, the number of firings of each reaction within this timestep is 
generated by a pseudo-random number from a Poisson distribution.  Subsequently, new 
states of the system are calculated by executing all reactions capable of firing.  This way of 
updating the system can be described as synchronous: in a given iteration of the simulation 
all reactions and substances are updated simultaneously.  While this algorithm is much 
faster and practical for systems containing large numbers of molecules, it is no longer exact, 
as arbitrary timesteps are introduced.  The synchronous updates may even lead to the 
generation of negative numbers of molecules if the number of reactants are not sufficiently 
large.  This algorithm cannot be applied to systems containing reactions with small numbers 
of molecules (e.g. transcription factors binding to bacterial genes).  As the τ-Leap method 
has not been used in this project, it will not be described in more detail.  A possible link 
between these approximate stochastic methods and the exact stochastic methods is the K-
Leap Method (Cai & Xu, 2007). 
Section 1.4.2 – Ordinary Differential Equations (ODEs) 
Deterministic modelling involves the representation of a systems as a set of coupled 
Ordinary Differential Equations (ODEs).  This method is the most frequently used 
representation of biological systems (Wu et al., 2008).  Individual model components are 
viewed as undergoing changes in concentration per unit time, as shown in Equation 1.4.2a.  
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A description of a system in this way requires an in depth knowledge of the system 
(Williamson et al., 2009).   
𝑑[𝑋]
𝑑[𝑡]
= 𝑘1[𝑌][𝑍] − 𝑘2[𝐴][𝐵] 
As shown in Equation 1.4.2a, an ODE describes changes in the concentration of a substance 
(𝑑[𝑋]) per unit time  (𝑑[𝑡]).  This rate of change is, therefore, the sum of all reactions that 
both consume and produce substance 𝑋 (Wu et al., 2008; Korkola et al., 2015).  In the 
example given in Equation 1.4.2a, the reaction involving 𝑌 and 𝑍 and described by the rate 
constant 𝑘1 produce 𝑋, whilst that described by the constant 𝑘2, and involving 𝐴 and 𝐵 
degrade substance 𝑋.  In a deterministic model, a series of ODEs is constructed to account 
for the synthesis and degradation of each model component.  In order for ODEs to be 
constructed it is essential that two conditions are satisfied.  Firstly, the temporal nature of 
the system must be known (Rangamani & Iyengar, 2008; Cowan et al., 2012).  Secondly, it is 
necessary to have knowledge of either the volume of the compartment in which the 
reactions occur or the initial concentrations of each species (Cowan et al., 2012).  In relation 
to the initial concentrations of model components, it is necessary to state that these values 
should be sufficiently large so as to view them as continuous variables (Rangamani & 
Iyengar, 2008). 
Numerical simulations of ODE systems is one of the most developed areas in applied 
mathematics, with an array of sophisticated methods having been developed since 
computers became available in the second half of the 20th Century (Press et al., 2007).  The 
common features of all algorithms is that at each iteration of the simulation a timestep is 
assumed.  The ODEs are then used to calculate the change in concentration of each 
Equation 1.4.2a 
 Page 51 
 
substance during this timestep.  Substance concentrations are then synchronously updated.  
Individual, highly optimised algorithms are implemented in numerical solver libraries, such 
as Sundials (Hindmarsh et al., 2005).  A detailed description of these methods is beyond the 
scope of this dissertation. 
Section 1.4.3 – Flux Balance Analysis (FBA) 
The application of ODE or exact stochastic simulations to large-scale, and potentially whole-
cell, molecular interaction networks is hindered by a lack of sufficient, quantitative data on 
the values such as reaction rate constants or numbers of molecules.  FBA offers a method 
for the analysis of whole genome-scale metabolic networks (GSMN).  The cost of using this 
method is the introduction of two approximations.  Firstly, the use of reaction fluxes rather 
than molecular amounts.  Secondly, this method only permits the analysis of the system at 
steady state.  As a consequence, the ODE model describing the steady state reactions 
between metabolites is expressed by the following equation (Equation 1.4.3a): 
𝑑𝑥
𝑑𝑡
= 0 = 𝑆𝑣 
In Equation 1.4.3a, the change in concentration per unit time is equal to the product of the 
Stoichiometric matrix (𝑆) and the flux vector (𝑣) (Raman & Chandra, 2009; Orth et al., 2010).  
The Stoichiometric matrix contains m rows and n columns denoting m metabolites and n 
reactions, respectively (Covert et al., 2001; Benyamini et al., 2010).  For example, the 
Stoichiometric matrix 𝑆𝑖𝑗 represents the stoichiometric coefficient of the 𝑖-th metabolite in 
the 𝑗-th reaction.  Flux vector 𝑣 would then contain information on the metabolic reaction 
fluxes of n reactions.  At steady state this becomes a vector with all components equal to 
zero.  (Covert et al., 2001).  If experimental data on some of the steady state flux values or 
Equation 1.4.3a 
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their ranges are available, the solution space can be further constrained by flux bounds, as 
shown in Equation 1.4.3b: 
𝑓𝑙 < 𝑣 < 𝑓𝑢 
where the flux vector (𝑣) must fall between upper (𝑓𝑢) and lower (𝑓𝑙) flux bounds (Orth et 
al., 2010).  Furthermore, it is worth noting that fluxes maybe positive or negative depending 
on the reversibility of the biochemical reaction being described by that particular flux (Ibid). 
The boundary conditions of the FBA problem are defined by external metabolites which are 
not subject to the balance constraints of Equation 1.4.3a.  These metabolites are treated as 
unlimited sources and sinks of metabolic fluxes.  Usually, external metabolites are used to 
represent nutrients available in the medium (e.g. glucose and amino acids).  The bounds of 
exchange reactions connecting external metabolites to the first balanced precursor in the 
network can be used to quantitatively constrain nutrient availability. 
Flux Balance Analysis is commonly used to study full GSMNs involving thousands of 
reactions (Orth et al., 2010).  In these systems it is never the case that enough fluxes are 
measured to solve Equation 1.4.3a and determine values of all fluxes.  However, it is 
possible to determine the maximal value of any linear combination of fluxes: 
max
𝒇𝑙,𝒇𝑢,𝑺
(𝒄 ∙ 𝒗), 𝑠𝑢𝑐ℎ 𝑡ℎ𝑎𝑡 
𝑺 ∙ 𝒗 = 𝟎 
𝑓𝑙 < 𝑣 < 𝑓𝑢 
where, 𝑐 is a vector of 𝑛 coefficients set by the user.  This vector defines an objective 
function, which expresses the metabolic functions of the cell under investigation.  A 
Equation 1.4.3c 
Equation 1.4.3b 
Equation 1.4.3d 
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common choice is biomass, for an objective function, where coefficients corresponding to 
reactions producing cellular biomass components are set according to measured biomass 
composition and other coefficients are set to zero.  The maximisation problem defined by 
Equation 1.5.3c is solved by linear programming algorithms, with the Simplex method being 
most frequently used (Orth et al., 2010).  This use of linear programming guarantees finding 
the maximal, unique value of the objective function, but there may be many solution 
vectors  𝒗 corresponding to this value.  A detailed understanding of linear programming 
(Kantorovich, 1939 (as cited by Bentobache & Bibi, 2012)) and the Simplex algorithm 
(Dantzig, 1951; Dantzig, 1963 (as cited by Bentobache & Bibi, 2012)) are beyond the scope 
of this thesis. 
One of the reasons why FBA has been widely adopted is that it offers a gradually changing 
level of quantitative model accuracy depending on available experimental data.  If no 
quantitative information is available, the maximisation of the objective function can be used 
to check whether a certain metabolic function is possible.  The conclusion drawn from a 
maximal value of the objective function equalling zero is that the metabolic function in 
question is not possible (Orth et al., 2010). Conversely, objective function values greater 
than zero can be interpreted as a qualitative indication of the metabolic function being 
feasible (Ibid).  This is particularly useful in evaluating effects of perturbations and gene 
knockouts.  For example, Beste et al. (2007) used the GSMN-TB model of Mycobacterium 
tuberculosis to test feasibility of growth (through a biomass objective function) for all single 
gene knockouts against metabolic genes.  The results of which were then compared with 
transposon site mutagenesis (Ibid).  Statistically significant predictive power has been 
achieved with this model (Beste et al., 2007).  As quantitative information about fluxes 
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become available, solution space can be further constrained.  For microorganisms growing 
in bioreactors, quantitative predictions of metabolic yields are possible and applied in 
metabolic engineering (Fisher et al., 2014). 
Recently, Flux Balance Analysis has been widely applied to modelling metabolism of human 
tissues (Gille et al., 2010; Thiele et al., 2013).  The capability of FBA to qualitatively predict 
feasible flux distributions has been further exploited in the mechanistic interpretation of 
transcriptome data.  For example, Leoncikas et al. (2016) have analysed the transcriptomes 
of 2,000 individual breast cancer tumours in the context of a human GSMN (Thiele et al., 
2013) and have identified metabolic pathways associated with poor prognosis. 
To summarise, Flux Balance Analysis is the first approach capable of mechanistically 
modelling the genotype-phenotype relationship at the full genome scale.  This is currently 
limited to metabolic genes and metabolic phenotypes only.  From this perspective, one of 
the aims of this project was to extend the scope of mechanistic modelling to large scale 
signalling and gene regulatory network that cannot be studied under steady state. 
Section 1.4.4 – The Petri Net Formalism 
This project extensively used the Petri Net framework to provide a graphical language and 
tools for model building, integration of models developed in different formalisms and the 
notion of qualitative dynamic modelling.  The Petri Net formalism was first developed by 
Carl Adam Petri in the 1962 dissertation, Kommunikation mit Automaten (Petri, 1962).  
While this formalism was developed to model engineering systems (Ibid), the modelling of 
chemical reactions has also been proposed.  Thus, the formalism can be easily extended to 
model biochemical reactions or cellular signalling events.  Before a biologically meaningful 
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description of this formalism is given in Section 1.4.6 – Translation of Petri Net Terminology 
for a Molecular Biologist, a formal definition is necessary.   
Petri Nets are bipartite graphs in which two types of nodes represent places and transitions 
(Petri, 1962).  Various types of edges link places to transitions and, given Petri Nets are 
bipartite graphs, no two nodes of the same type can be linked together with edges.  Pre-
places describe places that are linked to transitions with an edge instigated from that place, 
whilst a post-place is one linked to a transition by an edge originating from that transition 
(Wang, 2007; Breitling et al., 2008).  Places within the model are assigned non-negative, 
integer number of tokens.  The assignment of tokens to places is termed ‘marking’ (Breitling 
et al., 2008).  The firing of transitions moves tokens from pre-places to post-places via 
transitions and results in the state of the system being updated (Ibid).  The consumption or 
production of multiple tokens by one transition firing is possible.  The number of tokens 
moved upon transition firing is specified by the weight of the edges linking pre- and post-
places to transitions (Breitling et al., 2008).  Each transition is enabled when the associated 
firing rule, concerning the marking of pre-places with sufficient tokens to account for the 
weighting of edges, is satisfied (Breitling et al., 2008).  
Definitions of Petri Nets found in literature differ slightly in detailed notation (Wang, 2007; 
Breitling et al., 2008).  Following Wang (2007), Petri Nets can be defined as a quintuple (𝑃, 
𝑇, 𝐼, 𝑂, 𝑀0): 
 𝑃 = {𝑝1, 𝑝2, … , 𝑝𝑛}  and 𝑇 = {𝑡1, 𝑡2, … , 𝑡𝑚} are finite sets of places and transitions in 
which 𝑃 ∪ 𝑇 ≠ ∅ and  𝑃 ∩ 𝑇 = ∅ 
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 𝐼: 𝑃 × 𝑇 → 𝑁 describes an input function defining edges originating from pre-places, 
with 𝑁 being a non-negative integer set 
 𝑂: 𝑇 × 𝑃 → 𝑁 describes an output function defining edges linking transitions to post-
places, similarly, 𝑁, is a set of non-negative integers 
 𝑀0: 𝑃 → 𝑁 is the initial marking.  
Changing the distribution of tokens, through the firing of enabled transitions in Petri Nets, 
allows the complex and dynamic behaviour of a modelled system to be represented (Wang, 
2007).  The transitions, which can be fired are called ‘Enabled Transitions’.  The transition is 
enabled if the number of tokens marking all pre-places for transitions, 𝑡, are greater than 
the weighting of edges.  To put this another way, for place 𝑝:  
𝑀(𝑝) ≥ 𝐼(𝑡, 𝑝) 
Since enabled transitions are the only ones that can fire, the markings on places can only be 
non-negative integer values.  When a transition fires, tokens marking pre-places are 
removed by the amount equal to the weighting of the edges connecting the place to the 
transition (Wang, 2007), as shown in Figure 1.4.4a.  Concomitantly, tokens are added to the 
post-places with the increase in marking being equal to the weighting of edges linking the 
transition to the place (Ibid).  The new marking, 𝑀′, can be described mathematically in the 
following way for transition, 𝑡, and place, 𝑝: 
𝑀′(𝑝) = 𝑀(𝑝) − 𝐼(𝑡, 𝑝) + 𝑂(𝑡, 𝑝) 
 
 
Equation 1.4.4b 
Equation 1.4.4a 
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Figure 1.4.4a – Example of a Simple Petri Net.  Taken from Wang (2007), this Petri Net contains 
three transitions (𝑡1, 𝑡2 and 𝑡3) and four places (𝑝1, 𝑝2, 𝑝3 and 𝑝4).  Given Petri Nets are a form of 
bipartite graph, places can only be linked to transitions and vice versa.  Edges are used to link 
places to transitions and transitions to places.  The edge linking the pre-place 𝑝1 to transition 𝑡1 
has a weighting of two, meaning two tokens of species 𝑝2 are required for the transition to fire.  
Once 𝑡1 fires, two tokens of the post-place, 𝑝2, and one token of post-place, 𝑝3 are produced.  
Only one token of places, 𝑝2 and 𝑝3 are required to fire transitions, 𝑡2 and 𝑡3, respectively.  The 
firing of either of these transitions results in the movement of one token, in each iteration of the 
model, to place, 𝑝4. 
𝑝1 
𝑝3 
𝑝2 
𝑝4 
𝑡1 
𝑡2 
𝑡3 
2 
2 
 Page 58 
 
In the following case study, taken from Wang (2007), the state of the Petri Net shown in 
Figure 1.4.4a, can be described in the following way (Equations 1.4.4c – 1.4.4k): 
𝑃 = {𝑝1, 𝑝2, 𝑝3, 𝑝4} ; 
𝑇 = {𝑡1, 𝑡2, 𝑡3, 𝑡4} ; 
𝐼(𝑡1, 𝑝1) = 2, 𝐼(𝑡1, 𝑝𝑖) = 0 for 𝑖 = 2, 3, 4 ; 
𝐼(𝑡2, 𝑝2) = 1, 𝐼(𝑡2, 𝑝𝑖) = 0 for 𝑖 = 1, 3, 4 ; 
𝐼(𝑡3, 𝑝3) = 1, 𝐼(𝑡3, 𝑝𝑖) = 0 for 𝑖 = 1, 2, 4 ; 
𝑂(𝑡1, 𝑝2) = 2, 𝑂(𝑡1, 𝑝3) = 1, 𝑂(𝑡1, 𝑝𝑖) = 0 for 𝑖 = 1, 4 ; 
𝑂(𝑡2, 𝑝4) = 1, 𝑂(𝑡2, 𝑝𝑖) = 0 for 𝑖 = 1, 2, 3 ; 
𝑂(𝑡3, 𝑝4) = 1, 𝑂(𝑡3, 𝑝𝑖) = 0 for 𝑖 = 1, 2, 3 ; 
𝑀0 = (2 0 0 0)
𝑇 
If the enabled transition 𝑡1 then fires, the new marking becomes: 
𝑀1 = (0 2 1 0) 
The distribution of tokens following this is such that sufficient tokens are then present to 
enabled transitions 𝑡2 and 𝑡3 (Wang, 2007).  If 𝑡2 fires next, the token markings become: 
𝑀2 = (0 1 1 1) 
Should 𝑡3 then fire, the new token marking series would become: 
𝑀3 = (0 1 0 2) 
Equation 1.4.4c 
Equation 1.4.4d 
Equation 1.4.4e 
Equation 1.4.4f 
Equation 1.4.4g 
Equation 1.4.4h 
Equation 1.4.4i 
Equation 1.4.4j 
Equation 1.4.4k 
Equation 1.4.4l 
Equation 1.4.4m 
Equation 1.4.4n 
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In the Standard Petri Net formulation described so far, there is only one type of an edge 
linking places and transitions.  In Extended Petri Nets, additional edge types are used to 
introduce additional rules.  To model the action of enzymes and catalysis in biochemical 
systems, a read edge is used to link a pre-place to a transition (Breitling et al., 2008).  If this 
pre-place is marked with the necessary number of tokens, the transition is enabled.  The 
tokens marked on this pre-place are not consumed during the firing.  Similarly, inhibitory 
edges are used to express the act of inhibition (Ibid).  If a pre-place is linked to a transition 
through an inhibitory edge and this pre-place is marked with an adequate number of tokens 
to overcome the threshold value, then the firing of the transition is inhibited.  An example of 
a Petri Net containing these differing types of edges is given in Figure 1.4.4b which also 
illustrates how the Extended Petri Net notation can be used to construct signalling cascades. 
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Figure 1.4.4b – Extended Petri Net Notation.   i.    The extended Petri Net notation includes read edges to 
simulate the action of an enzyme.  In this pre-place, linked to a transition by such an edge must be marked with 
sufficient tokens to overcome the threshold to satisfy the firing rule but these tokens are not consumed during 
the firing of the transition.  An inhibitor edge is used to simulate the action of an inhibitor.  When the inhibitor 
is marked with sufficient tokens, the transition it is linked to is inhibited.  When the inhibitor is absent the 
transition is capable of firing.  ii. Many examples of enzymatic cascades exist in molecular biology.  The 
Extended Petri Net notation enables the construction of enzymatic cascades, including the Mitogen-Activated 
Protein Kinase cascades.  In such a cascade, the most upstream kinase (here KinaseA) is activated by 
phosphorylation in response to a particular environmental stimulus activating a receptor.  In the 
phosphorylated form, pKinaseA is able to activate via phosphorylation, a further kinase (KinaseB).  In this 
example phosphorylated KinaseB (pKinaseB) can phosphorylate KinaseC.  Phosphorylated KinaseC (pKinaseC) 
would then be free to act on downstream effectors, such as further kinases or transcription factors.  Individual 
reactions, or transitions in Petri Net terminology, are denoted as R1 to R6.   The forward reactions (R1, R3 and 
R5) are responsible for converting kinases to the phosphorylated kinases whereas reverse reactions (R2, R4 and 
R6) are those that mediate the dephosphorylation of kinase.  Such dephosphorylation of kinases would 
normally require the action of a phosphatase. 
ii 
i 
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Petri Net semantics refers to the algorithm used to fire enable transitions and the rules that 
govern which transitions are enabled.  Simulations, within Petri Net terminology, are 
referred to as Token Game simulations, with the result of such a simulation being termed a 
‘trajectory’ or ‘trace’ (Breitling et al., 2008).  In the semantics used in the example above 
(Figure 1.4.4b), if sufficient numbers of tokens are present in each pre-place, a transition is 
enabled (Ibid).  The simulation algorithm randomly chooses and fires one transition from a 
list of enabled transitions, in each iteration.  In such Petri Net simulations, the probability of 
selecting an enabled transition is equal for all enabled transitions (Breitling et al., 2008) and 
generates a trajectory detailing state changes but where such changes are not assigned 
times.  However, it is possible to determine if one transition is fired before or after another 
(Breitling et al., 2008).  Consequently, such a simulation is frequently termed time free. 
The full dynamic simulation where integer token numbers represent physical quantities 
changing in real time can be performed with Stochastic Petri Nets, where the rules of the 
Gillespie algorithm are used to fire transitions and calculate waiting times.  Each transition is 
assigned a propensity function calculated as a product of the pre-place markings and 
stochastic rate constant of the transition.  The Gillespie algorithm (discussed in Section 1.4.1 
– Exact Stochastic Simulations with the Gillespie Algorithm) is then used to determine 
which transition will occur next and after what waiting time.  Subsequently, a selected 
transition is fired and time is increase by the waiting time.   
It is possible to implement ODE simulations within Petri Nets.  In a Continuous Petri Net 
real, rather than integer, numbers of tokens are used.  The rate equations are then assigned 
to transitions and ODEs are constructed from the interactions in the Petri Net network 
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(Breitling et al., 2008).  State changes and simulations are carried out using the standard 
methods of numerically integrating ODE systems (Breitling et al., 2008). 
The unique feature of the Petri Net framework, which make it exceptionally suited for the 
modelling of complex biological systems, is the ability to combine multiple Petri Net types in 
to Hybrid Petri Net simulations (Breitling et al., 2007; Ghomri & Alla, 2007).  Rather than 
defining the entire model as Stochastic or Continuous, the Hybrid Petri Nets allow the 
construction of a model from both stochastic and continuous transitions.  Likewise, 
Standard Petri Net places, with integer numbers of tokens, can be used alongside 
continuous places with real number token marking.  Furthermore, the Hybrid Petri Net 
algorithm combines ODE simulations with the Gillespie algorithm to integrate different 
types of places and transitions (Breitling et al., 2007). 
Biological systems involve processes occurring at different spatial and temporal scales (Mast 
et al., 2014).  Different levels of cellular organisations are modelled in different formalisms.  
For example, metabolism is modelled by FBA, while regulatory processes are usually 
modelled at small scale by ODE systems.  As demonstrated above, Petri Nets are likely to 
become a commanding tool in computational systems biology. 
When applied to molecular biology, Petri Nets use places to represent species such as 
proteins, lipids or nucleotides, and transitions to denote the interactions and reactions 
between places.  Tokens denote the number of molecules and allow Token Game 
simulations to be executed.  In qualitative simulations, Token Game simulations represent 
‘abstract quantities whose changes, over time, correlate to changes that occur in the 
amounts of active proteins present in the cell’ (Ruths et al., 2008).  As remarked by Ruths 
and colleagues (2008), the ‘abstract’ numbers of tokens are similar to the qualitative levels 
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of proteins visualised in Western Blots.  Should quantitative parameters be available it is 
possible to use Stochastic Petri Nets.  Here the numbers of tokens marking a place represent 
the number of molecules directly.  For concentrations to be modelled, Continuous Petri Nets 
may be used. 
Section 1.4.5 – The Quasi-Steady State Petri Net Algorithm 
The Quasi-Steady State Petri Net (Fisher et al., 2013) is a recent extension to the Petri Net 
framework inspired by Systems Biology.  The Hybrid Petri Nets are capable of integrating 
Gillespie algorithm and ODE simulations.  The QSSPN algorithm allows further integration of 
Hybrid Petri Nets with Flux Balance Analysis, thus providing a unified framework for all three 
major algorithms of Computational Systems Biology.   
This project uses the QSSPN simulation engine (Fisher et al., 2013) to conduct all 
simulations.  While the majority of the simulations presented in this dissertation could have 
been done with standard Petri Net tools, QSSPN was chosen to allow the integration of 
models developed in this project with GSMNs in Chapter 5 – Integration of the 
Translational Control Model with a Genome Scale Metabolic Network of a RAW 264.7 Cell.  
Given that QSSPN is still a new approach and that the software is used extensively as a 
simulation engine throughout this project, it is necessary to provide extensive background 
to this method. 
In QSSPN models, the transitions are divided into two sets: quasi-steady state fluxes (QSSF) 
and dynamic transitions (DT) (Fisher et al., 2013).  The method then assumes quasi-steady 
state: following any state change resulting from DTs, the QSSF quickly reaches steady state.  
This requires time scale separation between two parts of the model with DTs being much 
slower than QSSF (Ibid).  This assumption is motivated and satisfied by biological systems 
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where metabolic reactions are much faster than gene regulation and signalling processes.  
The assumption that following state changes in the dynamic regulatory network, the 
metabolic network quickly reaches steady state has already been used to integrate Boolean 
models and ODEs with FBA.  The result of such integrations are rFBA (Covert et al., 2001) 
and iFBA (Covert et al., 2008).  In QSSPN, the DT part of the model is described by Hybrid 
Petri Net semantics allowing both stochastic and continuous transitions, while QSSF is 
simulated in the Flux Balance Analysis framework.  This makes QSSPN the first algorithm 
allowing integration of all three major frameworks of Computational Systems Biology: exact 
stochastic simulations, ODEs and FBA (Fisher et al., 2013). 
The integration of QSSF and DT parts of the model is achieved through the introduction of 
two new types of places: Constraint Places and Objective Places (Fisher et al., 2013).  The 
marking of the Constraint Place is determined by a dynamic simulation.  The Constraint 
Place then translates the marking to FBA flux bounds of selected transitions in QSSF (Ibid).  
The Objective Place requests evaluation of the objective function and then translates the 
value of this objective function into a marking.  For example, if an FBA model of glycolysis 
were to be linked to a Petri Net signalling network, the integration could be achieved by 
using a glycolytic enzyme regulated by the signalling network.  A glycolytic enzyme, such as 
Phosphofructokinase, featured in the Petri Net model would serve as the Constraint Place.  
This place would contain information on the flux boundaries of the reaction catalysed by 
Phosphofructokinase in the form of an activity table.  Such a table would state that if 
Phosphofructokinase is marked with one token, the flux boundary is set, for example, at 
(0.0, 100,000).  However, if the enzyme is not marked with tokens, the FBA reaction would 
be inactive with flux bounds set at (0.0, 0.0) (Fisher et al., 2013).  When the QSSPN 
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simulation is carried out, the qualitative Petri Net model would mark Phosphofructokinase 
with a token.  This would then update the flux bounds of the FBA model and, ultimately, the 
objective function representing the metabolic function of interest, such as maxiamal Acetyl 
Coenzyme A (Acetyl-CoA) production.  This objective can then be represented as an 
Objective Place and objective function fed back to the dynamic part of the model.  For 
example, one could set the activity table stating that if maximal Acetyl-CoA production is 
greater than zero, the Objective Place is marked with one token.  Should this condition not 
be satisfied then no tokens would mark the Acetyl-CoA place.  Given the diverse roles of 
glycolysis and Acetyl-CoA (Moussaieff et al., 2015), or metabolites in general, the integration 
of FBA models with Petri Net models would allow for a more complete understanding of 
how metabolic shifts are affected by cellular signalling pathways and vice versa. 
QSSPN uses a general formulation of a propensity function for each transition to facilitate 
qualititative simulations with thresholds (Fisher et al., 2013), as shown in Equation 1.4.5a: 
𝑃𝑡 = 𝑐𝑡∏𝜇𝑖(𝑥𝑖)
𝑁
𝑖=1
 
Where 𝑃𝑡 and 𝑐𝑡 describes the propensity function and rate constant of transition 𝑡, 
respectively.   𝑁 is the number of pre-places for transition 𝑡, and 𝑥𝑖  is the marking of pre-
place 𝑖.  The variable 𝜇𝑖 describes the acitivty of pre-place 𝑖 in the transition as a function of 
its marking.  The activity function, 𝜇, is a look-up table (Equation 1.4.5b) defining the 
contribution of a pre-place to a propensity function of a specific transition (Fisher et al., 
2013).  Within this table, 𝑇 thresholds, 𝑡𝑖, and activities, 𝑎𝑖, are contained and permit the 
pre-place contribution to be calculated. 
Equation 1.4.5a 
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𝜇(𝑥) = {
𝑥 ∈ [𝑡1, 𝑡2), 𝜇(𝑥) = 𝑎1
𝑥 ∈ [𝑡𝑖, 𝑡𝑖+1),      𝜇(𝑥) =  𝑎𝑖
…
𝑥 ∈ [𝑡𝑇−1, 𝑡𝑇),     𝜇(𝑥) = 𝑎𝑇
} 
For example, when the marking of the pre-place 𝑖 in transition 𝑡 exceeds the threshold 𝑡2, 
but is smaller than the threshold 𝑡3, the activity function contributes value 𝑎3 (Fisher et al., 
2013). 
Be it stochastic, continuous or immediate, the transition type lends an interpretation of the 
propensity function of the transition.  Regardless of the transition type, a propensity 
function equal to zero denotes a disabled transition (Fisher et al., 2013) as it cannot fire in a 
stochastic simulation scenario and does not contribute any state change in continuous 
simulations.  In the case of stochastic transitions, the propensity function is interpreted as 
the probability density of a transition firing in the next infinitesimally small timestep.  For 
continuous transitions, the propensity function is used as the reaction rate in the ODE 
simulation part of the hybrid algorithm.  Immediate transitions are only capable of firing 
when the propensity function is non-zero (Ibid).  Each such transition is then only fired once 
(Fisher et al., 2013).  Both continuous and immediate transitions are fired according to the 
function ‘fireDeterministicTransitions(Δ𝑡) (Ibid).  The ODE part of the hybrid algorithm has 
undergone significant upgrade since the first version of QSSPN solver was published in 2013. 
Technical details of an adaptive timestep ODE solver used within 
‘fireDeterministicTransitions(Δ𝑡)’  function are beyond the scope of this dissertation. 
Based on the marking of a constraint place, the upper- and lower-bounds of the fluxes in the 
QSSF model component are set using another look-up table (Equation 1.4.5c) (Fisher et al., 
2013).  Constraint Places are potentially linked to a number of fluxes within the QSSF model 
Equation 1.4.5b 
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component.  The look-up table related to a specific Constraint Place, using the number of 
tokens marking this node, sets the bounds of the fluxes (Fisher et al., 2013).  In the 
simplified example above, such as Constraint Place would be Phosphofructokinase.  The 
function (setQSSFbounds()) is used to this end (Ibid). 
(𝑙𝑏(𝑥), 𝑢𝑏(𝑥)) =
{
 
 
𝑥 ∈ [𝑡1, 𝑡2),            𝑙𝑏(𝑥) = 𝑓𝑙,1,          𝑢𝑏(𝑥) = 𝑓𝑢,1
𝑥 ∈ [𝑡𝑖 , 𝑡𝑖+1), 𝑙𝑏(𝑥) = 𝑓𝑙,𝑖,           𝑢𝑏(𝑥) = 𝑓𝑢,𝑖 
…
𝑥 ∈ [𝑡𝑇−1, 𝑡𝑇),       𝑙𝑏(𝑥) = 𝑓𝑙,𝑇 ,           𝑢𝑏(𝑥) = 𝑓𝑢,𝑇}
 
 
 
 
In this look-up table, the upper and lower bounds of flux are described by the variables 
𝑢𝑏(𝑥) and 𝑙𝑏(𝑥), respectively, while the 𝑥 denoted the the number of tokens, or state of 
the node (Fisher et al., 2013).  The variables describing the number of token thresholds are 
given by 𝑡1, … , 𝑡𝑇.  𝑓𝑙,𝑖 and 𝑓𝑢,𝑖, according to the state of the node, are the lower and upper 
flux bounds respectively (Fisher et al., 2013).  A Boolean variable (‘UpdateRequired’) set to 
TRUE is required to trigger an evaluation of the objective function of the FBA model 
component if the the lower or upper flux bounds change.  Once this has occurred, and prior 
to the looping over of Constraint Place, the Boolean variable is re-set to FALSE (Ibid). 
A QSSPN simulation, via the function evaluateObjective(), uses an Objective Place, for 
example Acetyl-CoA in the simplified case given earlier in this section, to evaluate the 
objective function in an FBA model.  Within the QSSF model component, the objective 
function may be a flux name or metabolite name.  As has been stated previously, the 
objective function is maximised by the Simplex algorithm (or other Linear Programming 
methods) in the case of the former, or, in the latter, by maximising the sums of the fluxes 
producing the objective function metabolite (Fisher et al., 2013).  The most computationally 
Equation 1.4.5c 
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demanding stage of the QSSPN algorithm occurs when the objective function requires 
evaluation by linear programming-mediated maximisation of the entire QSSF model 
component (Ibid).  Such evaluation of the objective function comes about through the 
variable ‘UpdateRequired’ being set to TRUE.  Moreover, such a variable ensures that the 
evaluation only occurs when the QSSF bounds have changed (Fisher et al., 2013). 
The dynamic part of the model requests information evaluation of the capabilities of steady 
state metabolism using the function, updateObjectiveNode() (Fisher et al., 2013).  Such a 
function, based upon the value of the objective function, sets the state of an Objective 
Place.  The state of the Objective Place is set using another look-up table (Fisher et al., 2013) 
(Equation 1.4.5d). 
𝑥(𝑜) = {
𝑜 ∈ [𝑡1, 𝑡2),                    𝑥(𝑜) = 𝑠1
𝑜 ∈ [𝑡𝑖, 𝑡𝑖+1),                 𝑥(𝑜) = 𝑠𝑖
…
𝑜 ∈ [𝑡𝑇−1, 𝑡𝑇),               𝑥(𝑜) = 𝑠𝑇
} 
In this, 𝑥(𝑜) is the state of the Objective Place.  Variable 𝑡1, … , 𝑡𝑇 defines the objective 
function thresholds while 𝑠1, … , 𝑠𝑇 are integer token numbers marking an objective node 
(Fisher et al., 2013).  The number of tokens marking this Place are determined by the 
magnitude of the objective function.  In this look-up table, the variable 𝑜 denoted the 
objective function (Ibid).  The calculation of the objective function value is performed by the 
variable ‘evaluateObjective()’ (Fisher et al., 2013). 
Boolean values are used to fire any transitions requiring a delay of (𝑡, 𝑡 + 𝑡).  TRUE or FALSE 
values are returned when such transitions are present or absent, respectively (Fisher et al., 
2013).  When a delayed transition is fired, at the scheduled time (𝑡𝑠), the simulation 
timestep (∆𝑡) is set to (𝑡𝑠 − 𝑡).  In a system with multiple delayed transitions, these are fired 
Equation 1.4.5d 
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sequentially with the order being determined by the magnitude of the 𝑡𝑠 (Fisher et al., 
2013).  The function ‘fireDelayedTransition(𝑡, 𝑡)’ is used for handling delayed transitions.  
Stochastic transitions with a non-zero delay time are handled by including them with 
delayed transitions using the function ‘scheduleDelayTransition(𝑚)’.  The delay of stochastic 
transitions is governed by the waiting time calculated using the Gillespie algorithm (Fisher et 
al., 2013).   
Now that basic operations within QSSPN method have been defined, it is possible to outline 
the algorithm.  The algorithm begins by evaluating the number of tokens marking each 
Constraint Place.  The state of these nodes updates the bounds of the QSSF model 
component.  The objective function of the Objective Place is then determined using FBA 
maximisation (Fisher et al., 2013).  Following this, using the processes described above, 
immediate and continuous transitions followed by stochastic transitions are executed. The 
firing of stochastic transitions is governed by the Gillespie algorithm (described in detail in 
Section 1.4.1 – Exact Stochastic Simulations with the Gillespie Algorithm).  Synchronisation 
of stochastic immediate and continuous transitions is implemented using the Maximal 
Timestep Method algorithm (Puchalka & Kierzek 2004). Delayed stochastic transitions are 
permitted.  Repeated iterations of this lead to the generation of simulation trajectories.  
Such trajectories are dynamic and permit the order of transition execution to be monitored.  
This allows identification of the effects of altering the initial marking of Constraint Places on 
the Objective Place and the associated objective function (Fisher et al., 2013).  The 
algorithm is summarised in Figure 1.4.5a. 
 
 
 Page 70 
 
 
Figure 1.4.5a – Summation of the QSSPN Algorithm.  Taken from Fisher et al. (2013), this figure 
summarises how the QSSPN algorithm orders various types of transitions and integrates the differing 
model types that form a QSSPN model. 
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Section 1.4.6 – Translation of Petri Net Terminology for a Molecular Biologist 
When applied to molecular biology, Petri Nets use places to represent molecular species 
such as proteins, lipids or nucleotides, and transitions to denote the interactions between 
the molecules (Breitling et al., 2008).  In this notation, marking of Petri Net places 
represents amounts of molecular species.  In Stochastic Petri Nets, the integer number of 
tokens represents numbers of molecules in the volume of the cell, cellular compartment or 
cell micro-environment.  In Continuous Petri Nets, the marking is a real number 
representing molecular concentrations.  In qualitative simulations, the integer number of 
tokens represents abstract, discrete activity levels.  As remarked by Ruths and colleagues 
(2008), the ‘abstract’ numbers of tokens are similar to the qualitative levels of proteins 
visualised in Western Blots. 
This project capitalised on the Extended Petri Net graphical notation.  The read edges used 
in the model of translational regulation created in this project denoted activation where, for 
example, there is a requirement for an enzyme or molecular co-factor that is not consumed 
by the reaction.  Inhibitory edges are used in situations where there is a need to represent 
inhibition: the reaction rate is decreased by the presence of the inhibitor and, furthermore, 
the inhibitor is not consumed by the transition. 
In the opinion of this author, one of the major challenges of interdisciplinary research is that 
it requires researchers, working in different, well established scientific fields, to agree on 
common terminology.  The development of such a common language is frequently more of 
a social than scientific issue: the experts in individual fields have to accept that the language 
in which interdisciplinary research is conducted will be different than the frequently strict 
terminology of their field of expertise.  This frequently creates barriers to interdisciplinary 
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work.  This project is a good example of such a challenge.  Should it use Petri Net 
terminology which is acceptable to Petri Net experts, but difficult to read for a molecular 
biologists or should it use molecular biology terminology that a Petri Net expert may find 
inacceptable as a language of algorithm description?  Should the variable of interest be 
referred to as places or molecular species?  Should mathematical terms that change 
variables be called transitions or interactions? 
This project will use original Petri Net terminology in the above sections (Section 1.4.4 – The 
Petri Net Formalism and Section 1.4.5 – The Quasi-Steady State Petri Net Algorithm), 
where Petri Net methodology is described.  However, subsequent chapters will use 
molecular biology terminology and will refer to the Petri Net terms in the way given at the 
start of this section.  This project uses published computational methods to investigate 
biological problems.  It does not introduce new algorithms.  The results of this project are in 
the biological domain and will therefore be described in the language appropriate to 
molecular biology. 
Section 1.5 – Aims & Objectives and Novel Contributions 
to Knowledge 
Section 1.5.1 – Aims & Objectives 
This project encompasses two main areas: first, the modelling of mammalian translation 
initiation and the upstream regulatory pathways and secondly, modelling the effects viral 
infection has upon this process.   
The factors involved in translation initiation and the regulation of this process are known to 
play roles in the pathogenesis of medically important disease states, including heart 
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diseases (Lu et al., 2014), cancer (Heikkinen et al., 2013) and neurological disease (Li et al., 
2004; Li et al., 2005a).  A better understanding of this process, and also the regulatory 
pathways surrounding it, are essential to understanding the pathology of human and animal 
disease. To this end, the overall aim of this project can be regarded as: 
Constructing and experimentally validating a literature-based, qualitative model of 
translation initiation and the signalling network that regulates this process in mammalian 
cells. 
In terms of the second aspect of this project, viral infection, at least from a systems biology 
standpoint, can be viewed as ‘equivalent to a systems-level perturbation’ to the cell 
(Garmaroudi et al., 2010).  Investigating the effects viral infection has upon the cellular 
translational machinery has not been attempted.  The second part of the project is to model 
viral infection.  The aim of this part of the project is to:  
Introduce the host-pathogen interactions into the model of translational regulation and 
establish the effects of these interactions on both the cellular translational machinery and 
the regulatory signalling network.   
The specific objectives of this work are: 
 Construct and iteratively refine a large-scale, qualitative model representing cellular 
translation initiation and the signalling pathways involved in regulating this process 
in a mammalian system 
 Validate the predictive power of this model by a comparison of model behaviours 
with literature data 
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 Apply the model to generate novel hypotheses on the regulation of translation 
initiation and experimentally validate these hypotheses  
 Simulate the effects of viral infection and experimentally validate predicted 
behaviours 
 Improve the predictive power of the model through the incorporation of detailed 
kinetic models of major regulatory hubs into the large-scale qualitative model 
 Integrate the model of translational regulation with a GSMN to facilitate the study of 
the coordinated translational regulation with whole-cell metabolic reprogramming 
Section 1.5.2 – Novel Contributions to Knowledge 
This project produced a number of key outputs which can be regarded as novel.  These 
include: 
 The production of an experimentally validated model from over 1,100 pieces of 
peer-reviewed literature of mammalian translation initiation regulated by a 
large-scale signalling network 
 Developing a benchmark concerning the effects of chemical inhibitors on key 
signalling effectors and using this to develop a method for the quantitative 
analysis of the predictive power of the model 
 Theoretical insight into the mechanism by which Rapamycin-mediated mTORC1 
inhibition can lead to an increase in eIF4E phosphorylation. 
 Extending and experimentally validating the model to investigate the effects of 
viral infection upon the translational machinery and the regulatory signalling 
network 
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 Constructing a model setting the foundation of work looking to link the 
regulation of translation initiation to the regulation of metabolism 
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Chapter 2 – Model Creation & 
Refining 
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The construction of the model of translation initiation regulated by a large-scale signalling 
network was the main aim of this project.  This chapter describes the work undertaken to 
not only construct the model from existing literature, but also to evaluate the predictive 
power of the model.  Furthermore, detailed in this chapter is work to establish a mechanism 
by which the main model prediction occurs. 
Section 2.1 – Materials & Methods 
Section 2.1.1 – Qualitative Petri Nets 
Despite recent advances in quantitative computational biology, it is still not possible to 
establish the rate constants of all the molecular interactions in large-scale models (Di 
Ventura et al., 2006).  A solution to this challenge, which is gaining acceptance in the 
literature is to use qualitative, time-free Petri Net modelling (Ruths et al., 2008; Fisher et al., 
2013).  The Petri Net methodology has been described in Section 1.4.4 – The Petri Net 
Formalism.  This Section and Section 2.1.2 – The Binary Model Formalism describe details 
of the specific time-free Petri Net approach used to build the translation initiation model.  
The terminology of the Petri Net field is translated into the vernacular more suited to 
molecular biology in Section 1.4.6 – Translation of Petri Net Terminology for a Molecular 
Biologist. 
This dissertation presents an Extended Petri Net model encompassing the translational 
machinery and surrounding signalling pathways.  Places represent molecular species and 
transitions denote the interactions between molecules.  Read edges model the activation of 
interactions by certain molecular species and inhibitory edges are used to model the act of 
inhibition.  Since there is an absence of sufficient quantitative information regarding the 
numbers of molecules in the cell to parameterise large-scale models, discrete activity levels 
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were used to represent molecular activity levels.  Likewise, the time is not parameterised to 
time units.  Time is exclusively used to state the order in which molecular interactions 
occurred during simulations.  Therefore, the model is used to simulate the sequence of 
molecular events changing the activity levels of molecular species.  In subsequent parts of 
this thesis, the sequence of molecular events will be referred to as a ‘trajectory’. 
Section 2.1.2 – The Binary Model Formalism 
The definition of the molecular activity levels, and the rules describing how molecular 
interactions change them, is the key aspect of the qualitative modelling approach.  One 
possibility involves using multiple activity levels representing concentration ranges of 
molecular species.  Activity levels are represented by integer numbers (tokens (or discrete 
activity levels)) and changed by interactions decreasing states of substrates (or pre-places in 
Petri Net parlance) and increasing the states of products (post-places).  Calder et al. (2005) 
analysed different maximal numbers of discrete activity levels in qualitative models of 
signalling pathways and concluded that experimental data can be approximated with ten 
levels.  Ruths and colleagues (2008) used a different strategy placing certain discrete activity 
levels numbers in the initial state of the signalling network and allowing Petri Net molecular 
interactions to exchange them without setting any upper limit.  The number of discrete 
activity levels was then considered to be proportional to the concentration of that particular 
molecular species (Ibid). 
The aim of this project is to build a large-scale model of the signalling network controlling 
protein synthesis.  The resulting model is considerably larger than previously published 
discrete models (Calder et al., 2005; Ruths et al., 2008).  For that reason it has been very 
difficult to calibrate the maximal number of discrete activity levels, or maximal numbers of 
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tokens, in the initial state.  To do this, calibration would have to be repeated for every new 
version of the model as substantial increases to the model, in terms of scale and complexity, 
could potentially affect the choice of arbitrary discretisation of parameters such as maximal 
numbers of activity levels or the numbers of tokens in the initial states.  Evaluation of the 
predictive power of the large-scale model is a complex exercise and it was not practical to 
repeat it frequently enough to optimise discretisation during model development.  
Therefore, more abstract, binary modelling formalisms have been developed, where 
molecular species were considered to be active or inactive and intermediate activity states 
were not considered.  The original contribution of this work is the approach of setting the 
rules changing active/non-active species states, in such a way that biological processes are 
reflected with sufficient realism, to achieve statistically significant and applicable predictive 
power. 
This work employs the following binary modelling approach.  Each molecular species in the 
network can have either zero or one discrete activity levels.  The state of zero discrete 
activity levels indicates that the molecular species is not present, in a sufficient amount, 
to activate interactions it initiates or is a substrate in.  The state of one discrete activity 
level indicates that there is a sufficient amount of a molecular species to ensure that 
molecular interactions consuming this species, or are activated by this species, can take 
place.  While the state of one corresponds to a higher amount than a state of zero, the 
proportionality between amount and discrete level is not assumed.  This is justified by the 
fact that many, if not most, reactions in the signalling network follow a sigmoidal 
input/output relationship (Kothamachu et al., 2013). 
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Having this basic notion of a molecular species present in a sufficient amount to activate a 
downstream molecular process, one can proceed to the construction of the signalling 
network model.  The elementary step of signalling transduction is an enzyme-catalysed 
covalent modification of a protein molecular species.  Protein A is modified by the 
attachment of a chemical moiety, such as phosphorylation, acetylation and ubiquitination.  
In a modified form, Protein A can be considered to be a distinct chemical species, termed 
Protein B.  Enzyme E is a protein that catalyses this post-translational modification of 
Protein A.  In this signalling cascade, Protein B is an enzyme catalysing the next step of signal 
transduction and E is a protein activated by covalent, post-translational modification during 
the previous step.  This signalling network could not function if the activation of B was 
permenant as it would lead to the permanent activation of downstream processes, even 
when the external signal initiating this cellular response, for example a cytokine, was no 
longer present.  In the cell, covalently modified proteins are inactivated, either by the 
removal of the chemical moiety or by the degradation of a protein.  Both of these processes 
are catalysed by specific enzymes, for example, phosphatases or a proteasome complex.  In 
both cases the signalling system is returned to a basal level of activity and is ready to 
respond to a new round of stimulation.  If Protein B is inactivated by the removal of the 
post-translational modification, then the concentration of Protein B falls and a concomitant 
rise in the concentration of Protein A is observed.  In this case the concentration of Protein 
B returns to a basal level.  However, in the case of the degradation of Protein B, the amount 
of Protein A is maintained by constitutive protein synthesis.  Frequently, the literature 
describing signal transduction networks describes the events of covalent modification 
leading to forward propagation of the signal. The details of the biological mechanisms 
surrounding how a return to the basal levels of signalling components is achieved, upon 
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removal of the stimulus, remain largely undefined.  In order to make a model as realistic as 
possible, one still needs to assume the existence of mechanisms to effectively ‘switch off’ 
signal propagation, and ensure the system returns to a basal state capable of reacting to 
repeated exposure to the stimulus. 
Figure 2.1.2a shows formalism used in the construction of the binary model, using the 
information presented earlier in this chapter, to represent the basic signal transduction 
step.  First, the connectivity of molecular species and biological processes are modelled 
using the Extended Petri Net formalism (detailed in Section 1.4.4 – The Petri Net 
Formalism), as shown in Figure 2.1.2ai.  In reaction r1, Protein A is covalently modified to 
form Protein B.  Common edges are used as this process must decrease Protein A levels in 
order to increase Protein B levels.  Reaction r2 is used to represent the net effect of 
potentially multiple, perhaps not clearly defined, molecular mechanisms that return the 
signal transduction apparatus to a basal level.  This molecular interaction serves to deplete 
the pool of Protein B and increase the level of Protein A and further requires the use of 
common edges.  Enzyme E is connected to reaction r1 by read edges to represent catalysis.  
Where the mechanism underlying reaction r2 can be directly attributed to a specific 
enzyme, for example a phosphatase, a read edge would also be used.  The situation 
presented here, and in the more common of situations, is where the mechanism of 
inactivation is not known in detail. 
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Figure 2.1.2a – Overview of the Binary Model Formalism.  Despite the advances in computational systems 
biology over the past decade, it is still not possible to produce large-scale quantitative models of biological 
systems (Di Ventura et al., 2006).  In order to construct a biologically meaningful model of mammalian 
translation initiation regulated by a large-scale signalling network it was necessary to introduce the Binary Model 
Formalism.  i. In a basic binary model the amount of a molecular species present can be thought of as the 
amount necessary to induce a particular behaviour.  Consequently, one discrete activity level of sufficient 
amounts of Protein A and Enzyme E are necessary within a cell to enable Protein B formation, through post-
translational modification, in a reaction termed r1.  As Enzyme E is merely a catalyst for r1 this molecular species 
is linked to the reaction via a read edge.  Reaction r2 is the reverse reaction in which the pool of Protein B is 
returned to the basal amount of Protein A, and, in a biological system may require an enzyme such as a 
phosphatase.  Such mechanism are, in many cases, ill-defined but necessary to include in a model of a biological 
system.  ii.  This formalism produces random oscillations which are unrealistic in a biological system as, although 
such systems are stochastic in nature, the majority of Protein A (shown in red) will be modified to Protein B 
(shown in green) until such time as Enzyme E is removed through physiological feedback mechanisms.  iii.  In 
order to eliminate these random oscillations, rules where introduced, via an inhibitory edge between Enzyme E 
and reaction r2, to ensure that until the stimulus (Enzyme E) is removed, the pool of Protein B is maintained to 
allow potential downstream signalling to occur.  iv. The Token Game simulation of this model demonstrates that 
oscillations are removed, with the pool of Protein B (shown in green) being maintained while the amount of 
Protein A (shown in red) is depleted.  v.  It is common in biological systems to contain feedback mechanisms in 
order to allow only the appropriate activation of signalling pathways.  The inclusion of rules in the model 
accounts for such mechanisms.  When the pool of Enzyme E is depleted, possibly due to a feedback mechanism 
originating from Protein B, reaction r2 can then occur to return Protein A to a basal level.  This system is then 
capable of responding, should the cell once again be exposed, to the environmental cue leading to Enzyme E 
activation.  vi.  Following the removal of the Enzyme E-mediated inhibition of reaction r2, the depletion of 
Protein B (shown in green) occurs through the removal of the post-translational modification and restores the 
basal level of Protein A (shown in red). 
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Figure 2.1.2aii shows the trajectory resulting from a Token Game simulation of the model 
presented in Figure 2.1.2ai.  This starts from the state where one discrete activity level is 
assigned to the molecular species representing Protein A, and no discrete activity levels are 
assigned to the Petri Net molecular species representing Protein B.  This dynamic has the 
following interpretation in the modelling framework used over the course of this project: 
The cellular pool of Protein A is depleted below the amount sufficient to allow the enzyme-
catalysed reaction r1 to occur, while the cellular pool of Protein B rises to the level required 
for reaction r2 to happen.  This system then returns to the initial state and the process 
repeats.  The resulting oscillatory nature is unrealistic.  If Protein A and Enzyme E are 
present in the cell, in sufficient amounts to function, the protein pool should shift towards 
the covalently modified form.  This situation should remain until Enzyme E is inactivated by 
an upstream process, in which case the system should return to the basal state.  This 
behaviour is more realistic in a biological system.  It can be achieved by the addition of the 
following rule to the structure of the biological process: Add an inhibitory edge between 
Enzyme E and reaction r2, as shown in Figure 2.1.2aiii.  This rule expresses the following 
biological understanding: If Protein A and Enzyme E are present in sufficiently large 
amounts, the net rate of all elementary molecular processes covalently modifiying Protein A 
is faster than the net rate of molecular processes returning Protein A to a basal level.  The 
Token Game simulation of the modified model is shown in Figure 2.1.2aiv.  The system has, 
therefore, moved to a state where the covalently modified form of the protein is constantly 
at a sufficient amount for the activation of downstream signalling.  The system will remain 
in this state until Enzyme E is depleted, after such time the system will return to a basal 
state, as shown in Figure 2.1.2av and Figure 2.1.2avi. 
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During model reconstruction, care was taken to build the model using the basic motif 
described above, or other simple sub-networks, obviously maintaining the state in {0,1} 
range and connected to the remaining part of the model only by read and inhibitory edges 
that do not need discrete activity levels.  This does not, however, constitute the formal 
proof that under no circumstances will molecular species be assigned two discrete activity 
levels.  Obtaining such proof would require the use of invariant analysis of Petri Net theory 
implemented in tools such as Integrated Net Analyzer (INA) (Roch & Starke, 2003) or Charlie 
(Heiner et al., 2015).  While these tools are integrated with Snoopy, they do not allow the 
analysis of networks that have read and inhibitory edges.  These edges are essential for the 
formulation of the transition rules, required for tackling the biological complexity, present in 
the large-scale model.  Additionally, invariant analysis is prone to a combinatorial explosion 
challenge (Sun & Zhang, 2011) and would be difficult for a full scale model, even assuming 
such a model was constructed as a standard Petri Net.  Consequently, in the absence of a 
practical way of formally verifying that no molecular species in the model presented in this 
dissertation can assume a state of more than one discrete activity level, a feature within the 
QSSPN solver has been used to enforce this condition within the model simulations (Fisher 
et al., 2013).  For any molecular species, the maximal number of discrete activity levels has 
been set to one.  If the simulator attempted to increase the number of discrete activity 
levels to a value of more than one, the number of activity levels was reset to one.  Due to 
the way in which the model was carefully constructed, this condition was rarely, if ever, 
invoked and did not influence conclusions based upon the examination of the large number 
of simulation trajectories. 
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Section 2.1.3 – Model Construction 
Section 2.1.3.1 – General Model Construction Process 
The binary formalism, described in Section 2.1.2 – The Binary Model Formalism, has been 
used to represent literature on molecular events controlling translation initiation in 
mammalian cells.  An illustration of this is shown earlier in Figure 1.1a and again in the 
information detailed in Section 1.1 – Cellular Translation Initiation and Section 1.2 – Key 
Points of Regulation & Upstream Signalling Pathways, as an executable, computational 
model capable of making predictions on the effects of molecular perturbations on the 
initiation of protein synthesis. 
A comprehensive search of the PubMed (US National Library of Medicine, Bethesda, MD 
(US)) database has been conducted for the articles, describing molecular events, in the 
system under investigation.  The use of the PubMed database was to ensure that only peer-
reviewed work was included and that it can be referenced in a rigorous format by giving a 
PubMed Identifier (PMID) numbers.  Given the differences in translation that exist between 
yeast and mammalian cells, such as in the composition of the Multi-Factoral Complex in 
yeast (Fletcher et al., 1999; Bieniossek et al., 2006; Sokabe et al., 2012), the articles 
describing the process in mammalian species have, without exception, been prioritised over 
articles describing the process in yeast.  However, where the process was described only in 
experiments conducted in yeast, this work has been used to fill gaps in the literature.  The 
scope of the literature search has been limited to the signalling pathways that are directly 
involved in the regulation of translation initiation in mammals.  These pathways include the 
PI3K, mTORC1, mTORC2 and the MAPK pathways: ERK1/2, p38α, JNK1 and ERK5.  It was 
decided that these signalling pathways would be extended back to a cell surface receptor 
and a literature search has been conducted accordingly. 
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The experimental biology literature articles, which provide evidence for individual 
interactions, are used to construct the rules of the binary model.  As detailed in Section 
2.1.2 – The Binary Model Formalism, every effort has been made to use the basic switch 
motif, in which the exchange of single discrete activity levels between forms of covalently 
modified proteins is controlled by both read and inhibitory edges.  However, the use of 
more complex motifs has, sometimes, been needed when this was not sufficient to 
represent literature data in a meaningfull and accurate way.  As indicated in a number of 
studies (Wang et al., 2013; Green et al., 2014), there is a growing need for standardised 
nomenclature.  In order to construct the model in a transparent and open way, protein, 
gene and micro RNA (miRNA) components of the model are labelled with Uniprot (The 
Uniprot Consortium, 2014), Entrez (NCBI Resource Coordinators, 2013) and miRBase 
(Kozomara & Griffiths-Jones, 2014) database identifiers, respectively, as shown in 
Supplementary Information E1 (available on the attached Flash Drive).  Similarly, a list of the 
papers used in the construction of the model is available in Supplementary Information E2. 
The focus of this section will now turn to describing the construction of the various parts of 
the model in the software Snoopy (Rohr et al., 2010; Marwan et al., 2012; Heiner et al., 
2012).  Section 1.2 – Key Points of Regulation & Upstream Signalling Pathways details the 
biological particulars of each key pathway included in the model and, as a result, this section 
will focus on illustrating the Petri Net versions of each model pathway and on describing the 
rationale behind the inclusion of various aspects of the pathways. 
The model details the synthesis of nascent polypeptides and describes the assembly of 80S 
ribosome (Figure 2.1.3.1a).  This component of the model was constructed using 
information taken from multiple peer-reviewed literature sources.  As already shown in 
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Figure 1.2a, this component of the model comprises only a small part of the overall model 
produced during the course of this work. 
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Figure 2.1.3.1a – Petri Net Representation of Translation Initiation. Produced in the software Snoopy, the 
translation initiation pathway is represented using the Binary Model Formalism.  This Petri Net model was 
extracted from the large-scale model produced over the course of this project and extends back to include 
the key points of regulation.  Although this figure includes key points of regulation, it is analogous to Figure 
1.1a. 
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One of the pathways most associated with the regulation of translation initiation is that of 
ERK1/2.  As such, it was necessary to include a model of this pathway.  It was decided to 
attempt to use an existing model of the activation of ERK1/2.  The BioModels database (Li et 
al., 2010) was searched for such a model and one was selected (BioModels identifier: 
BIOMD0000000270).  The model constructed by Schilling et al. (2009) concerned the 
activation of ERK1/2 via MEK1/2 in response to known ligand Erythropoietin (Seong et al., 
2006; Nairz et al., 2011).  In order to fully integrate this model, as a qualitative component 
of the larger model, it was necessary to reconstruct the model in the software Snoopy using 
the Petri Net formalism.  This reconstruction of the model involved expressing each reaction 
given in the working version of the model in the software Copasi (Hoops et al., 2006; 
Mendes et al., 2009) to a Petri Net (Figure 2.1.3.1b).  To put this component in the same 
notation as the rest of the model it was necessary to ensure that these molecular 
interactions were expressed using the Binary Model Formalism.  In keeping with the 
qualitative nature of the model, all molecular amounts were replaced with a marking of one 
discrete activity level, which as elsewhere in the model represented an amount of a 
particular molecular species needed to provoke a biological response.  Similarly, all rate 
constants within the model were expressed as one.   
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Figure 2.1.3.1b – Petri Net Representation of the ERK1/2 Signalling Pathway.  The ERK1/2 signalling 
pathway is a canonical component of the cellular signalling network and is integral to the regulation of 
translation initiation.  The model of the activation of ERK1/2 was taken from Schilling and colleagues 
(2009).  Once activated, ERK1/2 was able to phosphorylate numerous downstream components within 
several other signalling pathways.  Within this model, several inhibitors affecting ERK1/2 activation were 
incorporated: 5Z-(7)-Oxozeanol (FR1), PD184352 (PD1) and PD98059 (PD9).  This model was produced as a 
Petri Net using the software Snoopy. 
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Once reconstructed, the integration of this model with the full model was conducted.  This 
was first achieved by linking an early point within the model to an existing model 
component.  In this case it was achieved by linking the activation of the MEK1/2 kinase, Raf-
1 to Ras (MacDonald et al., 1993; Diaz-Meco et al., 1994; Fabian et al., 1994; Leevers et al., 
1994; Stokoe et al., 1994; Jelinek et al., 1996).  The model already contained a number of 
important ERK1/2 substrates, including MNK2 and RSK1, so it was possible to ensure the 
model functioned within the full model.  The final stage of this integration occurred during 
the stages of model refinement.  This included the modification of the model to take into 
account the activation of ERK1/2 through additional pathways.  These pathways included the 
Nuclear Factor-κB-induced kinase, Tumour Progression Locus 2 (Tpl2) (Dumitru et al., 2000; 
Eliopoulos et al., 2003; Rousseau et al., 2008; López-Pelaéz et al., 2012; Roget et al., 2012; 
Hirschhorn et al., 2014) and PKCζ (Monick et al., 2000; Lesseux et al., 2008). 
The other MAPK pathways were included in the model as they form part of the network that 
regulates the translational machinery.  The primary role of p38α in the regulation of 
translation is given in Section 1.2.2 – eIF4E Phosphorylation and The Role of ERK1/2 & p38.  
This pathway (Figure 2.1.3.1c) was reconstructed in the model from published, peer-
reviewed literature.  Reconstructing this pathway necessitated including not only the kinases 
involved in the activation of p38α, but also to extend this pathway to a cell-surface receptor.  
In the case of p38α, this receptor was TLR4.  It was not necessary to include this receptor per 
se, as a basal level of p38α has been reported in a number of cell-types, including the type 
used to experimentally validate the predictions generated by the model produced during the 
course of this work (detailed in Chapter 3 – Experimental Validation of Model Predictions) 
(Hsieh & Papaconstantinou, 2002; Carrozzino et al., 2009; Naidu et al., 2009; Bouazza et al., 
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2014). However, for completeness and to allow the effect of LPS stimulation to be studied in 
future, it was included. 
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Figure 2.1.3.1c – Petri Net Representation of the p38α Signalling Pathway.  The p38α signalling pathway 
regulates translation through controlling eIF4E phosphorylation and mRNA stability.  This kinase plays a 
role in regulating many other processes in the cell.  This pathway is extended back to Toll-Like Receptor 4.  
Key points of cross-talk between other signalling pathways are also included.  These include the negative 
regulation of Protein Kinase C ζ (PKCζ) and the inhibition of p38α by AKT1.  This model was created in the 
software Snoopy in the Petri Net notation.  
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The JNK1 pathway (Figure 2.1.3.1d) was constructed in much the same way, in that the 
pathway was extended back to a cell-surface receptor and that a basal level of activity 
(Javelaud et al., 2003; Sabapathy et al., 2004; Carrozzino et al., 2009; Cui et al., 2009; Zhu et 
al., 2016) was maintained.  With regards to the activation of JNK1 the model included the 
requirement, for the presence of the metabolite, ceramide (Mackichan & DeFranco, 1999; 
Medvedev et al., 1999; Monick et al., 2000; Brandt et al., 2010).  While not directly relevant 
to the regulation of translation initiation, the requirement for ceramide was included as it 
offered an opportunity to begin to understand the links between the cellular signalling and 
metabolic networks.   
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Figure 2.1.3.1d – Petri Net Representation of the JNK1 Signalling Pathway.  JNK1 has an emerging role in 
the regulation of translation initiation.  The main, yet not fully elucidated, role concerns regulating eIF4E 
phosphorylation.  This pathway was extended back to the Interferon Receptor.  As with the p38α pathway, 
this receptor was not necessary as a basal level of JNK1 was maintained in the model.  This model was 
extracted from the large-scale model of translational regulation and was constructed in Petri Net notation 
using the software Snoopy. 
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As already stated, mTORC1 is fundamental to the regulation of translation initiation.  This 
pathway, within the model, was extended back through the PI3K pathway to the Insulin 
Receptor (Figure 2.1.3.1e).  While mTORC1 is activated by AKT1, it serves as a point of 
integration for several other key signalling pathways.  It was necessary to include these 
pathways in the activation of this signalling component as it allowed the integration of a 
signal to produce more complex patterns of biological behaviour.  The complexity of this 
pathway was further augmented by the addition of feedback loops including the S6K1-
dependent inhibition of mTORC2 (Julien et al., 2010) (such mechanisms are discussed in 
more detail in Section 3.1.3 – Interplay Between mTORC1 & AKT1).  The inclusion of such 
feedback served to ensure that the pathway was better able to simulate a biological system 
responding to an external perturbation. 
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Figure 2.1.3.1e – Petri Net Representation of the PI3K and mTORC1 Signalling Pathways.  Created using 
the software Snoopy, this Petri Net model contains molecular interactions and species concerning the PI3K 
and mTORC1 signalling pathways.  Included in this model are key points of cross-talk from other signalling 
pathways, including ERK1/2, p38α and JNK1.  The PI3K pathway is one of the main activators of mTORC1. 
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One of the main features of the model, as a whole, is the implementation of cross-talk 
between the signalling pathways.  The main kinases found to be responsible for cross-talk 
were AKT1 and ERK1/2.  With regards to AKT1, this kinase was found, through ill-defined 
mechanisms, to inhibit both p38α (Gratton et al., 2001; Liao & Hung, 2003; Shi et al., 2005; 
Marderosian et al., 2006; Yu et al., 2006; Taniike et al., 2008) and JNK1 (Kim et al., 2001; Lu 
et al., 2002; Park et al., 2002; Aikin et al., 2004; Hui et al., 2005; Wang et al., 2006; Wang et 
al., 2007b).  ERK1/2 were shown to inhibit ERK5 (Sarközi et al., 2007) and JNK1 (Carter et al., 
1998; Reardon et al., 1999).  These inhibitory interactions were included in the construction 
of the model as such interactions are responsible for the complex patterns of behaviour 
visible in biological systems.   
Section 2.1.3.2 – Specific Examples 
Literature-based, bottom-up mechanistic model building is a manual process, where expert 
curators make decisions about how best to represent the content of literature detailing 
experimental biology in a particular framework.  While attempts have been made to 
formalise this process in particular domains, for example in GSMN (Thiele & Palsson, 2010), 
the key role of an expert modeller in making decisions remains.  This section presents the 
modelling approach used in this work by giving specific examples of how particular literature 
articles where represented. 
The bottom-up approach to model construction used in this project was achieved in three 
stages: i. manual creation, ii. model validation, iii. model refinement.  The first stage of 
manual creation involved the reconstruction of the translation initiation machinery in 
mammalian cells.  Such an approach initially required an understanding of the main steps of 
the process, for example the recycling of the Post-TCs, formation of the eIF4F complex and 
 Page 99 
 
mRNA circularisation, and the joining of the 60S ribosomal subunit, as outlined in Figure 1.1.  
This basic understanding came from review articles such as Jackson et al. (2010).  In order to 
represent this process as accurately as possible it was then necessary to undertake more 
targeted literature searches to gain an appreciation of how the various stages are 
undertaken.  For example while Jackson et al. (2010) were able to describe the process of 
recycling Post-TCs, the role and regulation of eIF6 in this process is largely overlooked by 
this work.  Consquently, it was necessary to carry out more targeted searches of existing 
literature to gain an appreciation of the role of this initiation factor.  As eIF6 functions to 
prevent aberrant binding of the 60S subunit (Valenzuela et al., 1982; Raychaudhuri et al., 
1984; Si et al., 1997; Wood et al., 1999) to the assembling 48S complex it has a clear role in 
the recycling process.  However, at this stage it should be clear that some form of regulation 
is necessary to ensure that this factor does not prevent the formation of the 80S ribosome 
when required.  To this end, it was necessary to investigate what is currently known about 
mechanisms of eIF6 regulation.  Given the work of Ceci et al. (2003) has shown that eIF6 is 
regulated through phosphorylation by PKC βII, it was possible to represent this stage using 
the basic switch motif decribed earlier. 
The second stage of model construction concerned model validation.  Although this stage 
had little to do with the construction of the translational regulation model per se, it was 
necessary to validate the model against available literature in order to further refine the 
connectivity of the model (Pattyn et al., 2013).  To this end, various chemical inhibitors were 
incorporated into the model (as detailed in Section 2.1.4.2 – Evaluation of the Predictive 
Power of the Model).  The effects of these chemical inhibitors on various model 
components were investigated.  Documented effects were recorded into benchmark 
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datasets.  A key point of regulating the formation of the eIF4F complex involves the 
sequestration of eIF4E by 4E-BP1 (Marcotrigiano et al., 1999).  The mTORC1-dependent 
phosphorylation of 4E-BP1 inhibits such interactions and allows the eIF4F complex to form 
(Beretta et al., 1996; von Manteuffel et al., 1996; Burnett et al., 1998; Gingras et al., 1998; 
Marcotrigiano et al., 1999).  However, the model simulation results failed to account for a 
link between 4E-BP1 phosphorylation and treatment with the inhibitor SP600125 (Bain et 
al., 2007; Ito et al., 2011) given in the benchmark dataset, as shown in Figure 2.1.3.2.  The 
third stage of model construction was refinement.  In order to account for this effect 
recorded in the benchmark dataset, it was necessary to establish a mechanism by which the 
JNK1 inhibitor, SP600125 (Wang et al., 2004), could affect 4E-BP1 phosphorylation.  A more 
detailed search of the literature concerning JNK1 substrates found that MSK1 was also 
capable of phosphorylating 4E-BP1 (Liu et al., 2002; Aggeli et al., 2006; Teng et al., 2009).  
The last two stages of model construction can be viewed as iterative as the model 
refinement process precipitated a further round of model validation. 
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Figure 2.1.3.2 – Example of Model Construction Process.  As discussed in Section 1.1.3 – eIF4F 
Components & mRNA Circularisation and Section 1.2.1 – eIF4E-Binding Proteins & The mTORC1 
Signalling Pathway, the availability of eukaryotic Initiation Factor 4E (eIF4E) is regulated by the eIF4E-
Binding Protein 1 (4E-BP1).  Mammalian Target of Rapamycin Complex 1 (mTORC1) phosphorylates 4E-BP1 
(p4E-BP1) and consequently, eIF4E is then free to form the eukaryotic Initiation Factor 4F complex.  The 
dephosphorylation of p4E-BP1 is mediated by Protein Phosphatase 2A (PP2A) (Peterson et al., 1999; Pham 
et al., 2000; Janzen et al., 2011).  This example of an Extended Petri Net model is constructed using the 
Binary Model Formalism (as described in Section 1.4.4 – The Petri Net Formalism and Section 2.1.2 – The 
Binary Model Formalism).  The frequency data given above was taken from the model produced during 
the course of this project and calculated using the software, Reachfq.  The initial model determined that, 
despite mTORC1 inhibition with Rapamycin being noted as negatively regulating p4E-BP1 formation in the 
Benchmark Dataset, no inhibition was present.  Such a finding led other parts of the Benchmark Dataset to 
be investigated.  The SP600125 model was identified and enabled a more targeted literature search to be 
conducted in order to elucidate a link between JNK1 and the phosphorylation of 4E-BP1.  This literature 
search revealed a link between JNK1 and a kinase noted to be involved in 4E-BP1 phosphorylation, 
Mitogen- and Stress-Activated Kinase-1 (MSK1) (Liu et al., 2002).  This process of initial construction 
followed by re-evaluation of the connectivity of the model through targeted literature searches was used 
throughout the project to refine the model. 
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Section 2.1.3.3 – Creation of the Benchmark Datasets 
Evaluation of the predictive power of the model is key for future applications.  Although no 
model is expected to provide absolute accuracy, there is always a risk that model 
predictions are wrong.  To make a model useful, it is essential to comprehensively evaluate 
the predictive power to give future user’s guidance about the likelihood of obtaining correct 
predictions and observing different types of errors, such as false predictions of positive or 
negative outcomes.  Ultimately, the model is a decision making tool with predictions being 
used to guide future experimental work.  From this perspective, informing the user about 
the risks associated with pursuing model predictions should be regarded with equal 
importance as the prediction itself.  For example, the user may decide that in the absence of 
hypotheses for the next step of experimental molecular biology work on a complex system, 
following model predictions is useful, even if there is a high probability of a particular 
prediction being false.  The user may be of the opinion that predictions from a literature-
based model are more likely to be accurate than a guess.  Even if such a prediction is false, 
the user would still learn from the experimental outcome.  On the other hand, a model with 
low predictive power would not be applicable for the design of a clinical trial, where 
subjects would be put at risk and where considerable financial investment was at stake. 
Therefore, in this project, the development of the model was accompanied by the creation 
of a benchmark dataset for the evaluation of predictive power.  The literature has been 
systematically examined to identify the effects of commonly used chemical inhibitors (as 
shown in Table 2.1.3.3a) on the activity of different molecular species in the model.  These 
chemical inhibitors were chosen because usually the effects of these on cell signalling 
components are well documented.  For each of the inhibitors, original research articles have 
been gathered, which describe whether the application of this inhibitor leads to an increase 
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or decrease in the activity of a molecular species present in the model.  The PMID identifier 
of these articles are included in the dataset.  Care was taken to ensure that data was 
collected on different inhibitors, applied under similar experimental conditions.  For 
example, all data was collected in the absence, or presence, of lipopolysaccharide 
stimulation, to ensure that a benchmark dataset was created, suitable for evaluating the 
predictive power of a model.  It should be noted that the systematic evalution of the 
literature to create the benchmark datasets was of comparible effort to the construction of 
the model itself.  This datset is unique and represents a major outcome of the project.  The 
benchmark dataset is presented in the subsequent results sections with the Final 
Benchmark dataset being given in Section 2.2.4 – Evaluation of the Predictive Power of the 
Final Model. 
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Inhibitor Target Reference 
BIX02189 MEK5 Tatake et al., 2008 
CGP57380 MNK1/2  Tschopp et al., 2000 
GSK2334470 PDK1 Najafov et al., 2011 
Ku0063794 mTORC1/2 García-Martínez et al., 2009 
LY294002 PI3K Vlahos et al., 1994 
PD184352 MEK1/2-ERK1/2 Allen et al., 2003 
 
PD98059 
 
 
MEK1/2-ERK1/2 & ERK5 
 
Alessi et al., 1995;  
Dudley et al., 1995 
Rapamycin mTORC1 Sabers et al., 1995 
SB203580 p38 Badger et al., 1996 
SP600125 JNK1 Wang et al., 2004 
XMD8-92 ERK5 Yang et al., 2010 
 
5Z-7-Oxozeaenol 
 
 
TAK1, MEK1/2 
Ninomiya-Tsuji et al., 2003;  
Choo et al., 2006;  
Windheim et al., 2007 
Acuña et al., 2012 
Table 2.1.3.3a - Chemical Inhibitors used in the Model.  The target given above is the marketed 
cellular target and does not take into account off-target effects.  Note that 5Z-7-Oxozeaenol was 
only used in the LPS model and Ku0063794 was replaced by Rapamycin in the binary model. 
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Section 2.1.4 – Simulation Method 
Section 2.1.4.1 – Monte Carlo Simulations 
Both example simulations shown in Section 2.1.2 – The Binary Model Formalism and all 
simulations leading to the results presented in Section 2.2 – Results have been performed 
with the QSSPN solver (described in Section 1.4.5 – The Quasi-Steady State Petri Net 
Algorithm) (Fisher et al., 2013).  While simulations presented in this chapter could have 
been run in other tools, such as Snoopy, the QSSPN solver was used to make the resulting 
model amenable to integration with the Flux Balance Analysis of GSMN (presented in 
Chapter 5 – Integration of the Translational Control Model with a Genome-Scale 
Metabolic Network of a RAW 264.7 Cell) – a unique feature of QSSPN not available in other 
tools.  The QSSPN solver performs qualitative simulations using the Gillespie algorithm 
(described in Section 1.4.1 – Exact Stochastic Simulations with the Gillespie Algorithm) 
with all reaction propensity functions set equal to one (Ibid).  It should be noted that this 
algorithm was used to generate alternative sequences of molecular interactions occurring in 
the binary formalism model, rather than the modelling of the dynamics of molecular 
amounts in a quantitative model.  Consequently, the propensity function could only assume 
two values: zero if the molecular interaction was not enabled, or one, if the molecular 
interaction was enabled.  Furthermore, the Gillespie algorithm time was used exclusively to 
order the sequence of molecular interaction occurences i.e. to determine which molecular 
interactions occurred either earlier or later.  It was not interpreted as physical time.  
Moreover, the Gillespie algorithm used time as a stop condition for the simulations.  For 
example, trajectories were run for 100 arbitrary time units.  Again, this number was not 
interpreted as a physical time. 
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The qualitative behaviour of the model has been explored by the simulation of an ensemble 
of trajectories.  Each trajectory was started from the same initial state and the only 
difference between individual trajectories was exclusively due to the pseudo-random 
numbers generated in the Gillespie algorithm simulation.  Therefore, trajectories represent 
the alternative sequences of molecular interactions possible, given the literature knowledge 
expressed by the rules of the binary model formalism.  These alternative scenarios of model 
behaviour were then analysed by two different approaches implemented in Reachfq and 
Eventfq scripts (developed by A. Kierzek as part of the QSSPN project). 
The Reachfq script calculates the number of trajectories where a particular molecular 
species reached a state of k discrete activity levels.  In simulations with the binary model, k 
was set to one.  This script reads every trajectory in the ensemble and moves sequentially 
through the states from time 0 to the end.  If this condition has been fulfilled, the script 
stops analysing that particular trajectory, increases the counter, and moves to the next 
trajectory.  If the end of the trajectory is reached and the condition was not satisfied, the 
counter remains unchanged and the script analyses the next trajectory in the ensemble. 
The Eventfq script calculates, for each molecular interaction in the model, the total number 
of firings in all trajectories in the ensemble.  Each trajectory is read in turn.  The first column 
of the trajectory file indicates which molecular interaction firing changed state.  The script 
reads each field in this column, in turn, and whenever the reaction name is encountered, 
the counter for this molecular interaction is increased.  The result is the total number of 
firings, across all trajectories calculated, for each molecular interaction in the model. 
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Section 2.1.4.2 – Evaluation of the Predictive Power of the Model 
Predictive power of the model was evaluated by simulating the application of inhibitors, 
accounted for in the benchmark datasets, and comparing the simulation results with 
experimentally observed effects.  First, the Wild Type model, representing a situation where 
no inhibitors were applied, was simulated and 1,000 simulation trajectories were collected.  
The Reachfq script was then used to calculate the number of trajectories reaching each of 
the key effectors from the important signalling pathways featured in the model, and 
described in Section 1.2 – Key Points of Regulation & Upstream Signalling Pathways.  The 
activity changes of these effectors, as a result of the application of inhibitors, were recorded 
in the benchmark datasets.  Subsequently, for each inhibitor, another variant of the model 
representing the application, was created.  The Monte Carlo simulation was then run and 
1,000 simulation trajectories were collected.  The effect of the inhibitor on a particular 
model effector has been evaluated by comparing the number of trajectories reaching this 
effector, in the Wild Type model, and the model accounting for the action of a particular 
inhibitor.  In the simulation, the inhibitor was considered to have had an effect on a 
particular effector, if the number of trajectories reaching this molecular species were 
significantly different between the Wild Type and inhibitor models.  A difference in the 
number of trajectories reaching a particular effector was considered significantly different if 
the Wild Type and inhibitor numbers displayed no overlap in the 99.99% Binomial 
Confidence Intervals (Marshall & Olkin, 1985).  These Intervals were calculated in the 
software R (R Core Development Team, 2013) using the binconf function, which is part of 
the Hmisc package (Brant et al., 1991-2016).  The application of confidence intervals, in 
comparing the numbers of Monte Carlo trajectories exhibiting behaviours of interest, is an 
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accepted methodology in the Statistical Model Checking field of computer science 
(Kwiatkowska et al., 2011). 
The predictive power of the model was evaluated using the well accepted approach of 
constructing Confusion Matrices.  The Confusion Matrix classifies comparisons of the model 
and simulation results to one of the four possible outcomes: 
                       True Positive (TP) – Positive Experiment & Positive Model 
                                    False Positive (FP) – Negative Experiment & Positive Model 
                 True Negative (TN) – Negative Experiment & Negative Model 
                False Negative (FN) – Positive Experiment & Negative Model 
In these outcomes, a Positive result denotes a difference in the frequency of trajectories, 
between the ‘Wild Type’ and inhibitor models, resulting in the activation of a particular 
effector.  A Negative outcome connotes that the incorporation of the inhibitor resulted in 
no change in the frequency of Monte Carlo simulation trajectories bringing about the 
activation of a particular effector.  A True or False designation for each effector is given 
based upon whether or not the simulation result is in agreement with the benchmark 
dataset. 
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Using the results of the Confusion Matrices, the Matthews’ Correlation Coefficient (MCC) 
(Matthews, 1975) was calculated for each model and each inhibitor.  This calculation was 
done using the equation (Equation 2.1.4.2a) shown in Gowthaman & Agrewala (2008) and 
Schloss &Westcott (2011): 
𝑀𝐶𝐶 =  
((𝑇𝑃 ×  𝑇𝑁) − (𝐹𝑃 ×  𝐹𝑁))
√((𝑇𝑃 + 𝐹𝑁) × (𝑇𝑁 + 𝐹𝑃) × (𝑇𝑃 + 𝐹𝑃) × (𝑇𝑁 + 𝐹𝑁))
 
 
The MCC value ranges from between +1 and -1 and has three points for interpretation (Shi 
et al., 2010; Jurman et al., 2012).  As the MCC value approaches +1, this indicates increasing 
agreement between the model predictions and what has been experimentally shown.  A 
value of +1 would, therefore, indicate complete agreement.  Conversely, a value 
approaching -1 indicates increasing disagreement between the model predictions and the 
experimental data contained within the benchmark datasets (Shi et al. 2010).  An illustration 
of this point can be found in a system in which a decrease in the phosphorylation of a 
particular model component is predicted, while the experimental evidence demonstrates an 
increase.  The final point for interpretation is 0.  As the MCC value approaches this, it 
indicates that the predictions generated by the model are essentially random (Shi et al., 
2010; Jurman et al., 2012).  One point to note with regard to MCC values is that in a system 
yielding limited numbers of both FP and TP values, the resulting value tends to be high 
(Baldi et al., 2000). 
An overall MCC value was also calculated, based upon the total numbers, pooled from each 
inhibitor model Confusion Matrix.  This was necessary to ensure that predictive power was 
calculated from sufficient data points to overcome the classic argument that small sample 
Equation 2.1.4.2a 
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sizes lead to the validity of a correlation coefficient being called into question (Quenouille, 
1949).  Therefore, this global MCC value was used to define the overall predictive power of 
the model, while the MCC values for the individual inhibitor models were used to re-assess 
the connectivity of the model, through targeted literature searches, during refinement. 
In order to confirm the validity of the overall MCC values, two additional tests were also 
carried out.  The first involved the calculation of the Approximate Coefficient (AC) (Burset & 
Guigó, 1996) and the calculation was carried out using the variables contained within 
Confusion Matrices using the following equations (Burset & Guigó, 1996; Baldi et al., 2000) 
(Equation 2.1.4.2b and Equation 2.1.4.2c): 
𝐴𝐶𝑃 =  
1
4
 ×  (
𝑇𝑃
𝑇𝑃 + 𝐹𝑁
 + 
𝑇𝑃
𝑇𝑃 + 𝐹𝑃
+ 
𝑇𝑁
𝑇𝑁 + 𝐹𝑃
+ 
𝑇𝑁
𝑇𝑁 + 𝐹𝑁
) 
 
𝐴𝐶 = (𝐴𝐶𝑃 − 0.5) 
 
The second additional test involved subjecting the overall Confusion Matrix of each binary 
model to a Chi Square Test.  This was done by comparing the observed number of Confusion 
Matrix outcomes to an expected number for each outcome (Baldi et al., 2000).  In this case 
the expected number of TP, TN, FP and FN outcomes can be viewed as being the total 
number of data points divided by four (as the number of possible outcomes).  In simple 
terms, if the total number of data points is 100, then it would be reasonable to assume that 
each of the four possible outcomes in the Confusion Matrix would occur 25 times.  If this 
were the case, the resulting MCC value would be equal to zero.  By performing this Chi 
Square analysis, the MCC value obtained is tested for a significant difference from an MCC 
Equation 2.1.4.2b 
Equation 2.1.4.2c 
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value of zero (Ibid).  Both this and the calculation of the AC value were limited to the 
evaluation of the models constructed using the binary model formalism as these were 
inherently more meaningful, as discussed in Section 2.1.2 – The Binary Model Formalism. 
Section 2.1.4.3 – Synchronous Simulation Methods 
The Gillespie algorithm (described in Section 1.4.1 – Exact Stochastic Simulations with The 
Gillespie Algorithm), which is the main simulation approach used in this work (detailed in 
full in Section 2.1.4.1 – Monte Carlo Simulations), is a stochastic and asynchronous 
method.  This means that the firing of individual Petri Net molecular interactions is not 
synchronised within the simulation timesteps.  In each iteration of the algorithm, only one 
molecular interaction is chosen randomly and fired.  The qsspn solver implements an 
alternative, synchronous simulation approach in which firing of molecular interactions is 
synchronised.  Rather than firing only one molecular interaction in a particular timestep, the 
algorithm attempts to fire all molecular interactions, which are enabled at this timestep.  
This however, frequently leads to a situation where two or more molecular interactions 
attempt to update the same molecular species.  If this molecular species contains only one 
discrete activity level, the synchronised execution of more than one molecular interaction 
would lead to negative numbers of discrete activity levels, which must not occur.  This 
conflict between more than one molecular interaction requesting discrete activity levels 
from the same molecular species is resolved by the stochastic method.  The order in which 
molecular interactions connected to the same molecular species remove discrete activity 
levels from that molecular species is randomised.  Molecular interactions consume discrete 
activity levels until none are left.  In other words, if multiple enabled molecular interactions 
are connected to the same molecular species, and the number of discrete activity levels 
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associated with this species is smaller than the number of molecular interactions, not all of 
these interactions will be fired and those which are fired are chosen randomly.  Therefore, 
this method is stochastic and synchronous. 
The τ-Leap method (already discussed in Section 1.4.1 – Exact Stochastic Simulations with 
the Gillespie Algorithm), proposed by Gillespie (2001), is a stochastic, synchronous 
algorithm frequently used in Systems Biology.  Briefly, in each timestep 𝜏, the number of 
firings, 𝑘𝑇, is randomly generated from a Poisson distribution for each molecular 
interaction, 0𝑇, in the system (Gillespie, 2001; Gillespie, 2007).  Subsequently, each 
molecular interaction is fired 𝑘𝑇 times.  This method does not resolve the problem of 
molecular interactions simultaneously accessing the same molecular species and, ultimately, 
it is likely that such a situation would lead to negative numbers of discrete activity levels in 
the qualitative model produced during the course of this project (Cao et al., 2006).  
Consequently, this method is not applicable to the binary model produced in this project 
and so will not be discussed further. 
The synchronous stochastic approach is attractive because it is less computationally 
demanding than the asynchronous method.  Since multiple molecular interactions are 
executed simultaneously, smaller number of simulation timesteps may be required to reach 
a biological outcome of interest.  Where multiple enabled molecular interactions compete 
for a substrate, one interaction is selected at random.  Furthermore, simulation trajectory 
files are smaller, requiring less storage space.  This reduced file size makes the analysis with 
the Reachfq script faster.  Given this, the synchronous stochastic approach implemented in 
the qsspn solver has been considered as an alternative to the Gillespie algorithm.  However, 
it has been established that the asynchronous method is better in terms of generating 
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biologically meaningful hypotheses and, therefore, the synchronous algorithm was not 
used.  A case study detailed in Section 2.1.4.3.1 – Case Study Identifying Differences in the 
Asynchronous Simulation Approach & the Synchronous Methods gives an example to show 
why this was the case. 
Section 2.1.4.3.1 – Case Study Identifying Differences in the Asynchronous 
Simulation Approach & the Synchronous Methods 
A small model (Figure 2.1.4.3.1a) has been extracted from the full molecular network.  This 
small model contains 65 molecular interactions and 53 molecular species, all relating to 
eIF4E availability and phosphorylation. 
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Figure 2.1.4.3.1a - Schematic of the Example Model of eIF4E Phosphorylation and Availability.  This 
Petri Net model was constructed in the software Snoopy and only encompasses the molecular 
interactions relating to the availability of eukaryotic Initiation Factor (eIF) 4E (eIF4E).  All interactions 
present in this model can be found in the large-scale model of translational regulation.  This model is 
constructed of 53 molecular species and 65 molecular interactions. 
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The simulation of 1,000 trajectories, of which an example is shown in Figure 2.1.4.3.1b, with 
the Gillespie algorithm, followed by the application of the Reachfq script yielded the 
following results: 
Model Effector Frequency Value 
Phosphorylated eIF4E 0.472 
Phosphorylated MNK1 0.472 
Phosphorylated MNK2 0.502 
Phosphorylated AKT1 0.511 
Phosphorylated JNK1 0.556 
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Figure 2.1.4.3.1b - Example Trajectory from the Simple Model Generated Using the Asynchronous 
Simulation Approach.  This approach uses the Gillespie algorithm to generate a sequence of enabled 
molecular interactions.  As this model incorporated molecular interactions only concerning eukaryotic 
Initiation Factor (eIF) 4E phosphorylation and availability, this trajectory ends with eIF4E phosphorylation 
(marked with the green L).  This trajectory starts with the Raf-1-mediated phosphorylation of the Mitogen-
Activated Protein Kinase (MAPK) Kinase, MEK1 (marked with the green A).  B concerns the activation of 
ERK1.   A prerequisite for MNK2 phosphorylation (D) is the activation of JNK1 through phosphorylation (C).  
The phosphorylation of eIF4E occurs through MNK2 and requires the PKCα-dependent eIF4G 
phosphorylation (E and F).  The availability of eIF4E is regulated through sequestration by 4E-BP1.  This 
sequestration is negative regulated by both mTORC1 and MSK1 (K).  The activation of mTORC1 (J) is 
dependent upon Rheb while MSK1 activation is carried out through p38α (H).  p38α phosphorylation 
occurs through MKK3 (G).  The model includes the phosphorylation of AKT1 (I).  In this model, AKT1 serves 
to inactivate JNK1.  This model is shown in detail in Figure 2.1.4.3.1a 
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By comparison, the simulation of 1,000 trajectories with the synchronous stochastic 
approach, followed by the application of the Reachfq script, yielded the following results: 
Model Effector Frequency Value 
Phosphorylated eIF4E 0.515 
Phosphorylated MNK1 1.000 
Phosphorylated MNK2 0.000 
Phosphorylated AKT1 1.000 
Phosphorylated JNK1 1.000 
 
An example trajectory yielded by this method is given in Figure 2.1.4.3.1c 
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Figure 2.1.4.3.1c - Example Trajectory from the Simple Model Generated Using the Synchronous 
Simulation Approach.  This model is shown in detail in Figure 2.1.4.3.1a.  This method fires all enabled 
molecular interactions in each simulation time interval.  In the trajectory shown above this is illustrated.  
All molecular species shown in red are updated first.  This is followed by the updating of dark blue, green, 
light blue and pink molecular species.  Given this trajectory, it is clear that MNK2 phosphorylation is not 
permitted during model simulations with this method.  While phosphorylated JNK1 (pJNK1) does form 
(shown in red/green), it is removed once the dual-phosphorylated form of AKT1 (ppAKT1) forms.  This is a 
result of how the synchronous simulation approach removes the temporal nature of signalling pathways 
imparted by the waiting time calculation of the Gillespie algorithm.  Molecular species consumed during 
the molecular interactions are not coloured, rather only molecular species formed during the firing of 
interactions.  An exception of this is pJNK1 which is central to the illustration of the limitations to this 
approach. 
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It can immediately be seen that the simulation with the Gillespie algorithm provided 
examples of the sequence of molecular events leading to MNK2 phosphorylation, while the 
synchronous stochastic approach predicted that the species cannot be phosphorylated.  
According to molecular biology literature, the phosphorylation of MNK2 is possible (Ueda et 
al., 2004).  Thus, the synchronous stochastic approach misses biologically meaningful 
trajectories of molecular events and, consequently, it should not be used in this work, 
despite the advantages this approach has, in terms of compuatational performance. 
Closer examination of the synchronous stochastic simulation results show that the 
biologically realistic behaviour arises as a result of the feedback surrounding the kinase, 
JNK1.  This kinase is inactivated by AKT1 (Kim et al., 2001; Lu et al., 2002; Park et al., 2002; 
Aikin et al., 2004; Hui et al., 2005; Wang et al., 2006; Wang et al., 2007b).  This synchronous 
approach exacerbates this feedback by removing the effects of waiting time, implemented 
in the asynchronous approach via the Gillepsie algorithm.  As all enabled molecular 
interactions fire as each simulation timestep occurs, this method assumes that each 
interaction takes the same length to occur.  In actual biological systems this is not the case 
as reactions have different rates.  While many of these rates are not known, the 
asynchronous approach allows the random sampling of alternative molecular sequences 
where molecular interactions do not occur simultaneously.  The example above 
demonstrates that this allows the identification of a known biological outcome.  Since there 
are many feedback loops within the large model, this example illustrates a general problem 
with the synchronous approach, rather than an example specific to this small example.  As a 
result of these deficiencies, the synchronous stochastic approach was taken forward but 
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only in a limited capacity (detailed in Section 5.3.2 – Proposed New Approaches and 
Section 5.3.2.2 – Synchronous Method). 
Finally, another example of a synchronous simulation algorithm is the integration of 
Ordinary Differential Equations, which is a workhorse of computational Systems Biology for 
the simulation of quantitative models.  As follows from the description in Section 1.4.2 – 
Ordinary Differential Equations (ODEs), all molecular species in the model are updated 
synchronously, but random numbers are not used to resolve competition between 
molecular interactions comsuming the same species.  Instead, molecular amounts are 
described as concentrations rather than numbers of molecules, but competing interactions 
decrease the concentrations to numbers possibly smaller than one.  However, these 
numbers remain positive.  Very sophisticated adaptive timestep strategies are used, within 
ODE solvers, to ensure that small molecular concentrations are simulated without leading to 
negative numbers (Press et al., 2007).  In terms of the discussion within this chapter, the 
ODE simulation algorithm is therefore synchronous and deterministic.  It generates only 
one trajectory representing the time evolution of the system.  While computationally even 
more attractive than the synchronous stochastic simulation approach, the application of this 
method is limited to fully parameterised, quantitative models.  An attempt to run 
simulations of models presented here led to a trajectory which did not have a clear 
biological interpretation.  As discussed earlier, quantitative parameterisation of the large-
scale molecular network model, described here, is not possible due to a lack of quantitative 
measurements in existing scientific literature.  However, as this approach was 
computationally attractive, it was applied to the full model.  The results are given in Section 
5.3.2.1 – Ordinary Differential Equation Method. 
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Section 2.1.5 – Investigation of the Interaction Between eIF4E Phosphorylation 
and mTORC1 Inhibition 
Once the binary model had been refined and the predictive power raised to a sufficient 
level, it was necessary to correct the decrease in eIF4E phosphorylation noted in the binary 
model (as discussed in Section 2.2.2 – Re-Evaluation of the Binary Model).  Moreover, a 
mechanism by which eIF4E phosphorylation is increased in response to the inhibition of 
mTORC1 was necessary.   
Several unsuccessful attempts were made to elucidate such a mechanism before the 
necessary circumstances surrounding this increase were identified.  The methods detailed in 
the subsequent section were used to achieve these objectives. Both efforts involved 
extracting information from trajectories, such as using Eventfq to establish the number of 
times individual molecular interactions fired and mining the sequence of molecular 
interactions occurring up to and including the phosphorylation of eIF4E.  The latter required 
a script created by D. Taylor using the Python programming language (van Rossum, 2012). 
Since neither Eventfq nor the use of Invariant files yielded a clear mechanism, it was decided 
that a new approach was necessary.  A smaller model was constructed that only 
encompassed the molecular interactions surrounding eIF4E phosphorylation and mTORC1 
activity.  The small scale and scope of this model allowed for easier identification of 
molecular species upon which eIF4E phosphorylation is dependent.  The small model was 
then changed in various ways so as to find a reason for the decrease in eIF4E 
phosphorylation. 
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The identification of factors in the small model permitted further, more targeted, work to be 
undertaken on the larger model.  The critical effectors for eIF4E phosphorylation were then 
identified and one-by-one, or in groups, they were subject to removal.  Following the 
removal of effectors, a new set of simulations was conducted.   
Section 2.2 – Results 
Once the model was constructed it was simulated with QSSPN calculating 1,000 trajectories.  
Reachfq was then used to interrogate these trajectories in order to establish the frequency 
of trajectories reaching a particular model effectors.  The mode of model construction 
enabled the data generated using Reachfq to be easily correlated to the components of the 
model.  Consequently, points of refinement were easily identified and, after going back to 
exisiting literature, were honed without difficulty. 
Section 2.2.1 – Binary Model of LPS Stimulation 
The binary model formalism was adopted because of the arbitrary discretisation and 
unrealistic oscillatory nature of the initial model in preliminary work.  This behaviour was 
produced by the unrealistic assumption that the switch-like activation and deactivation of 
enzymes is caused by equal kinetic parameters.  The binary model formalism and rationale 
for using this is described above in Section 2.1.2 – Binary Model Formalism.  In order to 
introduce the rule-based transitions, it was necessary to further extend the granularity of 
the signalling pathways contained within the model by elaborating on the annotation of 
these pathways back to the receptor-ligand interactions.  As several of the pathways were 
related to stress responses, the LPS-mediated Toll-Like Receptor 4 signalling (Poltorak et al., 
1998; Chow et al., 1999; Hoshino et al., 1999) was one such pathway to be modified. 
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Although this preliminary work is not shown, the predictive power of this initial model was 
found to be MCC = 0.2354.   
The following table (Figure 2.2.1a) shows an excerpt of the 99.99% Binomial Confidence 
Intervals calculated for the Reachfq analyses of the frequency of activation of model 
effectors in a binary model incorporating LPS stimulation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page 124 
 
Effector 
Wild Type PD98059 
Frequency Upper Lower Frequency Upper Lower 
ppERK1 1.000 1.000 0.989 0.000 0.011 0.000 
ppERK2 1.000 1.000 0.989 0.000 0.011 0.000 
ppMEK1 1.000 1.000 0.989 1.000 1.000 0.989 
ppMEK2 1.000 1.000 0.989 1.000 1.000 0.989 
pRSK1 1.000 1.000 0.989 1.000 1.000 0.989 
rpS6-Pi 1.000 1.000 0.989 1.000 1.000 0.989 
pMNK1 1.000 1.000 0.989 0.925 0.948 0.893 
pMNK2 1.000 1.000 0.989 0.000 0.011 0.000 
eIF4E-Pi 0.864 0.896 0.824 0.047 0.074 0.029 
Figure 2.2.1a – Example of the LPS Model Comparing the Effects of Inhibitors to a Wild Type 
Model.  Inhibitors are incorporated into the model and the effects are compared to a Wild Type 
model in which no inhibitors are included.  Reachfq was used to interrogate the QSSPN simulations 
to determine, for each model effector, the fraction of the 1,000 trajectories sampled in which this 
effector is activated.  99.99% Binomial Confidence Intervals were used to identify regions of 
significant difference (shown in red).   
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These frequency values, and the associated 99.99% Binomial Confidence Intervals, were 
then used to form Confusion Matrices (as summarised in Figure 2.2.1b).  The measures 
placed in the matrices are determined based upon the identification of perturbations 
resulting in significant changes in the trajectory frequencies.  The frequency value for a 
particular model effector in an inhibitor model was considered significantly different if the 
99.99% Binomial Confidence Interval for that effector if it did not overlap with the 
corresponding 99.99% Binomial Confidence Interval in the Wild Type model.  To form these 
Confusion Matrices, the behaviour of the model was compared to the LPS Benchmark which 
contained the expected behaviour of model components in response to the various 
chemical inhibitors.  This benchmark was composed of information taken from 122 
literature articles.  Supplementary Information 1b contains the bibliographic information of 
the articles contained with this benchmark, whilst Supplementary Information E5 contains 
the LPS Benchmark dataset itself. 
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  Confusion Matrix Values  
Model TP TN FP FN MCC Value 
CGP57380 2 0 1 3 -0.447 
LY294002 8 0 3 4 -0.302 
PD184352 5 2 1 2 0.356 
PD98059 2 1 1 6 -0.218 
Rapamycin 6 0 2 3 -0.289 
SB203580 2 1 0 11 0.113 
SP600125 2 5 0 1 0.745 
(5Z)-7-Oxozeaenol 3 0 0 5 Undefined 
OVERALL 30 9 8 35 -0.007 
Figure 2.2.1b – Overview of the Predictive Power of the Model Incorporating the Effects of 
Lipopolysaccharide Signalling.  The Petri Net model of translational regulation was interrogated with 
QSSPN followed by Reachfq.  The binomial confidence intervals of model effectors in the model 
including a chemical inhibitor were compared with those in the Wild Type model and regions of 
significant difference were identified.  By comparing the results of this evaluation to the LPS 
Benchmark it was possible to produce Confusion Matrices with results being characterised as either 
True Positives (TP), True Negative (TN), False Positive (FP) and False Negative (FN).  These qualitative 
measures of predictive power were used to produce the Matthews’ Correlation Coefficient (MCC).  
The overall predictive power was established by pooling the sums Confusion Matrix variables for 
each inhibitor and calculating an overall MCC value.  Due to the absence of TN and FP values, an 
MCC value for the (5Z)-7-Oxozeaenol was not quantifiable. 
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Whilst this overall MCC value suggests that the binary model leads to random predictions, it 
is worth noting that there is a smaller number of data points being used.  Moreover, the 
maximum time limit of the simulation was such that the majority of effectors reached 
frequencies of one.  These results prompted a re-evaluation of the simulation protocol.  
Therefore the binary model was re-tested against the initial, non-LPS dataset and the 
maximal time-step of the simulations adjusted so that the Wild Type effector frequencies 
should be approximately 0.50.  This approach, which had already been implemented by 
Fisher and colleagues (2013), allowed for the discovery of increases and decreases in the 
reachability of the model effectors in response to perturbations.  Despite this leading to 
larger 99.99% Binomial Confidence Intervals for the Wild Type model, it enabled more 
complex behaviour to be observed.  The results of applying this refined protocol are shown 
below in Section 2.2.2 – Re-Evaluation of the Binary Model. 
One of the main outcomes of the preliminary work was the finding that eIF4E 
phosphorylation was increased in response to mTORC1 inhibition.  As such, it is noteworthy 
that this behaviour was conserved in the LPS model with an increase in the phosphorylation 
of eIF4E being seen in the Rapamycin inhibitor model. 
Section 2.2.1.1 – Updated Benchmark Dataset 
Proteomic differences between cell types is well established (Pontén et al., 2009; 
Paulitschke et al., 2013) and the question was raised as to the validity of using data from a 
variety of cell lines as to the cellular effects of inhibitors.  The dataset constructed with 
publications, not using LPS stimulation, contains very few studies that use macrophage cell 
lines, let alone RAW 264.7 cells.  It was decided that the dataset containing studies that only 
use LPS stimulation would be more appropriate to evaluate this effect.  As LPS stimulation is 
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important in the innate immune system, more studies in this dataset use macrophage-
derived cell lines.  It is therefore possible to test this assumption with the LPS dataset, the 
intial results of which are given above in Section 2.2.1 – Binary Model of LPS Stimulation.  
Although there are undoubtedly differences in the functioning of different macrophage-
derived cell lines, in order to test this, in the least conservative way, all macrophage-derived 
cell lines will be included.  By eliminating any studies with cell types other than macrophage 
cell lines, the number of data points used for calculating the overall MCC and AC values was 
reduced from 82 to 41.  By performing a Chi Square Test (α = 1.55x10-4) it is clear that this is 
a significant reduction.  The information pertaining to these datasets can be found in 
Supplementary Information E5. 
Despite an overall increase in the global MCC value, by limiting the cell types included in the 
formation of the benchmark datasets, the number of possible data points was being 
severely reduced.  By doing so, the relevance of even the global MCC values is being 
reduced.  As such, the method of including multiple cell types in the benchmark dataset was 
the most appropriate.  In order to further enhance the value of this dataset, verifying results 
across multiple studies and cell types was best practise. 
Section 2.2.2 – Re-Evaluation of the Binary Model 
The adjusted maximal time-steps for each effector in the Wild Type was applied to each of 
the inhibitor models.  The frequency of each effector in the Wild Type model was 
approximately 0.5, as a result of the maximal simulation time being limited.  By ensuring the 
Wild Type frequency took this approximate value, more complex patterns of behaviour 
were visible.  For example, if the simulation time was extended to permit an effector to 
reach a frequency approaching 1.0, then it would not be possible to observe perturbations 
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resulting in an increase in the formation of a particular effector.  The frequencies, with 
associated 99.99% Binomial Confidence Intervals, for this model are shown in 
Supplementary Information E7 – Frequency Data Generated by Reachfq with Associated 
99.99% Binomial Confidence Intervals (Sheet entitled First Refinement of the Model).   
By changing back to an updated version of the original dataset, more points of analysis were 
available against which to test the binary model.  This updated version of the original 
dataset, termed the Revised Original Benchmark dataset (shown in Supplementary 
Information E6) contains information from 130 peer-reviewed articles on the effects of 
chemical inhibitors on key model effectors.  Such a change led to a slight improvement of 
the predictive power of the model (MCC = -0.007 vs MCC = 0.1393 (shown in Figure 2.2.2a) 
in the first round of model refinement.  However the predictive power of this binary model 
is lower than the initial model (MCC = 0.2354 vs MCC = 0.1393).  This being said, the changes 
made to the model during the transition to the binary model formalism allowed for 
improvements to be made.   
Further iterations of the model were made to improve the predictive power with the aim of 
approaching an MCC value of approximately 0.5.  The workflow process for these iterations 
is shown in Figure 2.2.2b and summarises the process used to refine the model through five 
iterations.  The first four iterations of are summarised in Figure 2.2.2a and show the overall 
MCC values increase as changes are made.  Whilst global improvements were made to the 
MCC values, these were subject to fluctuations when looking at individual Inhibitor Models.  
This highlights the need to view the MCC values of the individual models with caution.  
Furthermore, the changes to the model have made plain the importance of identifying and 
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increasing cross-talk between pathways.  The Revised Original Benchmark dataset was used 
in each comparison of the model in order to calculate the measure of predictive power. 
Of interest to the experimental work of this project, the earlier prediction concerning the 
effect of mTORC1 inhibition on eiF4E phosphorylation is still observed.  The frequency of 
trajectories producing eIF4E phosphorylation fell from 0.520 in the Wild Type model to 
0.110 when Rapamycin was included. 
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 First Round of 
Model 
Refinement 
Second Round of 
Model 
Refinement 
Third Round of 
Model 
Refinement 
Fourth Round of 
Model 
Refinement 
 
TP 
 
 
31 
 
34 
 
39 
 
43 
 
TN 
 
 
31 
 
35 
 
38 
 
42 
 
FP 
 
 
8 
 
6 
 
7 
 
5 
 
FN 
 
 
59 
 
51 
 
43 
 
43 
 
MCC 
 
 
0.1393 
 
0.2553 
 
0.3185 
 
0.3918 
 
AC 
 
 
0.1393 
 
0.2553 
 
0.3185 
 
0.3918 
 
Chi Square 
Test α-Value 
 
 
8.27x10-9 
 
2.78x10-7 
 
8.81x10-6 
 
5.18x10-7 
Figure 2.2.2a – Overall Predictive Power of the Model Through the Four Stages of Refinement.  The 
binary model of translational regulation was compared to the Revised Original Benchmark Dataset.  
The comparison of the dataset to the behaviour of the model led to the construction of Confusion 
Matrices with behaviours being classified as being True Positives (TP), True Negatives (TN), False 
Positives (FP) and False Negatives (FN).  These qualitative measures were converted to quantitative 
measures through the calculation of both the Matthews’ Correlation Coefficient (MCC) and 
Approximate Coefficient (AC) values.  Through four rounds of model refinement, it was possible to 
raise the level of predictive power from an MCC = 0.1393 to MCC = 0.3918.  Each refinement stage 
concerned the increase in the level of cross-talk between pathways and the elimination of FP values.  
To accomplish these, it was necessary to return to existing literature.  
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Figure 2.2.2b – The Model Refinement Workflow.  Over four iterations of the model, it was 
refined to improve the predictive power.  Simulations were run using QSSPN and Reachfq once the 
optimal simulation times were established for each model effector.  This was necessary to ensure 
that the Wild Type frequency of activation was approximately 0.5.  The 99.99% Binomial 
Confidence Intervals were calculated and the results were compared to the relevant Benchmark 
dataset.  Using these comparisons, the Matthews’ Correlation Coefficient (MCC) values were 
calculated to quantitatively measure the predictive power of the model.  Based upon the MCC 
values for the individual inhibitor models, the connectivity of the model was refined using 
additional literature.  The cross-talk of the signalling pathways was the main target for refinement 
so as to allow more complex patterns of behaviour. 
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The fifth round of model refinement was responsible for raising the predictive power of the 
model to an MCC value of approximately 0.5 (as shown in Figure 2.2.2c).  The frequency 
values, along with the 99.99% Binomial Confidence Intervals, are shown in Supplementary 
Information E7 – Frequency Data Generated by Reachfq with Associated 99.99% Binomial 
Confidence Intervals (sheet entitled Fifth Refinement of the Model).  Of particular interest is 
the finding that eIF4E phosphorylation was significantly altered by Rapamycin, as noted by a 
deviation in the frequency of trajectories reaching one discrete activity level (0.522 in the 
Wild Type model versus 0.005 in the Rapamycin model).  Such an affect was also noted in 
the preliminary work and the LPS containing model (outlined in Section 2.2.1 – Binary 
Model of LPS Stimulation). Moreover, this alteration is associated with a perturbation in 
MNK2, as noted by Stead and Proud (2013).  However, in this model eIF4E phosphorylation 
appears reduced despite the increase in the frequency of trajectories producing 
phosphorylated MNK2.  Work in subsequent sections of this chapter were aimed at 
eliminating this discrepancy and defining the mechanism by which Rapamycin can increase 
the phosphorylation of this initiation factor.   
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i.   
  Confusion Matrix Values  
Model TP TN FP FN MCC Value 
BIX02189 1 7 0 4 0.3568 
CGP57380 4 4 0 1 0.8000 
GSK2334470 2 12 0 2 0.6547 
LY294002 4 3 0 6 0.3651 
PD184352 5 1 0 7 0.2282 
PD98059 9 3 1 3 0.4472 
Rapamycin 5 3 0 5 0.4330 
SB203580 5 4 2 6 0.1177 
SP600125 10 2 0 5 0.4364 
XMD8-92 2 2 0 0 1.0000 
 
 
ii.        
 Confusion Matrix Values 
 
Measures of Predictive Power 
 TP TN FP FN MCC Value AC Value α-Value 
 
Overall 47 47 3 39 0.4652 0.4652 5.15x10-8 
 
Figure 2.2.2c – Evaluation of the Predictive Power of the Fifth Iteration of the Model.  (i) Once 
QSSPN and Reachfq had evaluated the model and regions of significant difference had been 
identified, it was possible to compare the effects of chemical inhibitors in the model to published 
effects of the inhibitor on particular model effectors (within the Revised Original Benchmark 
Dataset).  The result of this comparison was the formation of Confusion Matrices.  Consequently, the 
behaviour of the model was characterised as being either a True Positive (TP), True Negative (TN), 
False Positive (FP) or False Negative (FN).  In order to produce a quantitative measure of predictive 
power, these values were used to calculate the Matthews’ Correlation Coefficient (MCC).  (ii) To 
produce an overall measure of predictive power, the Confusion Matrices variables in (i) were pooled.  
The MCC and Approximate Coefficient (AC) values were calculated.  In order to show the predictive 
power was significantly different from random, the Chi Square Test α-Value was calculated. 
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Section 2.2.3 – Mechanism by Which mTORC1 Inhibition Affects eIF4E 
Phosphorylation  
Based upon the connectivity of the model, only four factors are directly linked to the 
phosphorylation of eIF4E: MNK1, MNK2, eIF4G phosphorylation and 4E-BP1 
phosphorylation.  Through the construction of a smaller model, again within Snoopy, a more 
detailed investigation of eIF4E phosphorylation was possible.  This smaller model contained 
only molecular interactions included in the original model and only molecular interactions 
that are proximal to eIF4E phosphorylation.  Given the reduced scale of the model, it was 
not possible to include the complex cross-talk between the signalling pathways present in 
the larger model.  However, as the aim of this smaller model was to explain the behaviour of 
the eIF4E phosphorylation seen when Rapamycin is present, much of this cross-talk was not 
deemed necessary in the first instance.   
Simulations with this model revealed that eIF4G phosphorylation and 4E-BP1 
phosphorylation appeared to act to reduce eIF4E phosphorylation in a model incorporating 
Rapamycin.  This raised three possible, but not necessarily mutually exclusive, mechanisms 
to explain how an increase in eIF4E phosphorylation was possible: 
i. The level of 4E-BP1 in the cell must lower than that of eIF4E so as to allow 
sequestration of eIF4E by hypophosphorylated 4E-BP1 and at the same time 
permit an increase in eIF4E phosphorylation.   
ii. mTORC2 cannot be the only kinase responsible for the activation of the eIF4G 
kinase, PKCα.   
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iii. The activity of a protein phosphatase may be suppressed by mTORC1 activity.  
Such a phosphatase may act on either MNK1 or MNK2, eIF4G, PKCα or even 
eIF4E directly. 
The first hypothesis is in agreement with the work of Eckerdt and co-workers (2014) who 
established that the concentration of 4E-BP1 had little influence on the increased 
phosphorylation of eIF4E.  Although difficult and costly, proteomic evaluation of RAW 264.7 
cells could reveal if this is the case and show if and to what extent the levels of eIF4E and 
4E-BP1 differ.  Several studies have employed proteomic approaches with RAW 264.7 cells 
(Martínez-Solano et al., 2009; Shi et al., 2009; Eichelbaum & Krijgsveld, 2014).  However to 
date no information regarding the relative levels of either protein have been reported in 
these studies.  Cai et al. (2014) and Decarlo et al. (2015) both remark that the ratio of eIF4E 
to 4E-BP1 is critical in the early transformation events of cells.  Quantitative immunoblotting 
was not considered here as the method is often regarded as pseudo-quantitative or, in the 
case of advanced quantitative immunoblotting, requires the expression of recombinant 
proteins in control samples to be used to aid the quantification (Janes, 2015).  Morevoer, 
the quantification of Western Blots with densitometry is affected by a great number of 
factors that may arise during the immunoblotting procedure, the scanning of blots or even 
during the quantification itself and consequently has little in the way of scientific foundation 
(Gassmann et al., 2009).  Taylor and co-workers (2013) even go so far as to state that the 
use of radiographic film is inferior to camera-based development systems when it comes to 
quantitative immunoblotting.  For these reasons, a proteomics based method would be 
preferred for the quantification of eIF4E and 4E-BP1 levels. 
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Whilst there is no direct evidence to support for the hypothesis that 4E-BP1 is expressed at 
a lower level than eIF4E, there is reason to believe this is the case.  Data taken from The Cell 
Line Atlas database, within The Human Protein Atlas (Uhlén et al., 2005; Uhlén et al., 2015), 
has revealed that in the majority of cases, across multiple human cell cancer lines, that the 
level of eIF4E (Analysis of Expression of EIF4E Website, taken from 
http://www.proteinatlas.org/ENSG00000151247-EIF4E/cell/CAB004077 [last accessed 
22/05/2015]) is higher than that of 4E-BP1 (Analysis of Expression of EIF4EBP1 Website, 
taken from http://www.proteinatlas.org/ENSG00000187840-EIF4EBP1/cell/CAB005032 [last 
accessed 22/05/2015]).  Using Immunohistochemistry (IHC) data, of the 46 cell lines tested, 
only four (8.7%) displayed evidence of 4E-BP1 being present at higher levels than eIF4E.  The 
data shown in The Human Protein Atlas, whilst supportive of the view that eIF4E is 
expressed to a higher degree than 4E-BP1, is not quantitative enough to provide conclusive 
support to this hypothesis.  This issue of IHC being quantifiable is summarized by Taylor and 
Levenson (2006). This work notes that there is some contention over whether a correlation 
exists between the amount of antigen staining and the actual amount of the antibody-
target.  Samples generated by IHC are also subject to a variable interpretation by observers 
and, thus, the resulting scoring of sample staining is subjective and open to vast 
interpretation.  As a result of this, and a lack of suitable experimental controls, 
reproducibility is often lacking even when analytical software is used (Ibid). 
Although mTORC2 has previously been found to be a kinase for PKCα (Guertin et al., 2006; 
Facchinetti et al., 2008; Ikenoue et al., 2008), experimental work presented in Chapter 3 – 
Experimental Validation of Model Predictions has demonstrated that the mTORC2 
phosphorylation site of AKT1, Ser-473 (Frias et al., 2006; Jacinto et al., 2006; Breuleux et al., 
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2009), displays a significant reduction in AKT1 phosphorylation when using the Human 
Phospho-MAPK Arrays following a one hour Rapamycin treatment.   It is worth re-iterating 
here that whilst AKT1 phosphorylation was reduced, the p-value calculated was only 
significant prior to a Holm-Sidak Correction.  However, the AKT Pan level remained 
significantly reduced after this correction.  Furthermore, immunoblotting of lysates treated 
for three hours displayed no significant difference in the level of Ser-473 phosphorylated 
AKT1.  It is possible that this is as a result of reduced antibody sensitivity with this method as 
the signal quantified was very low.  Given there is still reason to argue that AKT1 
phosphorylation is reduced, along with the simulation results and the Rapamycin-mediated 
increase in eIF4E phosphorylation, it is reasonable to argue that mTORC2 cannot be the only 
kinase responsible for phosphorylating PKCα, a kinase known to be responsible for eIF4G 
phosphorylation (Dobrikov et al., 2011).   
Although speculative, PDK1 has been shown to be capable of phosphorylating PKCα, and 
other PKC enzymes, in such a way as to be required for the activation of PKC (Dutil et al., 
1998; Le Good et al., 1998; Sonnenburg et al., 2001).  Gao and co-workers (2001) noted 
that, in PKCβII, PDK1 mediates phosphorylation of Thr-500 residue within the PKC activation 
loop.  Autophosphorylation of PKCβII can then occur when PDK1 has dissociated (Ibid).  
Several studies have noted that PDK1 is required to maintain the level of PKCα and other 
PKC isoforms expressed in cells (Collins et al., 2005; Wood et al., 2007).  When taken 
together with the work of Dutil et al. (1998) and Sonnenberg et al. (2001), which noted that 
PDK1 was capable of phosphorylating PKCα on the activation loop, these works suggest that 
PDK1 not only activates PKCα but also positively regulates the expression of this protein 
kinase.  Although PDK1 has been shown to be the kinase responsible for activating multiple 
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PKC isoforms (including PKCβ (Helliwell et al., 2003), PKCδ (Deb et al., 2003), PKCζ (Chou et 
al., 1998) and PKCθ (Bauer et al., 2001; Villalba et al., 2002) this occurs in a manner 
dependent upon the PI3K pathway.  It would not be unreasonable, based upon this 
evidence, to hypothesise that it is probable that PKCα activation would occur in an 
analogous fashion.   
Testing this hypothesis could be achieved with either chemical inhibition of PDK1, CRISPR or 
with transgenic mice (these are explained in Section 3.4.4 – Potential Future Work).  
However, for reasons stated previously, the relevance of both to this project is somewhat 
unclear.  At present CRISPR has not been used in RAW 264.7 cells and so it is not clear if this 
would be appropriate at this time.  Transgenic mice have been successfully used to create 
PDK1 knockout mice (Tawaramoto et al., 2012), however, the cells derived from these 
would be likely to display behaviour different to that of RAW 264.7 cells.  Chemical 
inhibition of PDK1 would at this time be the best option.  This being said, it would require 
treating the cells with multiple inhibitors and the issue of inhibitor-inhibitor interactions 
would then be raised.   
With regard to the third proposed mechanism, mTORC1 is known to regulate the 
functioning of several protein phosphatases, PP5 (Huang et al., 2004) and PP2A (Hartley & 
Cooper, 2002).  As Rapamycin has been shown to lead to an increase in the Ser-437 
phosphorylation of MNK2 (Stead & Proud, 2013), it follows that if a phosphatase were 
involved, that it must be suppressed during mTORC1 inhibition.  This suggested that the 
increase in eIF4E phosphorylation seen during Rapamycin treatment maybe a result of 
alterations to protein phosphatase activity.  Given that Hartley and Cooper (2002) found 
that Rapamycin enhanced PP2A activity, it is unlikely this phosphatase is a viable candidate.  
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Bishop and co-workers (2006) similarly noted that mTORC1 acts to limit PP2A activity.  
However, Huang and co-workers (2004) established that during Rapamycin treatment, the 
regulatory subunit of PP5, PR72, interacts with PP5 with reduced affinity and thus 
moderates PP5 activity.  This phenomenon appears to be dependent upon the expression of 
4E-BP1 but no mechanism has been proposed (Ibid).   
Whilst this would seem to indicate that that PP5 is possible candidate here, to date, no work 
has linked PP5 to the regulation of eIF4E phosphorylation or to either MNK1 or MNK2.  This 
being said, it has been reported that PP5 is capable of dephosphorylating sites targeted by 
PKC (Katayama et al., 2014).  Whilst not conclusive, this does intimate that eIF4G may be a 
substrate for PP5 in this system.  Furthermore, von Kriegsheim and co-workers (2006) noted 
that PP5 may serve to negatively regulate ERK1/2 signalling by dephosphorylating Raf-1 
which suggests that downstream effectors, such as eIF4E, may also be affected.   
Any potential work to elucidate a role for PP5 would be severely hampered by a lack of a 
suitable or specific inhibitor of PP5 (Swingle et al., 2007).  Studies of the function of PP5 
have been aided by RNA interference against it (Messner et al., 2006) as well as the 
generation of mice deficient in PP5 (Amable et al., 2011).  Nevertheless, given the problems 
detailed in Section 3.4.3 – Problems Encountered & Troubleshooting, these do not appear 
to be promising avenues.  However, both Gentile et al. (2006) and Messner et al. (2006) 
have used PP5 in which the Tyr-451 is mutated to an Alanine residue.  The result of this is a 
considerable reduction in sensitivity to the inhibitor, Okadaic Acid.  A comparison of the 
effects Okadaic Acid has upon wild type PP5 and the resistant PP5 may yield information on 
whether this phosphatase affects eIF4E phosphorylation or the activity of upstream 
signalling components, such as MNK1, MNK2 or eIF4G. 
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Whilst the only direct link between mTORC1 inhibition and PP2A appears to be one of 
activation, there is some evidence that PP2A may be positively regulated by negative 
feedback loops that exist between AKT1 and mTORC1 (as described in Section 3.1.3 – 
Interplay Between mTORC1 and AKT1).  Although AKT1 is negatively regulated by PP2A 
(Hong et al., 2008; Aceto et al., 2009; Kim et al., 2009b), there is some evidence to suggest 
that there is some dual-regulation of PP2A and AKT1.  In response to Insulin stimulation, the 
increase in AKT1 phosphorylation occurs concomitantly with an increase in PP2A 
phosphorylation (Kumar & Tikoo, 2015).  This phosphorylation occurs on the Tyr-307 residue 
(Ibid) which is noted as suppressing the phosphatase activity of PP2A (Chen et al., 1992).  
This suggests that enhancing the activity of AKT1 would increase the phosphorylation of the 
inhibitory Tyrosine residue of PP2A.  This could be achieved with, for example, low 
concentrations of Rapamycin.  Although not demonstrated, this could act to counter the 
increase in PP2A activity noted by Hartley and Cooper (2002) and Bishop et al. (2006).  
While both Src (Chen et al., 1992; Arif et al., 2014) and Glycogen Synthase Kinase 3β (Yao et 
al., 2011) are known to phosphorylate PP2A, it is not clear whether AKT1 is involved in 
either mechanism. 
Whilst somewhat subjective, the first and second explanations given towards the start of 
this section have been validated by keeping eIF4E at a higher level than 4E-BP1 and the 
removal of a dependence on MNK1 and phosphorylated eIF4G from the model.  Indeed, 
analogous changes in the small model had already been shown to result in the level of eIF4E 
phosphorylation increasing in response to Rapamycin.  The removal of these was shown to 
bring about an increase in eIF4E phosphorylation, as shown in Section 2.2.4 – Evaluation of 
the Predictive Power of the Final Model.  The removal of these effectors demonstrates that 
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MNK2 is the kinase responsible for the increase in eIF4E phosphorylation, even in the 
absence of any increase in ERK1 or ERK2 activity.  Whilst in this case it is harder to ascribe a 
role for the third hypothesis mentioned above, the inhibition of a phosphatase cannot be 
ruled out as it is a possibility that the increase in MNK2 phosphorylation accompanying 
Rapamycin treatment is associated with a reduction in phosphatase activity. 
Section 2.2.4 – Evaluation of the Predictive Power of the Final Model 
The final version of the Petri Net model contained 511 molecular species and 584 molecular 
interactions.  These species and interactions were derived from exisiting literature, detailing 
the interactions between mammalian cellular signalling components regulating a variety of 
eIFs and between the translation initiation machinery itself.   
Before starting the next phase of the project, implementing the effects viral infection has 
upon the signalling network and the cellular translational machinery (as detailed in Chapter 
4 – Modelling the Effects of Viral Infection), it was necessary to re-evaluate the predictive 
power of the model.  This was of particular importance once eIF4E phosphorylation was 
increased in response to Rapamycin.  The dataset against which this model is tested is 
shown in Supplementary Information 2.  Furthermore, work in this section will also address 
potential concerns that the model was over-trained to the Benchmark Dataset against which 
the behaviour of the model was compared. 
Prior to detailing the results of this final round of predictive power analysis, it is necessary to 
address a point mentioned in Section 2.1.2 – The Binary Model Formalism.  It must be 
demonstrated that the Binary Model Formalism is rigorous and does not lead to a model 
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which permits a molecular species to be loaded with more than one discrete activity level 
(Figure 2.2.4a). 
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Figure 2.2.4a – Confirmation of the Binary Nature of the Model Formalism.  A QSSPN simulation was run 
sampling 100 trajectories.  Rather than interrogating the model with Reachfq to see how many trajectories 
reach one discrete activity level of each molecular species, the interrogation determined how many 
trajectories resulted in each model effector reaching two discrete activity levels.  All model effectors in this 
list were included in the model refinement process.  Protein Synthesis was included here as the 
overarching aim of the project was to model the regulation of nascent protein synthesis. 
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Supplementary Information E7 – Frequency Data Generated by Reachfq with Associated 
99.99% Binomial Confidence Intervals (sheet entitled Final Binary Model) details the 
frequency values, and associated 99.99% Binomial Confidence Intervals, calculated from the 
results of the QSSPN simulations for each of the inhibitor models.   The frequency values 
and associated 99.99% Binomial Confidence Intervals of the common components, found in 
both the model and Human Phospho-MAPK Arrays (as discussed in Section 3.3.5 – 
Comparison of Model Results to Array Data) are shown in Figure 2.2.4b.  The final model 
file is provided in Supplementary Information E3 (as both a Snoopy model file (E3a) and an 
SBML file (.xml)) (E3b). 
Importantly, eIF4E phosphorylation was shown to be increased in response to Rapamycin.  
This was determined through an increase in the frequency of trajectories reaching one 
discrete activity level of phosphorylated eIF4E (0.492 in the Wild Type model versus 0.805 in 
the Rapamycin model).  Such an increase was expected based upon the findings of a number 
of studies (Sun et al., 2005; Wang et al., 2007c; Jin et al., 2008a; Grosso et al., 2011; Marzec 
et al., 2011; Stead & Proud, 2013; Eckerdt et al., 2014).  Moreover, the continued presence 
of an increase in trajectories reaching phosphorylated MNK2 in response to Rapamycin 
(0.463 in the Wild Type model versus 0.761 in the Rapamycin model), is in keeping with 
earlier work (Stead & Proud, 2013).   
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Wild Type Upper Lower Rapamycin Upper Lower 
ppERK1 0.520 0.570 0.468 0.525 0.576 0.473 
ppERK2 0.500 0.552 0.448 0.512 0.564 0.460 
pRSK1 0.577 0.627 0.525 0.560 0.611 0.508 
ppp38a 0.537 0.588 0.485 0.544 0.595 0.492 
pJNK1 0.594 0.644 0.542 0.625 0.674 0.574 
mTORC1-Act 0.555 0.606 0.503 0.000 0.011 0.000 
ppS6K1 0.153 0.194 0.119 0.000 0.011 0.000 
ppAKT1 0.569 0.620 0.517 0.006 0.021 0.002 
pMKK3 0.542 0.593 0.490 0.521 0.572 0.469 
pMKK6 0.534 0.585 0.482 0.529 0.580 0.477 
pMSK2 0.607 0.656 0.555 0.598 0.648 0.546 
pCREB 0.576 0.626 0.524 0.573 0.623 0.521 
pGSK3 0.546 0.597 0.494 0.256 0.304 0.213 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.4b – Components of the Model Common to Human Phospho-MAPK Array.  Model 
components for which the effects of Rapamycin were determined using the Human Phospho-
MAPK Arrays (the overall results of which are detailed in Section 3.3.2 – Evaluation of the 
Human Phospho-MAPK Arrays) were evaluated using QSSPN.  Binomial Confidence Intervals, 
calculated in R, were used to find regions of significant difference, shown in red, by comparing 
the frequency of activation for each effector in the Wild Type and Rapamycin model. 
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Figure 2.2.4c summarises the comparison between the behaviour of the model and either 
the Final Benchmark dataset of 134 literature articles concerning the effects chemical 
inhibitors have upon model effectors, or the results of the Human Phospho-MAPK Arrays.  
The Final Benchmark dataset is given in Supplementary Information 2, whilst the 
bibliographic information contained within it is given in Supplementary Information 1a. 
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i.   
  Confusion Matrix Values  
Model TP TN FP FN MCC Value 
BIX02189 1 7 0 4 0.3568 
CGP57380 4 4 0 1 0.8000 
GSK2334470 2 12 0 2 0.6547 
LY294002 4 3 0 6 0.3651 
PD184352 5 1 0 7 0.2282 
PD98059 9 3 1 3 0.4472 
Rapamycin 6 5 0 5 0.5222 
SB203580 5 4 3 6 0.0255 
SP600125 10 3 0 5 0.5000 
XMD8-92 2 2 0 0 1.0000 
Array Data 3 6 1 3 0.3858 
 
ii.        
 Confusion Matrix Values 
 
Measures of Predictive Power 
 TP TN FP FN MCC Value AC Value α-Value 
 
Overall 51 50 5 42 0.4558 0.4558 1.94x10-8 
        
Figure 2.2.4c – Evaluation of the Predictive Power of the Final Version of the Model.  (i) By 
comparing the Final Benchmark dataset with the behaviour of the model, it was possible to produce 
Confusion Matrices detailing a qualitative measure of predictive power.  Such matrices characterise 
the behaviour of the model as being either True Positive (TP), True Negative (TN), False Positive (FP) 
or False Negative (FN).  Additionally, under ‘Array Data’ it was possible to evaluate the behaviour of 
model effectors which are also found on Human Phospho-MAPK Arrays (as detailed in Section 3.3.2 
– Evaluation of the Human Phospho-MAPK Arrays).  For each inhibitor and the experimental data, a 
quantitative measure of predictive power is given in the form of the Matthews’ Correlation 
Coefficient (MCC).  (ii) The overall predictive power is found by pooling the Confusion Matrix 
variables and calculating a final MCC value.  Additionally, the Approximate Coefficient (AC) was also 
calculated.  The Chi Square Test α-Value was calculated to ensure the level of predictive power was 
significantly different from random. 
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Overall the final version of the binary model has considerable predictive power which is 
conserved following the alterations to the model that corrected the discrepancy in eIF4E 
phosphorylation following Rapamycin inclusion.  Whilst the predictive power does suffer a 
slight reduction (from MCC = 0.4652 (as calculated in Section 2.2.2 – Re-Evaluation of the 
Binary Model) to 0.4558) this is not significant (as determined by a Chi Square Test (α = 
0.2747)).  A further Chi Square Test revealed that the Matthews’ Correlation Coefficient for 
this model is significantly different from random (α = 1.94x10-8). 
Whilst it is not feasible to reconstruct the model multiple times, nor is it possible to perturb 
the parameters of a qualitative non-parametric model, it was possible to ensure that this 
MCC value is representative of a model which has not been over-trained to a particular 
dataset.  To this end, parts of the Final Benchmark Dataset were, randomly removed and 
the MCC value recalculated, as shown in Figure 2.2.4d.  Whilst this is not a cross-validation 
procedure in a machine learning sense, it is an analysis of the stability of the results 
obtained during this work and demonstrates that the model provides stable predictions of 
the perturbations induced by inhibitors.  
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Figure 2.2.4d – Stability Analysis of the Final Model.  In order to demonstrate that the model 
can provide stable predictions of the behaviour of inhibitors, subsets of the Final Benchmark 
Dataset were randomly chosen.  These subsets consisted of half of the data points within the 
Final Benchmark Dataset.  Using the recorded Confusion Matrix outcomes (True Positive (TP), 
True Negative (TN), False Positive (FP) and False Negative (FN)) of these data points, it was 
possible to recalculate the predictive power of the model using the Matthews’ Correlation 
Coefficient (MCC).  Whilst the five subsets used each have different levels of predictive power, 
the MCC values are not dissimilar to the Overall value calculated earlier in the section (shown in 
Figure 2.2.4b).  To demonstrate statistical significance a Chi Square Test was performed on all 
data.  The resulting α-value provides evidence of a model having a level of predictive power 
which is statistically significant from random. 
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Section – 2.3 - Discussion 
Section 2.3.1 – Mechanism of Increasing eIF4E Phosphorylation in Response 
to mTORC1 Inhibition 
With regards to the proposed mechanism by which Rapamycin leads to an increase in eIF4E 
phosphorylation, three theoretical mechanisms have been proposed to explain this.  
However, it is likely that a combination of the three would be required.  It seems possible in 
order for any phosphorylation of eIF4E to occur during Rapamycin treatment that the cell 
must contain a larger pool of this initiation factor than that of 4E-BP1.  Following on from 
this, experimentally a decrease in AKT1 phosphorylation on the mTORC2-dependent site is 
seen, it is logical to assume that mTORC2 inhibition occurs, therefore, for eIF4E 
phosphorylation to increase in response to Rapamycin, mTORC2 cannot be the only kinase 
responsible for activating the eIF4G kinase, PKCα.  Inhibition of an mTORC1-stimulated 
protein phosphatase, for example PP5, would then occur.  The result would be a system in 
which eIF4E is phosphorylated by both an increase in the positive regulatory signals and a 
decrease in the signals that negatively regulate eIF4E phosphorylation. 
While the work presented in this chapter, offered the circumstances required for the 
mTORC1-mediated increase in eIF4E phosphorylation, the finding that the phosphorylation 
of this initiation factor is increased is not novel.  Several studies have similarly noted this 
effect (Sun et al., 2005; Wang et al., 2007c; Jin et al., 2008a; Grosso et al., 2011; Marzec et 
al., 2011; Stead & Proud, 2013; Eckerdt et al., 2014).  A more detailed summary of the 
findings of these papers is given in Section 3.1.2 – eIF4E Phosphorylation During mTORC1 
Inhibition.   
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The 99.99% Binomial Confidence Intervals infer there is no effect of Rapamycin treatment 
on the activation of ERK1 or ERK2 and this is in agreement with Marzec et al. (2011) and 
Stead and Proud (2013).  The notion of Rapamycin treatment having no effect on ERK1/2 
activity (Oh et al., 2001b; Omura et al., 2005; Soares et al., 2013) is somewhat controversial, 
with other studies noting an increase (Carracedo et al., 2008; Chaturvedi et al., 2009).  
However, this can be explained by differences in the concentration of Rapamycin used 
(Chen et al., 2010).  This aside, and in agreement with the work of Stead and Proud (2013), 
the model does predict that MNK2 mediates this alteration to eIF4E phosphorylation in an 
ERK1/2-independent manner. 
Section 2.3.2 – Predictive Power of the Final Version of the Model 
The re-evaluation of the predictive power of the final version of the binary model displayed 
an increase in eIF4E phosphorylation.  This increase was achieved through the elimination of 
molecular interactions linking eIF4G phosphorylation and MNK1 to the phosphorylation of 
eIF4E.  The elimination of these molecular interactions goes some way towards proving that 
PKCα phosphorylation cannot rely solely upon mTORC2.  The second change to the model 
was to maintain a pool of eIF4E so that it was in excess over the level of 4E-BP1 and does 
prove that there must be some disparity in the cellular pools of these factors.  Only linking 
the decrease in activity of a phosphatase was not attempted here.  This was not investigated 
as the nature of the relationship between mTORC1 and cellular phosphatases is not clear 
and mechanistically difficult to implement. 
As the final version of this model, it was important to ensure the predictive power was 
maintained at a level at which the model is an accurate representation of the regulatory 
network that controls translation initiation.  The final version of the binary model was raised 
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to a values of MCC = 0.4558.  Given the probability of seeing this level of predictive power 
by chance was very low (α = 1.94x10-8), the model has achieved a significant predictive 
power. 
In addition to measuring the predictive power of the model, it was also necessary to ensure 
that the model had not been over-trained to the benchmark dataset against which it was 
tested.  To this end, a form of cross-validation was used.  Cross-validation is a term from the 
machine learning field (Bousquet & Elisseeff, 2002; Shipp et al., 2002; Arlot & Celisse, 2010).  
All available data is divided into ‘training’ and ‘validation’ sets.  Subsequently, the model is 
automatically trained on the ‘training’ set and evaluated against the ‘validation’ set.  This 
division is then randomly changed and the process repeated.  This methodology is not 
applicable in the field of GSMN model reconstruction, as such models are constructed 
manually rather than automatically.  Manual reconstruction of large-scale models cannot be 
repeated multiple times as it takes many months to complete by expert bio-curators (Terzer 
et al., 2009; Henry et al., 2010 (as cited by McCloskey et al., 2013)).  Consequently, none of 
the models in the Constraint Based Modelling field is formally cross-validated in the same 
way as in the machine learning field.  Despite this controversy, the Constraint Based 
Modelling field has achieved spectacular successes in biotechnology (Scheibe et al., 2009; 
Fang et al., 2011) and recently has been gaining applications in the pharmaceutical industry 
(Trawick & Schilling, 2006).  This work further extends the manual, expert reconstruction 
approach to the qualitative modelling of large-scale signalling networks. 
With this in mind, work was conducted to demonstrate the predictive power of the model.  
Firstly, the Benchmark Datasets of responses to external perturbations was constructed.  
Such datasets were not were not used in the initial round of model construction.  
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Consequently, the MCC of 0.2354 can be used to demonstrate the predictive power of the 
model, prior to any refinement.  This MCC value was found to be statistically significant.  
Furthermore, the model has been used to make predictions regarding biological behaviour 
which dedicated experimental work has been conducted to validate (detailed in Chapter 3 – 
Experimental Validation of Model Predictions). This established that the model can be used 
to make predictions which are useful in guiding future experimental work.  This is in fact the 
most important demonstration of the predictive power of the model. 
A further indication that the model is not over-trained in a machine-learning sense is that it 
is not perfect.  It would be relatively easy to construct rules, such that all responses in the 
Benchmark Dataset would be reproduced.  This has not been done.  Instead, the model has 
been modified exclusively when there is peer-reviewed literature supporting the relevant 
modification to a molecular interaction.  This approach did not lead to a model with perfect 
predictive power, but rather a model with statistically significant MCC value.  Such a value 
indicates that many discrepancies between the current state of knowledge on molecular 
interactions and the behaviour of the model still exist.  Such incongruities were left in the 
model rather than being removed by arbitrary over-training. 
Whilst the points listed above make a compelling argument against the model being over-
trained, the work detailed in Figure 2.2.4c provide an argument for a reader originating in a 
machine-learning field.  Each of the five subsets of the Benchmark Dataset were randomly 
selected and yield a level of predictive power that was comparible to the overall level of 
predictive power of MCC = 0.4558.  Moreover, these subsets were capable of producing 
levels of predictive power that were significantly better than random. 
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Section 2.3.3 – Problems Encountered & Troubleshooting 
The main problem encountered during the completion of work that contributed towards 
this chapter occurred when trying to correct the decrease in eIF4E phosphorylation in the 
Rapamycin model.  Two issues became evident here.  Firstly, dissecting useful data from the 
large model proved difficult given that there is a high degree of cross-talk between the 
signalling pathways.  Secondly, the interrogation of the model by either Reachfq or Eventfq 
did not readily lead to a potential mechanism.  
These problems were overcome through the generation of a small scale model.  This model 
allowed for the easy identification of effectors critical for eIF4E phosphorylation.  From here 
it was possible to use the knowledge of these effectors to construct a literature-based 
mechanism, as detailed in Section 2.2.3 – Mechanism by Which mTORC1 Inhibition Affects 
eIF4E Phosphorylation. 
Section 2.3.4 – Concluding Remarks 
Results of this project are novel because, to date, no computational model of mammalian 
translation has been produced.  In contrast to a yeast model of translation produced by 
Firczuk et al. (2013), the model presented here is entirely qualitative.  Moreoever, the 
model of Firczuk and co-workers (2013) is very much limited in scope with the model 
encompassing only the translational machinery.  The model presented here covers not only 
the translational machinery but also the signalling network that regulates this process and 
so is not comparable to the Firczuk et al. (2013) model.  A quantitative model of the 
signalling pathways regulating translation initiation could not have been constructed due to 
a lack of quantitative parameters. 
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The model has been subject to multiple rounds of model refinement.  As a result of this 
rigorous process, the predictive power has been raised from a questionable MCC = 0.2354 
to a more sound MCC = 0.4558.  This process has largely been achieved through increasing 
the cross-talk between signalling pathways.  Similarly, the main motivation of establishing 
more cross-talk has been to reduce the number of FP readings whilst simultaneously 
increasing the number of TP determinations.  This was of considerable importance given 
that these have more marked effects on the MCC values than either TN or FN numbers 
(Baldi et al., 2000).   
It has been argued that MCC values are inherently more meaningful than the AC values, as 
the AC does not necessarily equate random predictions with zero (Baldi et al., 2000).  
Furthermore, Baldi and colleagues (2000) take the view that the AC is ‘unnecessary’.  
However, in this case with the MCC and AC being calculated in different ways, it was 
included as a check to ensure that the calculated predictive power was significant.   
The formation of a benchmark dataset for each inhibitor can be viewed as adding 
considerable value to this work.  It ultimately allowed for the predictive power of the model 
to be quantified and improved upon.  By ensuring that stimulation of cells was restricted to 
the relevant dataset, it was possible to ensure that the inhibitors were the causative agents 
producing the effects.  Moreover, it has been shown that, although cell type differences 
may be important in some cases, it is necessary to include multiple cell types in order to 
ensure a large enough number of data points.  The importance of cell type differences can 
be reduced by verifying inhibitor effects across multiple studies using multiple cell types.     
Over the course of the iterations to the model, two main hypotheses were formulated 
about the regions of differences between the Wild Type and the Rapamycin models.  There 
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was an alteration in eIF4E phosphorylation when the Rapamycin was included in the model.  
This finding was relevant as it was a prediction that linked a signalling component of the 
model to the control of translation initiation and provided an opportunity to experimentally 
validate the model.  Secondly, the model inferred that AKT1 phosphorylation should also be 
affected by mTORC1 inhibition with Rapamycin.  Both of these predictions were be tested 
and the results are given in Chapter 3 – Experimental Validation of Model Predictions. 
While the work presented in this chapter, offered the circumstances required for the 
mTORC1-mediated increase in eIF4E phosphorylation, the finding that the phosphorylation 
of this initiation factor is increased is not novel.  Several studies have similarly noted this 
effect (Sun et al., 2005; Wang et al., 2007c; Jin et al., 2008a; Grosso et al., 2011; Marzec et 
al., 2011; Stead & Proud, 2013; Eckerdt et al., 2014).  A more detailed summary of the 
findings of these papers is given in Section 3.1.2 – eIF4E Phosphorylation During mTORC1 
Inhibition.   
The 99.99% Binomial Confidence Intervals infer there is no effect of Rapamycin treatment 
on the activation of ERK1 or ERK2 and this is in agreement with Marzec et al. (2011) and 
Stead and Proud (2013).  The notion of Rapamycin treatment having no effect on ERK1/2 
activity (Oh et al., 2001b; Omura et al., 2005; Soares et al., 2013) is somewhat controversial, 
with other studies noting an increase (Carracedo et al., 2008; Chaturvedi et al., 2009).  
However, this can be explained by differences in the concentration of Rapamycin used 
(Chen et al., 2010).  This aside, and in agreement with the work of Stead and Proud (2013), 
the model does predict that MNK2 mediates this alteration to eIF4E phosphorylation in an 
ERK1/2-independent manner. 
 
 Page 158 
 
 
 
 
 
 
 
 
 
 
Chapter 3 – Experimental Validation 
of Model Predictions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page 159 
 
Section 3.1 – Introduction 
In Chapter 2 – Model Creation & Refining two model predictions were generated, 
concerning the effect Rapamyin had upon AKT1 and eIF4E phosphorylation.  In the final 
version of the model (detailed in Section 2.2.4 – Evaluation of the Predictive Power of the 
Final Model) Rapamycin was found to increase eIF4E phosphorylation (as measured by an 
increase in the frequency of trajectories leading to the production of eIF4E 
phosphorylation), from 0.492 in the Wild Type model to 0.805 in the Rapamycin model.  
Furthermore, AKT1 phosphorylation was shown to be decreased by the incorporation of 
Rapamycin into the model, with the frequency of trajectories reaching phosphorylated AKT1 
falling from 0.569 in the Wild Type model to 0.006 in the Rapamycin model.  Both of these 
behaviours required experimental validation to corroborate the predictions which are 
detailed in this chapter. 
Section 3.1.1 – Rapamycin 
Rapamycin, or Sirolimus, is a macrolide agent derived from isolates of Streptomyces 
hygroscopicus (Sehgal et al., 1975; Vézina et al., 1975; Rani et al., 2013).  Rapamycin acts as 
an immunosuppressive agent and potent antifungal agent (Vézina et al., 1975; Martel et al., 
1977; Kino et al., 1987a; Kino et al., 1987b (as cited by Abraham & Wiederrecht (1996)).  
Both behaviours can be explained by Rapamycin acting to arrest the cell cycle in the G1 
phase (Heitman et al., 1991; Kawamata et al., 1998; Decker et al., 2003; Zinzalla et al., 
2007). 
The mechanism by which Rapamycin inhibits mTOR involves many of the 14 FK506-Binding 
Proteins (FKBP) but FKBP-12 predominates (Wandless et al., 1991; Chiu et al., 1994; Fruman 
et al., 1995; Kozany et al., 2009 (as cited by März et al., 2013)).  Rapamycin forms a complex 
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with FKBP12 which then binds to the FKBP12-Rapamycin Binding domain of mTOR located 
close to the mTOR active site (Vilella-Bach et al., 1999; Banaszynski et al., 2005; Yang et al., 
2013a).  As a consequence of this binding, the active site is hindered and thus, mTOR is 
inhibited (Yang et al., 2013a). 
Section 3.1.2 – eIF4E Phosphorylation During mTORC1 Inhibition 
The general information regarding phosphorylation of eIF4E is discussed in Section 1.2.2 – 
eIF4E Phosphorylation and The Role of ERK1/2 & p38.  A number of studies have noted 
that mTORC1 inhibition causes an increase in eIF4E phosphorylation (Sun et al., 2005; Wang 
et al., 2007c; Jin et al., 2008a; Grosso et al., 2011; Marzec et al., 2011; Stead & Proud, 2013).  
Stead and Proud (2013) noted that MNK2a appears to have greater inherent activity 
through a reduction in the level of phosphorylation of the Serine residue at position 437 in 
response to Rapamycin exposure.  Furthermore, this greater basal level of activation occurs 
without any input from the upstream mitogen-activated protein kinase, ERK1/2 (Ibid).  This 
finding is in keeping with the work by Eckerdt and co-workers (2014).  These authors noted 
that whilst eIF4E phosphorylation increased following Rapamycin treatment, there was no 
concomitant increase in MAPK activity.  Eckerdt et al. (2014) went further to find that the 
intracellular 4E-BP1 concentration had little or no bearing on this level of increased eIF4E 
phosphorylation. 
Other studies noted that various other signalling pathways may be involved in this increase 
in eIF4E phosphorylation.  Both Sun et al. (2005) and Wang et al. (2007c) noted that the 
PI3K pathway appears to be involved in this increase in eIF4E phosphorylation, with Wang 
and colleagues (2007c) suggesting that PI3K is capable of influencing MNK activity through a 
yet undefined mechanism.  It is possible that this mechanism involves affecting the 
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phosphorylation of the Serine residue identified by Stead and Proud (2013).  However, 
Marzec and colleagues (2011) found that this increase was independent of PI3K, ERK1/2 and 
p38 activity while Grosso et al. (2011) hypothesised that p38 activity was responsible for the 
phosphorylation of eIF4E in Rapamycin treated cells.   
By interpreting the results presented in these works, one obvious and logical conclusion can 
be drawn: mTORC1 inhibition leads to an increase in eIF4E phosphorylation.  It would also 
appear, based on these studies that the increase in activity of MNK1 or MNK2 that brings 
about this increase is dependent upon neither ERK1/2 nor p38 activity.  This suggests that 
an, as yet, undefined but mTORC1-dependent, pathway is responsible for this increase. 
Section 3.1.3 – Interplay Between mTORC1 & AKT1 
The model of translational regulation requires not only an understanding of how the 
mTORC1 pathway is activated, but also how feedback mechanisms regulate the upstream 
component AKT1.  By including such mechanisms in the model, it is then possible to better 
model the complex patterns of behaviour observed in vivo.  Such mechanisms include the 
degradation of the Insulin Receptor Substrate (IRS)-1 (Haruta et al., 2000) and the mTORC1-
mediated inhibition of mTORC2 (Julien et al., 2010) and account for the increase in the 
phosphorylation of AKT1 (Ikezoe et al., 2007; Breuleux et al., 2009; Chiarini et al., 2009), 
observed after inhibition of mTORC1.   
The first mechanism concerns the down-regulation of a protein responsible for the 
induction of insulin receptor signalling, IRS-1 (Paz et al., 1996).  Such down-regulation of IRS-
1 was initially noted as being Rapamycin-dependent (Haruta et al., 2000; Pederson et al., 
2001; Takano et al., 2001), as shown in Figure 3.1.3a, with S6K1 phosphorylating IRS-1 on 
multiple amino acid residues, including Ser-307 and Ser-636 (Shah & Hunter, 2006; 
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Tremblay et al., 2007; Zhang et al., 2008).  This phosphorylation leads to the ubiquitin-
mediated degradation of IRS-1 (Greene et al., 2003; Xu et al., 2008; Scheufele et al., 2014).  
As the activation of PI3K and AKT1 signalling is downstream of IRS-1, this mechanism limits 
AKT1 signalling (Wan et al., 2007).  A similar mechanism has also been shown for the 
adaptor protein, Growth Factor Receptor-Bound Protein 10 (Hsu et al., 2011; Yu et al., 
2011). 
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Figure 3.1.3a – Overview of the Feedback Mechanism between S6K1 and the Insulin Receptor 
Substrate 1 (IRS-1).  IRS-1, in response to Insulin, becomes phosphorylated, which results in the 
activation of the PI3K signalling cascade and ultimately the activation of the mTORC1 pathway.  
Once S6K1 is phosphorylated by mTORC1 and PDK1, this kinase is capable of phosphorylating 
alternative sites of IRS-1, such as Ser-307 and Ser-636.  This leads to the ubiquitination of IRS-1.  
From this it is easy to see how inhibition of mTORC1 results in an increase in the activity of PI3K 
signalling components including AKT1.  It is worth noting that full activation of AKT1 requires both 
PDK1 and mTORC2.  However, for simplicity, in this case, only PDK1 has been shown. 
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The second mechanism by which mTORC1 regulates AKT1, involves the negative regulation 
of mTORC2.  S6K1 is capable of phosphorylating the Thr-1135 residue of the Rictor 
component of mTORC2, resulting in impaired activity towards mTORC2 substrates, including 
AKT1 (Julien et al., 2010) as shown in Figure 3.1.3b.  Additionally, S6K1 and AKT1 have been 
shown to phosphorylate another mTORC2 component, mSIN1, to trigger mTORC2 inhibition 
(Liu et al., 2013).  
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Figure 3.1.3b – Overview of the Feedback Mechanism that Exists between S6K1 and 
mTORC2.  The full activation of AKT1 requires phosphorylation of two sites (Ser-473 and Thr-
308) by mTORC2 (Sarbassov et al., 2005) and PDK1 (Wan & Helman, 2003; Tsuchiya et al., 
2013; Dangelmaier et al., 2014), respectively. Downstream of AKT1 lies mTORC1 and the 
kinase S6K1.  mTORC1, along with PDK1, are responsible for the full activation of S6K1.  A 
feedback mechanism between mTORC2 and S6K1 has recently been identified by Julien et al. 
(2010).  In this mechanism the mTORC2 component, Rictor, is phosphorylated via S6K1 on 
Thr-1135.  A second, analogous mechanism may involve the S6K1- and AKT1-dependent 
phosphorylation of another mTORC2 component, mSIN1 (Liu et al., 2013).  Both mechanisms 
would result in an inhibition of mTORC2.  Phosphorylation, resulting in activation, is denoted 
with a blue circle whilst those having an inhibitory effect are shown by red circles.   
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Whilst both mechanisms could explain an increase in AKT1 phosphorylation during mTOR 
inhibition, neither can explain a decrease.  As such, it is necessary to consider that 
Rapamycin may affect mTORC2.  Only nascent mTOR, or mTOR from disassembled mTORC1 
and mTORC2, is free to interact with the FKBP12-Rapamycin complex to be incorporated 
into inhibited mTORC2 (Brown et al., 1994, Sabatini et al., 1994; Sabers et al., 1995 (as cited 
by Sarbassov et al., 2006)).  Diminished AKT1 phosphorylation has been noted after 
prolonged or excessive Rapamycin exposure, suggesting Rapamycin is perhaps capable of 
inhibiting mTORC2 in a cell-type or dose-dependent manner (Sarbassov et al., 2006; Zeng et 
al., 2007; Wang et al., 2008a; Chen et al., 2010).  In keeping with this, decreased AKT1 
phosphorylation was seen at higher Rapamycin concentrations while increased at lower 
concentrations (Chen et al., 2010).  However, the ability of Rapamycin to inhibit mTORC2 is 
dependent upon the ratio of FKBP12 to FKBP51 expression in cells.  Cell lines with a higher 
ratio of these proteins are more receptive to mTORC2 inhibition (Schreiber et al., 2015). 
Alongside the aim of creating a model of the translation initiation regulatory pathways, this 
project must experimentally validate predicted behaviours of the model.  The information 
presented in the introduction to this chapter highlights that the regulation of AKT1 and 
eIF4E by mTORC1 is not fully understood.  This chapter aimed to validate the predictions of 
the model but not to provide a hypothesised mechanism.  Work presented in Chapter 2 – 
Model Creation & Refining, details a computationally elucidated mechanism by which eIF4E 
phosphorylation is affected by Rapamycin.   
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Section 3.2 – Materials & Methods 
Section 3.2.1 – Growth & Passage of RAW 264.7 Murine Macrophage Cells 
RAW 264.7 cells are an Abelson Murine Leukaemia Virus-transformed murine macrophage 
cell line (Raschke et al., 1978).  These cells (from European Collection of Cell Cultures, 
Product Number: 91062702, Lot: 13J020) were cultured in a vented T75 flask (Nunc™, 
Thermo Fisher Scientific Inc., Rockford, IL (USA)) using media containing 89% high glucose 
(4.5g per litre) Delbecco’s Modified Eagle Medium, containing Sodium Pyruvate and L-
Glutamine, 10% Foetal Bovine Serum and 1% Penicillin and Streptomycin (Gibco®, Life 
Technologies Corp., Carlsbad, CA (USA)).  The cells were incubated at 37°C with 5% Carbon 
Dioxide in a humidified Galaxy S incubator (Wolf Laboratories Ltd, York (UK)).  Cells were 
passaged at around 70% confluence, with each passage requiring new media, and the cells 
were detached from the T75 flask using 3mm glass beads (Sigma-Aldrich Co. LLC, St. Louis, 
MO (USA)).   
Section 3.2.2 – Determination of Rapamycin Cytotoxicity 
Given the qualitative behaviour of the model, the action of inhibitors can best be described 
as ‘all or nothing’ with regard to the effect these chemicals have on the main target.  To this 
end it was decided that a high concentration of Rapamycin would be used.  Jin et al. (2009) 
had already established data concerning the viability of RAW 264.7 cells with a combination 
of Rapamycin, up to a concentration of 10μM, and LPS.  This paper was used to guide the 
selection of Rapamycin concentrations to test and three concentrations of Rapamycin would 
be tested (10μM, 1μM and 0.1μM) in the absence of LPS.   
Cytotoxicity of Rapamycin was determined by measuring the concentration of Adenosine 
Trisphosphate in the cell media after treatment.  For this purpose the CellTiter Glo® 
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Luminescent Cell Viability Assay kit (Promega UK, Promega Corp., Madison, MI (USA)) was 
used.  The Rapamycin (Tocris Biosciences, R&D Systems Inc., Minneapolis, MN (USA)) was 
reconstituted in Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich Co. LLC, St. Louis, MO (USA)).  
Rapamycin was diluted to the desired concentration in RAW 264.7 cell media (the 
composition of which is detailed in Section 3.2.1 – Growth and Passage of RAW 264.7 
Murine Macrophage Cells).  Care was taken to ensure that the final concentration of DMSO 
was not greater than 1%.   
At approximately 70% confluence, RAW 264.7 cells were seeded in a white-walled 96-well 
plate (Corning Incorporated, Tewksbury, MA (USA)) and incubated overnight.  The cells were 
treated with three concentrations of Rapamycin (10μM, 1μM and 0.1μM) and two controls 
of 1% DMSO and cell media.  Additionally, to control for potential inherent luminescent 
properties of Rapamycin, DMSO or indeed the media, some samples containing no cells 
were also included.  In all cases, samples were seeded in triplicate. 
After three hours of incubation, the plate was left at room temperature for 30 minutes.  
Reconstituted CellTiter Glo® Reagent was added to each well in a one-to-one ratio with the 
amount of media already present in the well.  Following a ten minute incubation at room 
temperature, the luminescence of each well was recorded by a Glomax® 96 Microplate 
Luminometer (Promega UK, Promega Corp., Madison, MI (USA)). 
The results of this assay were analysed by subtracting the average luminosity of the wells 
containing no cells from each of the readings for the corresponding treatment.  The data 
was then normalized to the DMSO control.  Statistical analysis of this data will be discussed 
in Section 3.2.7 – Statistical Analysis. 
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Section 3.2.3 – Cell Harvesting & Bicinchoninic Acid (BCA) Assay 
RAW 264.7 cells, at around 70% confluence in a T75 flask, were seeded into untreated 6-
well plates (Nunc™, Thermo Fisher Scientific Inc., Rockford, IL (USA)) and incubated 
overnight at 37°C with 5% Carbon Dioxide.  The following day, the cells were treated with 
either 10μM Rapamycin or 1% DMSO for a period of either one or three hours (as stated in 
the subsequent Section 3.2.4 – Human Phospho-MAPK Array and Section 3.2.5 – 
eIF4E/Phosphorylated eIF4E & AKT1/Phosphorylated AKT1 Western Blot Analysis).    
Prior to lysis it was necessary to remove the treatment media and ensure as much serum 
was removed as possible, thus ensuring accurate measurement of cellular protein 
concentration.  To this end the cells were washed twice in chilled, sterile one-times 
Phosphate-Buffered Saline (PBS) solution.  The cells were then lysed in 70μl of Lysis Buffer 6, 
taken from the Human Phospho-MAPK Array kit (R&D Systems, Inc., Minneapolis, MN 
(USA)), and incubated at 4°C for 30 minutes to complete lysis.  The lysate was centrifuged at 
4°C for 5 minutes and the pellet discarded. 
The supernatant would later be used for both Western Blot analysis and the Human 
Phospho-MAPK Arrays.  Prior to this however, it was necessary to determine the 
concentration of protein within the lysates.  This was done using a BCA Assay kit (Pierce™, 
Thermo Fisher Scientific, Inc., Rockford, IL (USA)) and a 96-well Nunclon™ plate (Nunc™, 
Thermo Fisher Scientific Inc., Rockford, IL (USA)).  The standard curve was produced 
according to the manufacturer’s instructions.  25μl of each sample was loaded, in duplicate, 
onto the plate.  The resulting colour change was analysed with a Victor™ X5 Multilabel Plate 
Reader (Perkin Elmer, Inc., Waltham, MA (USA)).  Based upon the results of this assay, the 
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protein concentration in the samples could be adjusted to either 400μg or 50μg of protein 
per ml, for the Human Phospho-MAPK Array or Western Blotting, respectively. 
Section 3.2.4 – Human Phospho-MAPK Arrays 
RAW 264.7 cells were treated for one hour with either 10μM Rapamycin or 1% DMSO and 
harvested, according to the method outlined in the previous section.  Following the BCA 
assay, the protein concentrations in both lysates were adjusted to 400μg of protein per 
millilitre with MIlli-Q® Ultrapure (EMD Millipore Corp., Merck KGaA, Darmstadt (DE)) water 
and carried out in accordance with the manufacturer’s instructions.  This method required 
20μl of the Detection Antibody Cocktail being incubated with the lysate at room 
temperature for one hour prior to incubation with the membrane overnight at 4°C.  The 
array was subsequently developed onto Super-RX radiographic film (Fujifilm Corporation, 
Tokyo (JP)).  These arrays were done in triplicate, each with new lysates.   
The results of the array were analysed in the software ImageJ (Rasband, 1997-2012).  This 
software analyses the pixel colour density of each spot on the membrane.  As each protein 
is represented on the membrane in duplicate, the average is taken for each protein.  A value 
for the background pixel colour density is also taken and subtracted from the average value 
for each protein.  Normalization of all the data to the DMSO-treated controls allows for the 
identification of trends.  
Section 3.2.5 – eIF4E/Phosphorylated eIF4E & AKT1/Phosphorylated AKT1 
Western Blot Analysis 
Once determined by the results of the BCA assay, the protein concentration of each lysate 
was adjusted to 50μg of protein with MIlli-Q® Ultrapure water and Red Loading Buffer (New 
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England BioLabs Inc., Ipswich, MA (USA)).  Protein samples were separated using 4-20% 
gradient Mini-PROTEAN® TGX (Bio Rad Laboratories, Inc., Hercules, CA (USA)) Sodium 
Dodecyl Sulphate (SDS) Polyacrylamide Gel Electrophoresis (SDS-PAGE) gels with an SDS-
based Running Buffer (for solutions which are made in-house, the constituents are shown in 
Supplementary Information 4.  Prestained Protein Marker (P7706) (New England BioLabs 
Inc., Ipswich, MA (USA)) with a resolution of between 190kDa and 11kDa was included 
alongside the samples.  Samples were heated to 100°C for five minutes prior to loading.  
Proteins were transferred from the gel onto Immobilon-P (EMD Milipore Corp, Merck KGaA, 
Darmstadt (DE)) Polyvinylidene Fluoride (PVDF) membrane at 100V for 60 minutes in 
Transfer Buffer solution.  Ponceau staining solution was used to confirm the transfer from 
the gel to the PVDF membrane.  The membrane was cut to avoid the need for stripping the 
membrane between primary antibodies.  A blocking solution was added to the membrane 
and incubated for one hour, or in the case of the primary α-Tubulin antibody, overnight at 
4°C.  The antibodies used in testing the model validity are shown in Table 3.2.5a. 
Following the appropriate incubation period for each antibody, it was removed and washed 
in PBS-Tween solution.  The secondary antibody solutions were prepared in 0.5% (w/v) 
Marvel® milk powder (Premier Foods PLC, St. Albans (UK)) in PBS-Tween solution.  For α-
Tubulin and both eIF4E and Phospho-eIF4E antibodies, the anti-mouse (Dako Denmark A/S, 
Glostrup (DK)) and anti-rabbit (Dako Denmark A/S, Glostrup (DK)) secondary antibodies, 
respectively, were incubated at room temperature for one hour.  All antibodies used in the 
testing of the AKT1 phosphorylation prediction required anti-rabbit secondary antibodies 
(Dako Denmark A/S, Glostrup (DK)). 
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Antibody  Diluting 
Solution 
Amount of 
Antibody 
Incubation 
Period 
Supplier 
Rabbit Phospho-
eIF4E (Ser-209) 
#9741 
5% BSA in PBS-
Tween 
15μl  (1:667) Over Night Cell Signaling 
Technology, Inc., 
Danvers, MA (USA) 
Rabbit eIF4E 
#9742 
5% BSA in PBS-
Tween 
10μl (1:1000) Over Night Cell Signaling 
Technology, Inc., 
Danvers, MA (USA) 
Rabbit AKT1 
#9272 
5% BSA in PBS-
Tween 
10μl (1:1000) Over Night Cell Signaling 
Technology, Inc., 
Danvers, MA (USA) 
Rabbit Phospho-
AKT1 (Ser-473) 
#4060 
5% BSA in PBS-
Tween 
15μl (1:667) Over Night Cell Signaling 
Technology, Inc., 
Danvers, MA (USA) 
eIF6 
10291-1-AP 
5% BSA in PBS-
Tween 
10μl (1:1000) Over Night Proteintech Group, Inc., 
Chicago, IL (USA) 
α-Tubulin 
T9026 
PBS-Tween 2μl (1:5000) One Hour Sigma-Aldrich Co. LLC, 
St. Louis, MO (USA) 
Table 3.2.5a – Summary of the Antibody Solutions Used in Testing eIF4E and AKT1 
Phosphorylation. 
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The PVDF membranes were then washed in PBS-Tween solution and incubated for one 
minute in SuperSignal West Pico Chemiluminescent Substrate (Pierce®, Thermo Fisher 
Scientific Inc., Rockford, IL (USA)).  Each membrane was then developed onto Super-RX 
radiographic film.  As with the Human Phospho-MAPK Array kit, quantification of each band 
was carried out in ImageJ and normalized to the DMSO lysate which acts as a control. 
Section 3.2.6 – Re-Evaluation of the Model Based Upon the Results of the 
Human Phospho-MAPK Arrays 
Using the methods described in Chapter 2 – Model Creation & Refining the binary model 
was interrogated against the data collected in the by the Human Phospho-MAPK Array kits.  
Simulations were run looking at the activation of effectors that are found in both the model 
and the array.  The length of simulations was adjusted to ensure that the frequency of 
activation of each effector was around 0.5 in the Wild Type model.  Simulations of the 
model containing Rapamycin was run for the same lengths of time.  By comparing the 
99.99% Binomial Confidence Intervals for each effector it was possible to find regions of 
significant difference.  As previously stated, the Binomial Confidence Intervals were 
calculated in the statistical software R (R Core Development Team, 2013).   
To ensure that the only rigorous differences in the activation are found, only array 
constituents displaying a difference that remains significant after the Holm-Sidak Correction 
(as described in Section 3.2.7 – Statistical Analysis) was considered.  Given the qualitative 
nature of the model, only an increase, decrease or no effect were recorded. 
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Section 3.2.7 – Statistical Analysis 
This section will cover the methods used to evaluate the significance of results obtained in 
the cell viability assay, array or in Western Blotting.  Most of the statistical analysis was 
done using GraphPad Prism 6 (Version 6.05, for 64 bit Windows, GraphPad Software, Inc., La 
Jolla, CA (USA)).  In all cases the statistical analysis applies only to normalized data. 
The CellTiter Glo® Assay generated results for five independent variables (namely the three 
inhibitor concentrations, one DMSO treatment and the untreated, media-only, control).  
With this in mind, it was necessary to determine the distribution of the data.  Whilst it was 
not possible to determine, using GraphPad Prism, if the data points for each variable were 
normally distributed, it is possible to determine if the Standard Deviation of each group 
displays no significant difference.  This can be done using the Brown-Forsythe Test (Brown & 
Forsythe, 1974) calculated as part of the Analysis of Variance (ANOVA) function.  Given that 
the normality of the data cannot be determined, and assuming that the Standard Deviation 
of each group is not significantly different, the Kruskal-Wallis Test should be used in 
preference of a one-way ANOVA (Kruskal & Wallis, 1952).  No significant difference being 
found between concentrations of Rapamycin or between the concentrations and the DMSO 
or media controls, infers that cell viability is not affected by the presence of this inhibitor. 
The data collected from both the Human Phospho-MAPK Array data and Western Blot 
analysis is suitable to analysis with t-tests.  Once the average intensity of each 
phosphoprotein on the array is known and normalized (in triplicate), it can be analysed in 
GraphPad Prism using the multiple t-test function.  In order to correct for individual tests 
returning significant results solely due to multiple testing, a Holm-Sidak Correction (Sidak, 
1967; Holm, 1979) was applied.   The Western Blot data was also corrected, but in this case 
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a Bonferroni Correction was applied.  The p-value, calculated using an unpaired, non-
parametric t-test, was multiplied by the number of t-tests it was possible to carry out on a 
dataset (Emily et al., 2009).  In this case, the p-value was multiplied by three as the results 
were obtained in triplicate.  This method of p-value correction is preferable as it is viewed as 
very orthodox and results in ‘over-corrected’ (McIntyre et al., 2000 (As cited, and quoted, by 
Klein et al., 2005)) test statistics.  
Section 3.3 – Results 
Section 3.3.1 – Cytotoxicity of Rapamycin 
As the behaviour of a qualitative model treats the action of inhibitors as binary, in that the 
result is complete inhibition or complete activity of the target effector, it was decided that 
for experimental validation of predictions a high concentration of inhibitor would be used.  
To determine which concentration of Rapamycin does not have any effect on cell viability, 
the CellTiter Glo® Assay was used which measures the concentration of ATP released from 
cells lysed due to exposure to Rapamycin.   
As shown in Figure 3.3.1a, it appears that the mTORC1 inhibitor has mild, positive effects on 
cell viability.  As determined by the Kruskal-Wallis test though, none of these effects are 
significantly different from either the 1% DMSO treatment or the effects of media alone 
with the resulting p-values never reaching below 0.5437 (comparing 0.1μM Rapamycin and 
1% DMSO).  Although none of the concentrations tested produced a significant effect on cell 
viability, a concentration of 10μM was chosen as it represented the highest concentration 
tested.  Consequently, this concentration would be most in keeping with the qualitative 
behaviour of the model in which the action of inhibitors is viewed in an all or nothing 
manner.  
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Figure 3.3.1a – Evaluation of the Effects of Three Hour Treatments with Differing 
Concentrations of Rapamycin (Rapa) or 1% DMSO on the Murine Macrophage RAW 264.7 Cells.  
The effects on viability were measured by changes to the amount of ATP present in the 
supernatant following cell lysis.  The concentration of DMSO was never higher than 1%.  All data 
is given as relative to the effect of 1% DMSO.  The Kruskal-Wallis test was used to evaluate 
significance, with ‘ns’ denoting non-significant.  Error bars represent Standard Error of the Mean 
values for each dataset. 
  
ns 
ns ns ns 
ns ns ns ns 
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Section 3.3.2 – Evaluation of the Human Phospho-MAPK Arrays 
The binary model of translational control demonstrated that whilst eIF4E phosphorylation 
was affected by the presence of an mTORC1 inhibitor, the MAPKs, ERK1/2 and p38, were 
not.  Similarly, the level of phosphorylated AKT1 is predicted to be reduced during exposure 
to a high concentration of this macrolide.  It was important to establish if either MAPK or 
AKT1 was affected by treatment with Rapamycin.  The Human Phospho-MAPK Array kits 
offered a viable method to test all of these effects in a simple way.  RAW 264.7 cells were 
treated with either 10μM Rapamycin or 1% DMSO for one hour.  The array demonstrates, as 
shown in Figure 3.2.2a, that Rapamycin treatment has broad implications for MAPK 
signalling in RAW 264.7 cells. 
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Figure 3.3.2a – Evaluation of the Broad Early Effects of 10μM Rapamycin Treatment to the Murine Macrophage RAW 264.7 Cells.  Following treatment of RAW 264.7 
cells with either 10μM Rapamycin or 1% DMSO for one hour, cells were lysed using the Lysis Buffer 6 from the Human Phospho-MAPK Array Kit (R&D Systems Inc., 
Minneapolis, MN (USA)).  After the protein concentration of each lysate was adjusted to 400μg, the array was carried out in accordance with the manufacturers’ 
instructions.  The results were analysed in ImageJ.  T-tests were carried out on each phosphoprotein and were adjusted for multiple comparisons using the Holm-Sidak 
Correction.  Those phosphoproteins that were significant after the t-test are denoted with *. If they remained significant after the Holm-Sidak Correction they are 
denoted with **.  Error bars represent the Standard Error of the Mean.  
** * * * * 
Kinases 
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It was necessary to prove that Rapamycin was having an effect on the marketed, target 
substrate.  The Human Phospho-MAPK Array allows for measuring the level of mTOR 
phosphorylated on the Ser-2448 residue.  The phosphorylation of this Serine residue has 
been linked to S6K1 and 4E-BP1 phosphorylation (Dickinson et al., 2011) and has been used 
as a marker of mTORC1 activity (Altman et al., 2011).  This phosphorylation site has been 
shown to be responsive to Rapamycin treatment (Copp et al., 2009; Tyler et al., 2009; 
Carayol et al., 2010).   In this MAPK array, it was established that Rapamycin produced a 
statistically significant 41% decrease (p=1.95x10-4) in the phosphorylation of Ser-2448 of 
mTORC1, as shown in Figure 3.3.2a.  This p-value is that calculated after a Holm-Sidak 
Correction was applied. 
Establishing the activity of ERK1/2 and p38 in response to Rapamycin was an important 
determination with regards to experimentally validating the alterations to the level of 
phosphorylated eIF4E in Rapamycin treatment.  As shown in Figure 3.3.2a, neither kinase 
was affected by Rapamycin treatment.  The effect of Rapamycin on both ERK1/2 and p38 is 
not fully understood.  ERK1/2 has been shown to be subject to a diverse array of effects, 
with one study noting an increase (Chaturvedi et al., 2009), another a decrease (Chen et al., 
2010) and several displaying no effect (Omura et al., 2005; Soares et al., 2013).  Although 
the work of Chaturvedi et al. (2009) and Chen et al. (2010) indicated that the concentration 
of Rapamycin may be important in determining the direction of change, the work presented 
here is more in keeping with Omura et al. (2005) and Soares et al. (2013).  Several studies 
have noted that a feedback mechanism exists between ERK1/2 and mTORC1 (Carracedo et 
al., 2008; Melemedjian et al., 2013), however the finding that Rapamycin does not affect 
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ERK1/2, after a treatment of one hour at least, suggests that this mechanism could either be 
absent in RAW 264.7 cells or become important much later.   
As with ERK1/2, the published view of the relationship between Rapamycin and p38 is 
equally contradictory.  Oh et al. (2001b) and Omura et al. (2005) both found that p38 
activity was increased by Rapamycin.  Despite these publications contradicting the work 
presented here, several other studies are in agreement and note that Rapamycin has no 
effect on p38 activity (Cuenda & Cohen, 1999; Huang et al., 2003).   Whilst no definitive 
explanation for this can be given, it may reflect differences in cell type. 
With regards to regions of significant difference, 18 regions were noted as being different 
and, of these, nine regions were found to remain significant after the Holm-Sidak Correction 
was applied.  These regions are denoted with * and ** respectively in Figure 3.3.2a.  Of 
particular interest here is the finding that both AKT1 and AKT2 display significant inhibition 
of 65.7% and 50.5%, respectively.   Whilst the phosphorylation of both AKT1 and AKT2 was 
significantly reduced (with p = 0.018 and p = 0.014) neither were found to remain significant 
following the Holm-Sidak Correction.  However, the reduction (on average of 51.5%) of AKT 
Pan phosphorylation, representing the total of phosphorylated AKT1, AKT2 and AKT3, in 
response to Rapamycin remains significant after this correction.  Other differences that are 
significant in this robust sense are JNK3, MKK3, MKK6, Ribosomal Protein S6 Kinase α-4 
(MSK2), p38δ, p53 and RSK2. 
The results outlined in Figure 3.3.2a clearly demonstrate that Rapamycin has a pronounced 
inhibitory effect on a broad range of cellular targets.  This could reflect the central role of 
mTORC1 in the signalling network of the cell.  The work of Caron and co-workers (2010) 
clearly demonstrates that mTORC1 is linked to a wide variety of cellular processes and 
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pathways.  It is feasible that short-term exposure to Rapamycin, as used here, would have 
such pronounced effects on the signalling pathways examined by with these Human 
Phospho-MAPK Arrays.   
Section 3.3.3 – Alterations to eIF4E Phosphorylation Levels 
Phosphorylated eIF4E was not present on the Human Phospho-MAPK Arrays and thus it was 
not possible to test the effects of Rapamycin on the level of eIF4E phosphorylation using the 
approach described in the previous section.  In order to test the hypothesis that inhibition of 
the mTOR pathway by Rapamycin alters the level of eIF4E phosphorylation, immunoblotting 
was used.  Murine Macrophage RAW 264.7 cells were treated with either 10μM Rapamycin 
or 1% DMSO for one hour and lysed using the Lysis Buffer 6 supplied with the Human 
Phospho-MAPK Array kit.  After this time period, the protein concentration was adjusted to 
50mg per millilitre.  Although this was only conducted once, there was a mild, 18% increase 
in phosphorylated eIF4E in response to Rapamycin treatment (data not shown).   
In order to further investigate this effect, RAW 264.7 cells were treated for three hours with 
either 10μM Rapamycin or 1% DMSO.   As expected, quantification of the pixel intensity in 
ImageJ revealed that the increase in treatment length resulted in a greater increase in 
phosphorylated eIF4E of, on average, 44.0% (range of between 36.4% and 52.2%, p = 
0.0318) in the Rapamycin-treated RAW 264.7 cell lysates (as shown in Figure 3.3.3ai-ii).  The 
significance of this increase was determined using a two-tailed t-test with a Bonferroni 
Correction being applied to the resulting p-value.  The Bonferroni Correction was applied 
and the results of the two-tailed t-test were multiplied by three to account for the three 
independent, biological replicates conducted.   
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Figure 3.3.3a – Rapamycin-Induced Increase in Phosphorylation of eIF4E.  RAW 264.7 Cells were 
treated with 10μM Rapamycin or 1% DMSO for three hours.  50mg per ml of protein, from each 
lysate, were separated using SDS-PAGE and phosphorylated eIF4E (25kDa), eIF4E (25kDa) and α-
Tubulin (50kDa) were detected using immunoblotting.  i)  A representative blot of the increase in 
eIF4E phosphorylation due to Rapamycin treatment.  The levels of total eIF4E and the α-Tubulin 
loading control remain constant.  ii)  The pooled quantitative data of three independent 
replicates showing the mean ± Standard Error of the Mean.  This data is expressed as the level of 
phosphorylated eIF4E relative to the 1% DMSO control.  This quantification was tested using a 
two-tailed t-test after which a Bonferroni Correction was applied to the calculated p-value. 
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Section 3.3.4 – Confirmation of the Effect Rapamycin has Upon AKT1 
Phosphorylation 
Despite the fairly conclusive result generated in the Human Phospho-MAPK Arrays regarding 
a decrease in AKT1 phosphorylation on the Ser-473 residue, the effect was further 
investigated using immunoblotting.  RAW 264.7 cells were treated with either 10μM 
Rapamycin (in 1% DMSO) or 1% DMSO for three hours.  As was the case for the 
eIF4E/Phospho-eIF4E immunoblotting experiment, it was decided to attempt to accentuate 
the affect by increasing the length of Rapamycin treatment to three hours.   
As shown in Figure 3.3.4a, only a small, non-significant difference in the levels of Ser-473 
phosphorylated AKT1 was found between the Rapamycin-treated and control lysates.  On 
average the level of phosphorylated AKT1 was 20.4% (range of between 3.2% and 31.5%, p = 
0.4344) higher in the Rapamycin-treated lysates.  Reasons for this lack of significant 
difference are discussed in Section 3.4.2 – Validation of the AKT1 Phosphorylation 
Prediction.   
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Figure 3.3.4a – Effect of Rapamycin on the Levels of AKT1 Phosphorylation (Ser-473). RAW 264.7 
Cells were treated with either 10μM Rapamycin (in 1% DMSO) or 1% DMSO for three hours.  50mg 
per ml of protein from each lysate were separated using SDS-PAGE and phosphorylated AKT1 
(60kDa), AKT1 (60kDa) and eIF6 (27kDa) were detected using immunoblotting.   i)  The blot shown is 
representative of the results obtained.  Only very low levels of AKT1 phosphorylation (Ser-473) were 
noted.  The levels of the eIF6 loading control and total AKT1 remain constant.  ii)  The pooled data 
collected from three independent replicates ± the Standard Error of the Mean.  The data shown was 
quantified in the software ImageJ and is expressed as a ratio of the DMSO control.  The p-value 
shown was calculated using a Bonferroni Correction applied to the results of a two-tailed t-test. 
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Section 3.3.5 – Comparison of Model Results to Array Data 
Out of all the phosphoproteins recorded on the array, 13 were found to be present in the 
binary model.  As shown in Figure 3.3.5a, nine effectors displayed behaviour that was in 
agreement with the model.  Simulations performed to generate these results were run using 
QSSPN on the final version of the binary model, the overall results of which are detailed in 
Section 2.2.4 – Evaluation of the Predictive Power of the Final Model.  The results shown in 
this section were included in the overall analysis of the final model. 
The comparison of the model to the array data was done to show that the behaviour of the 
model correlates to experimental outcomes detailed in this chapter.  Furthermore, the 
additional testing of the model can be seen as adding further weight behind the view that 
the model is capable of mimicking experimental data.  The Matthews’ Correlation 
Coefficient (MCC) for this comparison is calculated using the equation given in Section 
2.1.4.2 – Evaluation of the Predictive Power of the Model.  The MCC calculated for 
available array data is 0.3958.   
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Effector Behaviour of the Effector in the Array Predicted
ppERK1 No Effect TN
ppERK2 No Effect TN
pRSK1 No Effect TN
p38α No Effect TN
pJNK1 No Effect TN
mTORC1-Act Inhibition Demonstrated TP
ppS6K No Effect FP
ppAKT Inhibition Demonstrated TP
pMKK3 Inhibition Demonstrated FN
pMKK6 Inhibition Demonstrated FN
pMSK2 Inhibition Demonstrated FN
pCREB No Effect TN
pGSK3 Inhibition Demonstrated TP
Figure 3.3.5a – Comparison of Array Data with the Behaviour of the Binary Model.  In 
keeping with the qualitative nature of the model, the array data was analysed as 
showing 10μM Rapamycin having no effect or being an inhibitor or activator of an 
effector.  The Binomial Confidence Intervals calculated for each effector allowed for 
differences to be found between the Wild Type or Rapamycin models.  Comparing the 
two datasets permitted a quantitative analysis of the predictive power of the model. 
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Section 3.4 – Discussion 
Section 3.4.1 – Validation of the eIF4E Phosphorylation Prediction 
The mTORC1 pathway is integral to growth and proliferation of cells (Laplante & Sabatini, 
2013) and, as of 2010, can be viewed as including close to one thousand molecular species 
(Caron et al., 2010).   Despite this broad knowledge base regarding the interactions of 
mTORC1 with other signalling components and pathways, the exact nature of the mTORC1 
input into many processes, for example eIF4E phosphorylation, remains unclear. 
In keeping with the prediction generated by the model, a number of studies have reported 
an increase in eIF4E phosphorylation in response to mTORC1 inhibition (Sun et al., 2005; 
Wang et al., 2007c; Jin et al., 2008a; Grosso et al., 2011; Marzec et al., 2011; Stead & Proud, 
2013).  Marzec and colleagues (2011) noted that this increase may be independent of 
ERK1/2 or p38α activity.  However, Grosso et al. (2011) argued that the remaining p38 
activity following mTORC1 inhibition, may account for the apparent increase in eIF4E 
phosphorylation.  The former is supported by the work of Stead and Proud (2013).  In this, 
they argued that the interaction between ERK1/2 and MNK2 is not affected by Rapamycin-
mediated mTORC1 inhibition (Ibid).   
The experimental results derived in this project have shown that the Rapamycin treatment 
produces a notable increase in eIF4E phosphorylation after just three hours of exposure.  
Whilst no attempt was made to distinguish whether this was through MNK1 or MNK2 
(discussed in Section 3.4.3 – Problems Encountered & Troubleshooting) the activity of both 
ERK1/2 and p38 were recorded in response to Rapamycin treatment.  After one hour of 
exposure there was no indication of the activity of either kinase increasing.     
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It can be argued that the work here is in agreement with that shown by Stead and Proud 
(2013).  In this work it was noted that Rapamycin was able to increase eIF4E 
phosphorylation through a MNK2-dependent but ERK1/2-independent manner.  Here the 
array data has shown no effect on the levels of phosphorylated ERK1/2 or p38α.  In fact, 
even one hour of Rapamycin treatment seemed to produce a reduction, albeit non-
significantly, in the levels of these phosphorylated kinases.  In keeping with this concept, the 
idea that at higher concentrations (at greater than 1μM) of Rapamycin there is concomitant 
inhibition of mTORC1 and mTORC2 which leads to inhibition of not just ERK1/2 but also 
AKT1 has been demonstrated (Chen et al., 2010).  This suggests that increasing the 
treatment length would produce ERK1/2 inhibition rather than activation. 
As already noted in Section 1.2.2 – eIF4E Phosphorylation and The Role of ERK1/2 & p38, 
eIF4E phosphorylation is now being seen as a mechanism by which genes associated with 
stress responses are being preferentially up-regulated (Andersson & Sundler, 2006; Herdy et 
al., 2012; Royall et al., 2015).  It is also of interest to note the MNK kinases are also capable 
of phosphorylating the Sprouty proteins (DaSilva et al., 2006; Sharma et al., 2012) and the 
Heterogenous Nuclear Ribonucleoprotein  A1 (hnRNP A1) (Buxadé et al., 2005).  Both of 
these have roles in the physiological response to cellular stress.  The Sprouty proteins are 
required for the negative regulation of Interferon-Stimulated Gene 15 and p38 (Sharma et 
al., 2012), and the response is MNK-dependent.  Furthermore, phosphorylated hnRNP A1 is 
known to play a role in the movement of mRNA to stress granules (Guil et al., 2006).   
The role of phosphorylated eIF4E in the physiological response to stress and the finding that 
inhibition of mTORC1 leads to increased resting activity of MNK2, suggest that mTORC1 is 
capable of suppressing the cellular stress response through modulation of MNK activity, as 
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shown in Figure 3.4.1a.  This hypothesis is supported, albeit indirectly, by the finding that 
S6K1 is capable of inhibiting Transforming Growth Factor-β-Activated Kinase 1 (TAK1) 
resulting in increased signalling through Nuclear Factor-κB (Kim et al., 2014).  Additionally, 
Shin et al. (2013) found that TAK1 was also capable of inhibiting S6K1 activation by 
preventing an interaction with the RAPTOR subunit of mTORC1.  These findings support the 
hypothesis presented here by demonstrating a link between cellular stress responses and a 
major pathway regulating cellular growth.  These works highlight that cell growth pathways 
and cell stress pathways appear to be able to negatively regulate each other as one 
becomes more necessary.  Upon mTORC1 activation, there is less requirement for the cell 
stress responses, and thus, there is less need for eIF4E phosphorylation to facilitate the 
associated gene expression change.  In this scenario the basal activity of MNK2, and the 
inducible MNK1 (Ueda et al., 2004), would be kept lower.  However, if the stress response is 
required, the level of mTORC1 activity could be decreased and bring about MNK1 induction 
as well as an increase in the basal level of MNK2 activity to allow such as a response. 
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Figure 3.4.1a – Hypothesis Linking mTORC1 to the MNK-Dependent Stress Response.  Given that 
eIF4E phosphorylation, via MNK2 (Stead & Proud, 2013), has been shown to increase during 
inhibition of mTORC1, it supports the hypothesis that inhibition of cell growth induces the cellular 
stress response.  In such a scenario, inhibition of mTORC1 leads to an increase in the basal activity 
of MNK2.  As a result, the phosphorylation of eIF4E and other substrates of the MNK kinases, 
hnRNP A1 and the Sprouty proteins occur.  eIF4E phosphorylation would promote the translation 
of mRNAs associated with the stress response.  hnRNP A1 would facilitate this by promoting the 
formation of Stress Granules.  The Sprouty proteins may then, through a feedback mechanism, 
serve to return the cell to an unstressed state once the inhibition of cell growth was removed.  
Links experimentally shown, either in the literature or here, are denoted by the unbroken green 
arrows, also denoting hypothesised links.  The red arrow illustrates the suppressive effect active 
mTORC1 has upon MNK2 to lower the level of basal activity. 
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Section 3.4.2 – Validation of the AKT1 Phosphorylation Prediction 
Due to the presence of a variety of feedback interactions, AKT1 can be viewed as being very 
tightly regulated by mTORC1.  One feedback loop is mediated by the phosphorylation, and 
subsequent degradation, of the IRS-1 by S6K1 (Tremblay et al., 2007; Xu et al., 2008; Zhang 
et al., 2008).  In this case, AKT1 is inhibited by this phosphorylation (Shah et al., 2004; Xu et 
al., 2008).  The importance of this mechanism of feedback inhibition can be seen in cases of 
Simian Virus 40 infection in which the proteolytic degradation of IRS-1 is inhibited.  This 
results in adherent activation of AKT1 and the ERK1/2 pathway components (Hartmann et 
al., 2014).  In the second case, S6K1 phosphorylates the Rictor subunit of mTORC2 (Julien et 
al., 2010) resulting in diminished output of mTORC2.  The result is a decrease in AKT1 
phosphorylation (Ibid).  There is also some evidence that mTORC2 may also play a role in the 
degradation of IRS-1, via phosphorylation, of the Serine residue at position 83, and thus, 
increasing the stability of the ubiquitin ligase Fbw8 (Kim et al., 2012). 
Rapamycin is known to affect AKT1 differently depending upon the concentration of the 
mTORC1 inhibitor used (Sun et al., 2005; Chen et al., 2010; Saores et al., 2013).  This leads to 
the conclusion that differing concentrations of Rapamycin are capable of affecting these 
feedback loops in different ways.   
Given the qualitative nature of the model, inhibitors behave in an all-or-nothing fashion 
with complete inhibition being found when they are present and complete activity of the 
target when absent.  As Rapamycin is capable of inhibiting mTORC2 (Sarbassov et al., 2006; 
Lamming et al., 2012; Schreiber et al., 2015), Rapamycin is viewed in the model as inhibiting 
this component so as to replicate the effects of exposure to prolonged or high 
concentrations of Rapamycin.   
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A by-product of testing the effects of Rapamycin treatment on the activity of ERK1/2 and 
p38α in RAW 264.7 murine macrophage cells was the investigation of AKT1 
phosphorylation.  The Human Phospho-MAPK Array data revealed that AKT1 and AKT2 
displayed significant inhibition in the presence of Rapamycin compared with the 1% DMSO 
control.  However, only AKT Pan remained significantly inhibited following the Holm-Sidak 
Correction.  To further validate this prediction, immunoblotting was carried out against 
AKT1 phosphorylation.  During this investigation, only very low levels of AKT1 
phosphorylated on the Ser-473 site was found, as shown in Figure 3.3.4a.  This very low 
signal resulted in accurate quantification becoming very difficult and raises the possibility 
that sensitivity of the differing antibodies (between the Human Phospho-MAPK Array and 
Western Blotting) may have been a contributing factor here.  Indeed the low signal may 
explain the relatively large Standard Error of the Mean values, as shown by the large error 
bars in Figure 3.3.4a.  Additionally, there is some evidence that the activation of AKT1 is 
governed, at least partly, by the cell cycle (Liu et al., 2014).  Given that the RAW 264.7 cells 
were growing asynchronously, it is possible that the reduction in AKT1 phosphorylation 
predicted by the model does occur despite not being observed in the Western Blotting work 
shown in Figure 3.3.4a.  Moreover, given the large change in AKT Pan phosphorylation, 
shown in Figure 3.3.2a it is not unreasonable to conclude that following a one hour 
treatment with 10μM Rapamycin, Ser-473 phosphorylation is discernibly reduced in a 
manner that is consistent with Rapamycin may be capable of inhibiting the Rictor subunit of 
mTORC2.  Based solely upon the results of the immunoblotting experiments presented in 
Section 3.3.4 – Confirmation of the Effect Rapamycin has Upon AKT1 Phosphorylation, it is 
however, not possible to say if this trend continues or if the situation is reversed.   
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From a modelling perspective both situations (of Rapamycin bringing about either an 
increase or decrease in AKT1 phosphorylation) are easily explainable.  If AKT1 
phosphorylation is to increase, the removal of Rapamycin-mediated mTORC2 inhibition is 
required.  Similarly, if a decrease is observed, the inhibition can remain.  Although not 
shown, both cases have been observed in silico during model simulations.   
Section 3.4.3 – Problems Encountered & Troubleshooting 
The work outlined in this chapter represented one of the most demanding points of the 
project in terms of the length of time taken.   
Initially, the intensity of bands obtained from Western Blotting was very low.  Several 
reasons were suggested that may account for this:  The method of cell lysis being such that 
samples were degrading during the harvesting process or the cells were not sufficiently 
stimulated to see background effects.  Thirdly, the method of development may not be 
sensitive enough to detect the relatively low signal of phosphorylated eIF4E.  LPS treatment 
of the RAW 264.7 cells was attempted which resulted in significant activation of multiple 
signalling pathways, as measured by both Western Blotting and Human Phospho-MAPK 
Arrays.  However, the stimulation of RAW 264.7 cells with LPS was found to be obscuring 
effects that Rapamycin was having upon the signalling pathways.  The results presented in 
Section 3.3.2 – Evaluation of the Human Phospho-MAPK Arrays show the effects that 
Rapamycin is capable of exerting upon the cell.  However during initial testing with the array 
kits, far fewer regions of difference were found between the 1% DMSO and 10μM 
Rapamycin samples when both were exposed to 10ng per ml LPS (from Escherichia coli 
Serotype O55:B5, TLRgrade™ Enzo (Life Sciences, Inc., Farmingdale, NY (USA))).   
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It would be interesting to examine the effects of Toll-Like Receptor (TLR) ligands other than 
LPS.  Other TLR ligands, such as Polyinosinic-Polycytidylic Acid (Poly(I:C)), are relevant to the 
cellular response to viral infection.  Poly(I:C) is a synthetic double-stranded RNA analogue 
(Field et al., 1967; Levy et al., 1969).  Consequently, the use of this TLR3 ligand would have 
produced an experimental system in which signalling pathways were activated in a manner 
that is similar, but not identical, to a virus-infected cell (Li et al., 2005b).  Although chemical 
stimulation of signalling pathways was attempted to overcome the problem of low signal 
intensity, it is worth noting that at this stage of the project, it was necessary to produce a 
model that accurately reproduced the cellular regulation of translation and not a system in 
which viral translation is modelled.  
This problem also extended to the evaluation of AKT1 phosphorylation with 
immunoblotting.  The very low signal generated is likely due to very low levels of AKT1 
phosphorylation in cells without stimulation.  This issue could have been intensified by 
potentially considerable differences in antibody sensitivities.  To address these two issues, 
stimulating RAW 264.7 cells with either a growth factor or TLR ligand could be of benefit if 
the experiments were going to be repeated.  Furthermore, the role of cell cycle progression 
in AKT1 phosphorylation should be investigated, possibly through the synchronisation of cell 
growth. 
The second potential problem was addressed by changing the lysis buffer used in harvesting 
the cells.  Several buffers were trialled and all produced a marked increase in the signal 
found after exposure to chemiluminescent substrate.  These methods included lysing the 
RAW 264.7 cells directly into sample buffer, as described in Simmonds et al. (2009).  It was, 
however, decided that using the Lysis Buffer 6 supplied with the Human Phospho-MAPK 
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Array kits would give some degree of uniformity to these experiments and thus ensure that 
the cells were handled in the same way across experiments.  
The method of developing the initial blots was limited to the FluorChem®Q apparatus (Alpha 
Innotech, ProteinSimple Inc., San Jose, CA (USA)).  Whilst this system was capable of 
detecting bands of high intensity, such as loading controls, it was not capable of detecting 
low intensity bands.  Even replacing the SuperSignal West Pico Chemiluminescent Substrate 
with SuperSignal West Femto Chemiluminescent Substrate (Pierce®, Thermo Fisher 
Scientific Inc., Rockford, IL (USA)) did not alleviate this problem and resulted in even higher 
levels of background signal.   
It was possible to overcome these problems with a combination of a traditional radiographic 
film based development process and switching to a new lysis buffer.  This suggests that a 
combination of signal degradation and insufficient sensitivity of the development process 
were to blame for these initial setbacks.  This being said, one point is still unresolved with 
regards to the method used to quantify radiographic film using pixel counting (as used in 
Section 3.3.2 – Evaluation of the Human Phospho-MAPK Arrays, Section 3.3.3 – 
Alterations to eIF4E Phosphorylation Levels and Section 3.3.4 – Confirmation of the Effect 
Rapamycin has Upon AKT1 Phosphorylation): the fact that exposure of radiographic film to 
the fluorescent signal of chemiluminescence does not produce a linear response (Gassmann 
et al., 2009).  Consequently, it may not be the most accurate method of quantification, 
although this method was recommended for use with the Human Phospho-MAPK Arrays by 
the manufacturer. 
One question is still unresolved with regards to Rapamycin leading to an increase in eIF4E 
phosphorylation.  This problem lies with the identification of the MAPK-Interacting Kinase 
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responsible for this increase.   Attempts have been made by other members of the research 
group, as part of the Royall et al. (2015) study, looking at using small interfering RNA (siRNA) 
to knock-down MNK1 and MNK2 in RAW 264.7 cells.  However, this work was not taken 
forward due to a lack of suitable internal controls and in some cases, knock-down of MNK1 
with siRNA targeted against MNK2.  Similarly, there is a lack of specific MNK1 or MNK2 
antibody, thus preventing direct visualisation of specific MNK phosphorylation during 
Rapamycin treatment.  The potential benefit of an additional approach, Clustered, Regularly 
Interspaced, Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein (Cas) (Cong et 
al., 2013; Mali et al., 2013) is discussed in Section 3.4.4 – Potential Future Work. 
Section 3.4.4 – Potential Future Work 
eIF4E phosphorylation is now being viewed as playing a part in mediating changes in gene 
expression.  mRNA transcripts involved in cellular stress appear to require the 
phosphorylation of the 5’ cap-binding protein in order for efficient translation initiation 
(Herdy et al., 2012).  Given this and that mTORC1 plays a vital role in regulating cell growth, 
it would be of interest to determine if eIF4E phosphorylation occurring during mTORC1 
inhibition is accompanied by global changes to the transcriptome of the cell.  Moreover, 
establishing if other MNK substrates, such as hnRNP A1, exhibit a Rapamycin-induced 
increase in phosphorylation may help to demonstrate if mTORC1 inhibition leads to a global 
stress response. 
As AKT1 phosphorylation has been shown to be negatively regulated in a manner implying 
mTORC2 inhibition following a one hour treatment with 10μM Rapamycin, establishing the 
sensitivity of mTORC2 to Rapamycin in RAW 264.7 cells would be of importance.  Schreiber 
and colleagues (2015) have shown that a high ratio of relative FKBP12 to FKBP51 expression 
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is an important determinant in the degree of mTORC2 inhibition in response to Rapamycin 
treatment.  Determining this ratio in RAW 264.7 cells could, potentially, be of interest.   
Determining if MNK1 or MNK2 is responsible for mediating the Rapamycin-induced increase 
in eIF4E phosphorylation, although technically demanding, would be important.  If this area 
were to be pursued, the use of the CRISPR/Cas technique could be considered over the 
development of a transgenic mouse.  Given the ease and efficiency of CRISPR/Cas, the 
technique could be of benefit and has proven useful in knocking out genes on a large scale 
in mammalian cells (Shalem et al., 2013; Walsh & Hochedlinger, 2013; Auer et al., 2014; 
Wang et al., 2014).  However, this approach does suffer from the limitation that it requires a 
Protospacer Adjacent Motif (PAM), to which the Cas protein can bind (Ibid), surrounding, 
what in this case would be the MNK1 or MNK2 genes.  A lack of this PAM site, or insufficient 
sequence homology between the Cas protein and this sequence, would result in reduced 
efficiency (Fu et al., 2013; Hsu et al., 2013 (As cited by Walsh & Hochedlinger, 2013)).    
Although this approach has been successfully used in vivo to create knockout mice (Wang et 
al., 2013; Fujii et al., 2013), to date no such studies have used this technique on RAW 264.7 
cells.  Walsh and Hochedlinger (2013) noted that additional research, such as that by Hou et 
al. (2013), in identifying novel Cas proteins may mean that this approach will become more 
applicable here. 
The use of transgenic mice is costly in the terms of financial implications, time and the high 
failure (Hall et al., 2009).  There are also ethical considerations.  The number of animal 
experiments required in any project should be minimised.  Furthermore, experimental 
validation of predictions in this project is aimed at improving a model which was to be used 
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to mimic viral infection, as such using primary cells taken from a mouse would, most 
probably, behave in a different manner to the transformed RAW 264.7 cells.    
Section 3.4.5 – Concluding Remarks 
Despite experimental challenges, the effect of Rapamycin on eIF4E phosphorylation, 
predicted by the model, has been shown.  Although there were also problems regarding the 
effect this macrolide has upon AKT1 phosphorylation, there is sufficient evidence to 
conclude that a considerable reduction does occur following one hour of treatment.  From 
this perspective, given the qualitative nature of the model, this prediction has also been 
validated.   
By using more of the data from the array in the comparison to the binary model behaviour, 
it has been shown that the model is in the majority of cases behaving in a manner 
reminiscent of the model system, the murine macrophage RAW 264.7 cell.  In doing so the 
validity of the model has increased and, although the comparison was of a relatively small 
number of data points, without further refinement or adjustment, the final model has 
produced a positive MCC value. 
The experimental validation of these two predictions was a major step forward in this 
project.  Although these two predictions are well documented in the literature, in 
experimentally corroborating these hypothesised behaviours, it has been shown that the 
model is proficient in predicting complex and non-trivial patterns of behaviour.  In keeping 
with this, at this stage the rationale for conducting these experiments was not to necessarily 
provide solid mechanistic data regarding the link between the phosphorylation of AKT1 and 
eIF4E and Rapamycin-mediated inhibition of mTORC1, but rather to provide clear evidence 
that the behaviour of the model is predictable when certain, specific perturbations are 
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applied.   In doing so, it has been shown that the model was ready to be used in novel ways, 
such as the investigation of the interactions between a virus and the host signalling network 
regulating translation initiation.   
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Section 4.1 – Introduction 
Viruses are pathogens which commandeer cellular machinery to prioritise the synthesis of 
viral proteins.  The validated model presented in this work gives a unique opportunity to 
study these host-pathogen interactions.  Within Chapter 2 – Model Creation & Refining and 
Chapter 3 – Experimental Validation of Model Predictions, the model of translational 
regulation was created and experimentally validated.  The predictive power of the model 
was raised significantly, to MCC = 0.4558.  This improved predictive power and the 
experimental validation of two predicted behaviours meant than the model was behaving in 
a reliable way.  In order to demonstrate the value of model, in a broad context, the 
incorporation of viral effects into the model was carried out. 
Controlling and combatting viral infection is a major challenge facing modern science.  
Despite considerable advances in the field of virology, there is a limited spectrum of viable 
treatments for viral infections.  Moreover, some of these diseases are causes of 
considerable morbidity and mortality and represent a major burden on the National Health 
Service and other healthcare systems and public health services worldwide.  With the use of 
systems biology techniques to study viral infection, it is hoped that new cellular targets for 
treating viral infection will emerge. 
Whilst the main focus of this project has been to create a model of mammalian translation, 
the possibility of using this model to mimic the effects viral infection has on the translational 
machinery and upstream regulatory signalling pathways was investigated.  Three viruses 
have been selected on the basis that they perturb different cellular pathways and have 
different effects on the translational machinery.  JUNV, ANDV and Murine Norovirus (MNV) 
are all considered important human pathogens or models of such pathogens.  Although two 
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of these viruses may not infect RAW 264.7 cells, they have been included here as they 
produce different effects on the cellular signalling network and manipulate the host 
translational machinery in ways that MNV does not.   
Section 4.2 – Model Changes & Simulation Methods 
For each virus it was necessary to run simulations with two models.  The models were 
identical in every respect except that one was used to represent an ‘infected’ system and 
one as the ‘mock’, uninfected control.  QSSPN simulations were carried out on the ‘infected’ 
or ‘mock’ models.  The ‘mock’ model was initially tested to ensure that the simulation times 
were adjusted to result in the frequency of each effector being equal to around 0.5.  
Binomial Confidence Intervals, calculated in the software R, were used to identify regions of 
significant difference between the ‘infected’ or ‘mock’ models.  The final model presented 
at the end of Chapter 2 – Model Creation & Refining and experimentally validated in 
Chapter 3 – Experimental Validation of Model Predictions was used here.  More model 
effectors, than used in previous chapters, were monitored as it was hoped that new effects 
or, in the case of MNV, testable predictions could be found. 
Section 4.2.1 – Junin Virus Model 
To mimic the large scale changes to the host translation factors, two features of Junin Virus 
infection were considered.  Firstly, JUNV contains the same conserved amino acids believed 
to be found in the active site of the L endonuclease that are found in other Arenaviruses 
(Morin et al., 2010).  Therefore, it is reasonable to assume that a cap-snatching mechanism 
is employed by JUNV.  Secondly, like many of the other New World Arenaviruses, JUNV 
replication occurs with the Nucleoprotein acting as the cap-binding protein in place of eIF4E 
(Linero et al., 2013).  The ability of the Arenaviridae to actively use eIF4E is controversial.  As 
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noted by Knopp and colleagues (2015), the Old World Arenaviruses, such as Lassa Fever 
Virus, may differ from the New World Arenaviruses in the need for this cellular factor 
(Volpon et al., 2008; Volpon et al., 2010; Kranzusch & Whelan, 2011).  Furthermore, 
Arenaviruses contain RNA that is not polyadenylated (Emonet et al., 2009).  This would 
suggest that PABP is redundant in JUNV infection. 
To date JUNV infection is known to require the activation of two fundamental signalling 
pathways.  Although displaying an oscillatory nature, JUNV requires the activation of ERK1/2 
(Rodríguez et al., 2014).  Of most significance here is the fact that at 24 hours post infection 
the level of ERK1/2 activation is significantly increased.  This period of activation co-insides 
with the finding of Linero and colleagues (2013) that viral infection and protein synthesis 
were not affected by a knock-down of eIF4E.  Rodríguez and co-workers (2014) posit that 
the N protein mediates the increase in ERK1/2 activation. Given these events occur at the 
same time point it is possible to model these events simultaneously.  The second pathway 
upon which JUNV infection depends is the PI3K pathway (Linero & Scolaro, 2009).  The 
significance of this pathway at 24 hours post infection is not clear as there is an absence of 
data at this time point regarding the activation of AKT1 or another PI3K substrate.  This 
being said the presence of a PI3K inhibitor after 24 hours post infection did markedly reduce 
viral replication (Ibid).  No clear data regarding other signalling pathways is known in respect 
of this virus.  Boswick et al. (2007) have shown that the related Pichinde Virus induces p38 
activation at earlier time points but no work has been carried out with JUNV.  
Given that the model is entirely qualitative and provides no temporal information, both the 
ERK1/2 and PI3K pathways were activated in the ‘infected’ model.  The use of both cap 
snatching and substitution of eIF4E were also applied in the model. 
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The effects that JUNV is capable of inducing, in the cellular signalling pathways and 
translational machinery, were incorporated into the final version of the Petri Net model.  
Building on this model, 17 new molecular species were included in the model, to account for 
different translational intermediates and viral proteins that effect signalling pathway 
components.  These new species are involved in 27 new molecular interactions, which 
include viral translation and the effects of viral components on cellular signalling pathways. 
Section 4.2.2 – Murine Norovirus Model 
The role of the various initiation factors in MNV infection is complex and not fully 
understood.  The VPg protein of MNV is known to function in place of the 5’ cap structure 
(Chaudhry et al.¸ 2006).  However, the interactions between this protein and cellular 
initiation factors are still not fully understood.  Whilst an interaction between VPg and eIF4E 
has been reported (Ibid) the significance is not clear.  Chaudhry and co-workers (2006) 
found that a reduction of cellular eIF4E or the overexpression of 4E-BP1 did not preclude 
viral protein synthesis.  It has since been proposed that the interaction between the viral 
protein and eIF4E only functions to help circumvent a change in gene expression to bring 
about an immune response (Chung et al., 2014).  In terms of an integral interaction, Chung 
and co-workers (2014) demonstrated that VPg must interact with eIF4G.  Indeed this finding 
is corroborated by the view that eIF4E depletion does not affect viral translation (Chaudhry 
et al., 2006).   
Whilst eIF4E is not required for the translation of MNV proteins, there is a dependence on 
the phosphorylation of this initiation factor (Royall et al., 2015).  This work established that 
the increase in eIF4E phosphorylation serves to bring about a change in gene expression 
including an increase in the expression of an inhibitor of Nuclear Factor κB (Ibid).   Whilst 
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both ERK1/2 and p38 phosphorylation were shown to be increased during MNV infection, 
only the axis of p38α-MNK1 was required for the increase in eIF4E phosphorylation (Royall 
et al., 2015).  Additionally, unpublished data (generated by N. Doyle and E. Royall (University 
of Surrey)) indicates that MNV-1 infection produces a marked increase in the 
phosphorylation of AKT1 on the residue Ser-473.  This Human Phospho-MAPK array data 
also demonstrated that the signalling axes of mTORC1-S6K1 and JNK1 were unaffected by 
MNV-1 infection.  
The MNV model, building on the final model, included 13 new molecular species involved in 
20 novel molecular interactions.  These interactions were involved in viral translation and 
the interactions between viral factors, and the cellular translational machinery and 
signalling factors.  These interactions were documented in existing literature or taken from 
experimental data generated in-house. 
Section 4.2.3 – Andes Virus Model 
Whilst not explicitly shown to be the case for ANDV, the Hantaviruses are widely believed to 
use cellular 5’ methylguanosine caps to initiate viral translation (Mir et al., 2010; Cheng & 
Mir, 2012).  However, the work of Heinemann and colleagues (2013) has suggested that 
selective host mRNA degradation occurs in ANDV infection and is mediated by the L protein.  
When taken together these works suggest that the RdRp L protein may function to 
selectively degrade cellular mRNA in ANDV infection whilst the N protein may then 
sequester the cleaved cap fragment to prevent further cell-mediated degradation (Cheng & 
Mir, 2012; Heinemann et al., 2013).  Furthermore, the N-terminal domain of the L protein, 
which is thought to mediate the cleavage of mRNA, is well conserved amongst the 
Hantaviruses (Reguera et al., 2010). 
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There is additional evidence that suggests translation of at least one ANDV protein, the NSs 
protein is encoded by a Small segment of viral RNA (Vera-Otarola et al., 2010) that does not 
require the use of PABP.  Rather, the untranslated region within the 3’ end of the Small 
transcript is used (Vera-Otarola et al., 2012).  These authors suggest that an unknown 
cellular protein may mediate Small RNA translation (Ibid).  It would be of interest to 
compare the translation of histone mRNA to the translation of the Small genomic segment.  
The 3’ UTR of histone mRNAs contains a stem-loop structure to which SLBP must interact for 
translation to occur (Sànchez & Marzluff, 2002).  As noted by Vera-Otarola and co-workers 
(2010) no base pairing between the 5’ and 3’ structures could occur.  It raises the possibility 
that viral translation could occur through a mechanism that involves circularisation of viral 
mRNA by SLBP interacting with the 40S subunit, possibly through eIF3 (as is the case for 
histone mRNA (Ling et al., 2002)) and potentially by the N protein replacing the eIF4F 
complex (Mir & Panganiban, 2008).  
In addition to the effects that ANDV imposes on the translational machinery, infection with 
this Hantavirus has the potential to exert large effects on the cellular signalling network.  
ANDV is capable of inducing mTORC1 activation through the autophagic degradation of the 
viral protein Gn (formed during cleavage of the GPC protein (Löber et al., 2001), which 
serves to maintain the pool of amino acids within the lysosomes (McNulty et al., 2013).  
Whilst mTORC1 activation has also been demonstrated by Gavrilovskaya et al. (2013), there 
is some disagreement over the level of S6K1 activity.  Gavrilovskaya and co-workers (2013) 
showed that ANDV infection, in conjunction with hypoxia, resulted in increased S6K1 
phosphorylation whereas no such increase in either this or 4E-BP1 phosphorylation was 
noted by McNulty et al. (2013).  An obvious difference in these works is the induction of 
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hypoxia, however no S6K1 phosphorylation was found in hypoxic cells alone (Gavrilovskaya 
et al., 2013).  These works do however suggest that the result of mTORC1 activation by 
ANDV is to bring about induction of a variety of mTORC1-dependent pathways such as 
Hypoxia Inducible Factor 1α (HIF-1α).   
Additionally, no change in the activation of the inflammatory regulator Nuclear Factor-κB 
was noted in cells infected with ANDV (Khaiboullina et al., 2013).  ANDV infection was 
capable of increasing Nuclear Factor-κB activation in cells pre-treated with Tumour Necrosis 
Factor α (Ibid). 
Building on the final version of the Petri Net model of mammalian translational regulation, 
the effects of ANDV infection were incorporated.  To this end, 17 new molecular species 
were added to the model to account for various viral factors and translational intermediate 
stages, where viral factors or viral RNA were incorporated.  To model viral protein synthesis 
and the effects ANDV has upon the cellular signalling network, 22 additional molecular 
interactions were added to the model. 
Section 4.2.4 – Experimental Validation of the Murine Norovirus Model 
Upon examination of the behaviour of the MNV model, the level of phosphorylated Cyclic 
AMP-Responsive Element-Binding Protein (CREB) was found to be increased during MNV 
infection.  Using Human Phospho-MAPK Arrays, it was possible to test this behaviour. 
The experimental work presented in this chapter was conducted by N. Doyle and E. Royall 
using the method detailed in Royall et al. (2015).  RAW 264.7 cells were cultured as per the 
method given in Royall et al. (2015).  These cells were then infected with MNV strain CW1 at 
a Multiplicity of Infection (MOI) of ten 50% Tissue Culture Infectious Dose units and were 
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incubated at 37°C with 5% Carbon Dioxide for either two or 12 hours.  Uninfected control 
samples for each time point were also taken.  Human Phospho-MAPK Arrays were carried 
out using 300μg of protein, as determined by a BCA Assay, from each lysate.  These Human 
Phospho-MAPK Arrays were carried out according the manufacturers’ instruction and were 
developed on to radiographic film.  Quantification of each phosphoprotein, also carried out 
by N. Doyle, was conducted in ImageJ.  As detailed in Royall et al. (2015), the values for 
CREB phosphorylation were expressed as relative pixel density.  Prior to this, these values 
were expressed as relative values of the array control spots CREB.  The statistical analysis of 
the data was carried out using two-way ANOVA with Tukey’s post-hoc test in GraphPad 
Prism 6.     
Section 4.3 – Results 
Section 4.3.1 – Simulation of the Junin Virus Models 
The effects of JUNV infection were incorporated into the final version of the binary model.  
QSSPN simulations and Reachfq analyses were performed and the results, shown in Figure 
4.3.1a, reveal multiple differences between the ‘infected’ and ‘mock’ models.  As expected, 
both ERK1/2 and PI3K activity was increased in the ‘infected’ model.  Similarly, the 
production of viral protein was limited to the ‘infected’ model.  A significant reduction in 
host protein synthesis was also observed (as seen in the reduced frequency of trajectories 
resulting in protein synthesis).  The activity of many substrates for either ERK1/2, such as 
MAPK Phosphatase 7 (MKP-7) or RSK1, or PI3K, such as AKT1 or PDK1, also exhibited 
increases.   
The most unexpected results concerned the nature of feedback mechanisms between the 
ERK1/2 and JNK1 signalling pathways.  Viral infection appeared to negatively affect eIF4E 
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phosphorylation through both MNK1 and MNK2 activity.  mTORC1 signalling also appears to 
be, for the most part, increased.  Interestingly, transcription factors, such as HIF-1α and Elk-
1, were also up-regulated and suggest that JUNV infection would promote large scale gene 
expression changes.  The HIF-1α expression also suggests that the metabolic network, as 
discussed in Section 5.1.1 – Linking mTORC1 to the Regulation of Metabolism, of the 
infected cell would exhibit considerable metabolic changes.  It would therefore, be of 
considerable future interest to evaluate the nature and degree of impact on the metabolic 
network by simulations of the integrated signalling network model and GSMN.  Chapter 5 – 
Integration of the Translational Control Model with a Genome Scale Metabolic Network of 
a RAW 264.7 Cell describes the preliminary results obtained in this direction. 
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Mock Upper Lower Infected Upper Lower 
ppMEK1 0.521 0.572 0.469 0.496 0.548 0.444 
ppMEK2 0.507 0.559 0.455 0.455 0.507 0.404 
ppERK1 0.521 0.572 0.469 0.992 0.997 0.976 
ppERK2 0.534 0.585 0.492 0.989 0.996 0.972 
pRSK1 0.430 0.481 0.380 0.726 0.770 0.677 
rpS6_Pi 0.550 0.601 0.498 0.718 0.762 0.669 
pMNK1 0.540 0.591 0.488 0.147 0.188 0.114 
pMNK2 0.448 0.500 0.397 0.149 0.190 0.115 
eIF4E_Pi 0.480 0.532 0.429 0.134 0.173 0.102 
pJNK1 0.460 0.512 0.409 0.138 0.178 0.106 
cJun_Pi 0.552 0.603 0.500 0.119 0.157 0.089 
ppp38a 0.541 0.592 0.489 0.552 0.603 0.500 
pERK5 0.448 0.500 0.397 0.259 0.307 0.216 
PI3K_Local 0.450 0.502 0.399 0.944 0.964 0.915 
PIP3 0.508 0.560 0.456 0.912 0.937 0.878 
PDK1_Local 0.553 0.604 0.501 0.910 0.935 0.876 
pPKCz 0.490 0.542 0.438 0.768 0.809 0.721 
ppAKT1 0.562 0.613 0.510 0.849 0.883 0.808 
ppS6K1 0.150 0.191 0.117 0.008 0.024 0.003 
p4EBP1 0.523 0.574 0.471 0.762 0.803 0.715 
mTORC1_Local_Pi 0.482 0.534 0.430 0.731 0.774 0.683 
pTSC12 0.489 0.541 0.437 0.895 0.923 0.859 
eIF4B_Pi 0.511 0.563 0.459 0.668 0.715 0.617 
Protein_Synthesis 0.515 0.567 0.463 0.324 0.374 0.277 
pCREB 0.531 0.582 0.479 0.758 0.800 0.711 
pMSK2 0.586 0.636 0.534 0.584 0.634 0.532 
pMKK3 0.542 0.593 0.490 0.512 0.564 0.460 
pMKK6 0.534 0.585 0.482 0.524 0.575 0.472 
pGSK3 0.575 0.625 0.523 0.625 0.674 0.574 
pMSK1 0.538 0.589 0.486 0.886 0.914 0.848 
pMK2 0.533 0.584 0.481 0.510 0.562 0.458 
pTTP 0.551 0.602 0.499 0.599 0.649 0.547 
HIF1a 0.535 0.586 0.483 0.716 0.760 0.667 
pSTAT3 0.481 0.533 0.429 0.697 0.742 0.647 
pElk1 0.529 0.580 0.477 0.895 0.923 0.859 
pATF2 0.534 0.585 0.482 0.496 0.548 0.444 
pTpl2 0.533 0.584 0.481 0.543 0.594 0.491 
ppPKCa 0.537 0.588 0.485 0.540 0.591 0.488 
pMKP7 0.486 0.538 0.434 0.997 0.999 0.984 
eIF4G_Pi 0.574 0.624 0.522 0.437 0.489 0.386 
Viral_Protein 0.000 0.011 0.000 0.335 0.386 0.288 
 
 
 
 
Figure 4.3.1a – Modelling the Effects of JUNV Infection.  Comparison of the impact JUNV infection 
has upon the cellular signalling network and the translation initiation pathway.  Significant 
differences between the models are found by comparing the 99.99% Binomial Confidence 
Intervals, as calculated in R, of the QSSPN simulation results for each effector.  Significant 
differences are shown in purple and indicate no overlap in the confidence intervals.  
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Section 4.3.2 – Simulation of the Murine Norovirus Models 
MNV was chosen as it is permissive in RAW 264.7 cells, the experimental system used in this 
project.  The effects of MNV were incorporated into the final version of the binary model 
and simulations were run with QSSPN.  Reachfq was used to calculate the frequency of 
1,000 trajectories which resulted in the activation or production of each effector.  99.99% 
Binomial Confidence Intervals were calculated for each effector, as shown in Figure 4.3.2a.  
Significant differences were identified by no overlap being present in these 99.99% 
confidence intervals.  The model incorporating MNV infection is given in Supplementary 
Information E4 (given as both a Snoopy model file (E4a) and an SBML file (.xml)) (E4b). 
In order to accurately model MNV infection, the activity of several pathways was altered.  
The activity of the ERK1/2 and p38 MAPK pathways was increased in keeping with 
experimental findings.  Similarly, the activation of AKT1 was also promoted.  This Human 
Phospho-MAPK Array data also confirmed that neither JNK1 nor mTORC1 activity was 
increased.  One of the main findings of this model was the raised eIF4E phosphorylation.  
The production of viral protein was only found in the ‘infected’ model.  The ‘infected’ model 
also displayed no significant reduction in cellular protein synthesis.  This model prediction is 
somewhat in agreement, the work of Royall et al. (2015).  When using polysome profiling, 
this work noted that the translational profile of the cell changes in response to infection.  
This being said, the level of a housekeeping gene, Glyceraldehyde 3-Phosphate 
Dehydrogenase, was not affected by MNV infection (Ibid) and whilst not conclusive proof, it 
is indicative of no global reduction in host cell protein synthesis.   
These simulations, the results of which are outlined in Figure 4.3.2a, have predicted 
numerous molecular targets that have not, to date, previously been identified as being 
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affected by MNV infection.  Several transcription factors, namely CREB, Elk-1 and ATF-2, 
downstream of ERK1/2 and p38 were found to exhibit increased phosphorylation.  An 
increase in the activation of various signalling components was also noted.  The majority of 
these components (MNK1, MNK2, MSK1, MSK2, MK2 and MKP-7) are, again, downstream of 
either ERK1/2 or p38.  This model also suggests that AU-Rich Element-containing mRNA is 
stabilised as a result of increased phosphorylation of TTP.  Experimental work to validate the 
increase in CREB phosphorylation is detailed in Section 4.3.2.1 – Experimental Validation of 
the Hypotheses Resulting from Simulations of the Murine Norovirus Model.    
The perturbations to the model also led to the level of phosphorylation of several initiation 
factors to be altered.  eIF4B phosphorylation is strikingly increased.  This affect can be linked 
to the increase in the ERK1/2-mediated phosphorylation of RSK1.  Despite no change in 
PKCα phosphorylation, eIF4G phosphorylation suffers a slight, but significant, reduction.  As 
already noted, eIF4E phosphorylation is increased.  The work of Royall and co-workers 
(2015) determined that MNK1, via p38, is responsible for this increase.  Whilst this picture is 
somewhat confirmed by the behaviour of the model, this work also notes an increase in 
MNK2 phosphorylation.   
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    Mock Upper Lower Infected Upper Lower 
ppMEK1 0.538 0.589 0.486 0.504 0.556 0.452 
ppMEK2 0.510 0.562 0.458 0.521 0.572 0.469 
ppERK1 0.534 0.585 0.482 0.994 0.998 0.979 
ppERK2 0.540 0.591 0.488 0.992 0.997 0.976 
pRSK1 0.462 0.514 0.411 0.832 0.867 0.790 
rpS6_Pi 0.471 0.523 0.420 0.744 0.787 0.696 
pMNK1 0.000 0.011 0.000 0.931 0.953 0.900 
pMNK2 0.515 0.567 0.463 0.775 0.815 0.729 
eIF4E_Pi 0.511 0.563 0.459 0.827 0.863 0.784 
pJNK1 0.468 0.520 0.417 0.452 0.504 0.401 
cJun_Pi 0.462 0.514 0.411 0.450 0.502 0.399 
ppp38a 0.444 0.496 0.393 0.882 0.912 0.844 
pERK5 0.458 0.510 0.407 0.284 0.333 0.240 
PI3K_Local 0.448 0.500 0.397 0.456 0.508 0.405 
PIP3 0.441 0.493 0.390 0.484 0.536 0.432 
PDK1_Local 0.551 0.602 0.499 0.569 0.620 0.517 
pPKCz 0.460 0.512 0.409 0.462 0.514 0.411 
ppAKT1 0.461 0.513 0.410 0.616 0.665 0.564 
ppS6K1 0.127 0.166 0.096 0.078 0.111 0.054 
p4EBP1 0.479 0.531 0.428 0.435 0.487 0.384 
mTORC1_Local_Pi 0.479 0.531 0.428 0.447 0.499 0.396 
pTSC12 0.507 0.559 0.455 0.730 0.774 0.681 
eIF4B_Pi 0.572 0.622 0.520 0.814 0.851 0.770 
Protein_Synthesis 0.386 0.438 0.337 0.293 0.342 0.248 
pCREB 0.507 0.559 0.455 0.915 0.940 0.881 
pMSK2 0.480 0.532 0.429 0.803 0.841 0.758 
pMKK3 0.461 0.513 0.410 0.437 0.489 0.386 
pMKK6 0.442 0.494 0.391 0.435 0.487 0.384 
pGSK3 0.444 0.496 0.393 0.462 0.514 0.411 
pMSK1 0.464 0.516 0.413 0.946 0.965 0.917 
pMK2 0.577 0.627 0.525 0.859 0.891 0.819 
pTTP 0.542 0.593 0.490 0.705 0.750 0.656 
HIF1a 0.497 0.549 0.445 0.475 0.527 0.424 
pSTAT3 0.477 0.529 0.426 0.447 0.499 0.396 
pElk1 0.466 0.518 0.415 0.952 0.970 0.924 
pATF2 0.472 0.524 0.421 0.786 0.825 0.740 
pTpl2 0.526 0.577 0.474 0.510 0.562 0.458 
ppPKCa 0.557 0.627 0.525 0.610 0.659 0.558 
pMKP7 0.483 0.535 0.431 0.998 1.000 0.986 
eIF4G_Pi 0.498 0.550 0.446 0.357 0.408 0.309 
Viral_Protein 0.000 0.011 0.000 0.377 0.428 0.328 
 
 
 
Figure 4.3.2a – Modelling the Effects of MNV Infection.  Outline of the effects MNV infection 
has upon the cellular signalling network and translation initiation pathway.  QSSPN simulations, 
followed by Reachfq, generated information on the activation or production of various model 
effectors.  Comparison of the Binomial Confidence Intervals revealed regions of significant 
difference, as shown in red. 
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Section 4.3.2.1 – Experimental Validation of the Hypotheses Resulting from 
Simulations of the Murine Norovirus Model 
The MNV model demonstrates a clear, significant increase in CREB phosphorylation in 
response to MNV infection.  Additionally, no significant differences were noted in the 
phosphorylation of Glycogen Synthase Kinase 3 (GSK3), MKK3 and MKK6.  The data collected 
by N. Doyle and E. Royall using Human Phospho-MAPK Arrays enabled validation of this 
prediction.  To this end, RAW 264.7 cells were infected with MNV strain CW1 at an MOI of 
10.  Uninfected cells were used as a control.  Both infected and uninfected cells were 
incubated for two and 12 hours prior to lysis.  Cells were lysed using Lysis Buffer 6 according 
to the manufacturers’ instructions.   
As shown in Figure 4.3.2.1a, although no difference in the phosphorylation state of CREB 
was seen at 2 hours post infection (hpi), there is a significant difference between the 
uninfected, mock and infected samples at 12hpi (p = 0.0019).  At 12hpi, MNV infection 
induces the phosphorylation of this transcription factor.  Moreover, a comparison between 
the infected samples at 2hpi and 12hpi reveals a significant increase in CREB 
phosphorylation (p < 0.0001).  No significant difference between the mock, control time 
points was seen.   
In the cases of GSK-3, MKK3 and MKK6, the experimental results demonstrated no 
significant differences in the level of phosphorylated forms of any of these kinases at either 
2hpi or 12hpi (data not shown).  These findings indicate the model is capable of predicting a 
diverse array of signalling behaviours. 
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Only one point of difference was noted between the behaviour of the model and the 
experimental data.  MSK2 phosphorylation was predicted to increase however, the 
experimental data failed to detect a significant increase.  It is worth noting that a non-
significant increase in MSK2 phosphorylation (p = 0.1792) was noted in the Human Phospho-
MAPK Array.  This increase may become significant if the time course were extended. 
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p = 0.0019  
p < 0.0001  
Figure 4.3.2.1a – Effect MNV Infection has Upon CREB Phosphorylation.  
RAW 264.7 cells were infected for either two or 12 hours.  These cells 
(MNV), along with uninfected samples (mock) incubated for the same 
length of time, were lysed.  The protein concentration was determined 
using the BCA Assay.  Human Phospho-MAPK Arrays using 300μg of protein 
from each lysate were carried out in accordance with the manufacturers’ 
instructions.  Quantification was carried out in ImageJ.  Statistical analysis, 
using GraphPad Prism 6, involved two-way ANOVA with Tukey’s post-hoc 
test of significance.  The data presented has been normalized to the array 
control spots, as detailed in Royall et al. (2015), and therefore expressed as 
Relative Pixel Density.  Error bars represent the Standard Error of the Mean.  
The data presented above was supplied by N. Locker and obtained by N. 
Doyle and E. Royall. 
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Section 4.3.3 – Simulation of the Andes Virus Models 
The final virus investigated in this project was ANDV.  In terms of the effects this virus has 
upon the signalling network, only very few documented affects were previously noted and 
consequently this virus has the smallest number of perturbations implemented into the final 
version of the binary model.   
Reachfq analyses were performed on the QSSPN simulation results.  A comparison of the 
Binomial Confidence Intervals calculated for each of the results, shown in Figure 4.3.3a, was 
used to find regions of significant difference (as shown in dark purple).  The only pathway 
altered in this model was the mTORC1 pathway.  As can be seen in Figure 4.3.3a, this 
pathway was significantly increased. Surprisingly, although viral protein was produced and 
this required a cap-snatching mechanism, no significant reduction in host protein synthesis 
was observed.  It is worth noting that the work of Jääskeläinen and co-workers (2007) 
demonstrates that other Hantavirues, namely Tula Virus and Puumala Virus, do not induce a 
strong inhibition of cellular protein synthesis.  This work is somewhat supportive of the 
finding here.  The polymerase encoded by the Large genome segment has been shown to 
not decrease the expression of cellular proteins in general, but it has been shown to 
specifically limit the production of thoses proteins only of high molecular weight 
(Heinemann et al., 2013).  It could be argued, therefore, that the non-significant reduction 
of cellular protein synthesis, shown in Figure 4.3.3a, is in agreement with the view that no 
general suppression of protein synthesis is seen during ANDV infection. 
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  Mock Upper Lower Infected Upper Lower 
ppMEK1 0.521 0.572 0.469 0.550 0.601 0.498 
ppMEK2 0.507 0.559 0.455 0.499 0.551 0.447 
ppERK1 0.521 0.572 0.469 0.503 0.555 0.451 
ppERK2 0.534 0.585 0.482 0.527 0.578 0.475 
pRSK1 0.430 0.482 0.380 0.444 0.496 0.393 
rpS6_Pi 0.466 0.518 0.415 0.491 0.543 0.439 
pMNK1 0.481 0.533 0.429 0.496 0.548 0.444 
pMNK2 0.478 0.530 0.427 0.467 0.519 0.416 
eIF4E_Pi 0.455 0.507 0.404 0.408 0.460 0.358 
pJNK1 0.516 0.568 0.464 0.555 0.606 0.503 
cJun_Pi 0.511 0.563 0.459 0.491 0.543 0.439 
ppp38a 0.530 0.581 0.478 0.514 0.566 0.462 
pERK5 0.448 0.500 0.397 0.454 0.506 0.403 
PI3K_Local 0.514 0.566 0.462 0.536 0.587 0.484 
PIP3 0.508 0.560 0.456 0.516 0.568 0.464 
PDK1_Local 0.464 0.516 0.413 0.460 0.512 0.409 
pPKCz 0.490 0.542 0.438 0.498 0.550 0.446 
ppAKT1 0.562 0.613 0.510 0.577 0.627 0.525 
ppS6K1 0.156 0.197 0.122 0.242 0.289 0.200 
p4EBP1 0.476 0.528 0.425 0.916 0.941 0.882 
mTORC1_Local_Pi 0.568 0.619 0.516 0.996 0.999 0.982 
pTSC12 0.431 0.483 0.380 0.419 0.471 0.369 
eIF4B_Pi 0.511 0.563 0.459 0.513 0.565 0.461 
Protein_Synthesis 0.515 0.567 0.463 0.491 0.543 0.439 
pCREB 0.531 0.582 0.479 0.515 0.567 0.463 
pMSK2 0.586 0.636 0.534 0.594 0.644 0.542 
pMKK3 0.542 0.593 0.490 0.538 0.589 0.486 
pMKK6 0.534 0.585 0.482 0.533 0.584 0.481 
pGSK3 0.575 0.625 0.523 0.606 0.655 0.554 
pMSK1 0.538 0.589 0.486 0.562 0.613 0.510 
pMK2 0.581 0.631 0.529 0.584 0.634 0.532 
pTTP 0.474 0.526 0.423 0.508 0.560 0.456 
HIF1a 0.535 0.586 0.483 0.974 0.986 0.952 
pSTAT3 0.496 0.548 0.444 0.986 0.994 0.968 
pElk1 0.529 0.580 0.477 0.559 0.610 0.507 
pATF2 0.500 0.552 0.448 0.505 0.557 0.453 
pTpl2 0.533 0.584 0.481 0.528 0.579 0.476 
ppPKCa 0.537 0.588 0.485 0.527 0.578 0.475 
pMKP7 0.486 0.538 0.434 0.463 0.515 0.412 
eIF4G_Pi 0.421 0.473 0.371 0.287 0.336 0.242 
Viral_Protein 0.000 0.011 0.000 0.150 0.191 0.117 
 
 
 
 
Figure 4.3.3a - Modelling the Effects of ANDV Infection.  These simulation results show the 
effects ANDV infection has upon the cellular signalling network and the translation initiation 
pathway.  Binomial Confidence Intervals of Reachfq analyses were calculated for each 
model effector from the QSSPN simulations.  Regions of significant difference, shown in 
dark purple, are found where no overlap in confidence intervals is present. 
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Section 4.4 – Discussion 
The elaboration of the binary model to include viral effects was necessary to further validate 
the benefits of taking a systems approach to understanding complex biological systems.   
Section 4.4.1 – Problems Encountered & Troubleshooting 
Given that up until this point it has been possible to give a quantitative measure of the 
predictive power of the model, the single biggest problem encountered in this part of the 
work was the lack of a suitable benchmark dataset to establish the predictive power of the 
models.  Data concerning the effects of these viruses is very limited and the action of 
inhibitors is not directly transferable from the datasets used to quantify the predictive 
power of the cellular translational control model.   
The only solution to this would be to test the effects each of the inhibitors has when 
combined with infection.  However, this is not feasible and so the solution implemented 
here is to evaluate the effects qualitatively.  For example, Rodríguez et al. (2014) noted that 
ERK1/2 activity is promoted by JUNV infection and so this effect was incorporated into the 
model.  By comparing the simulation results for the ‘mock’ and ‘infected’ models it is 
possible to qualitatively prove that the model is functioning in accordance with published 
data.  Furthermore, even if efforts were made to quantify these effects, such as by 
comparing the literature and simulation results in a Confusion Matrix, the small number of 
data points available for each model would mean that the resulting MCC value is of little 
benefit.    
As already noted in Section 3.4.4 – Problems Encountered & Troubleshooting, the use of 
pixel counting to quantify the Human Phospho-MAPK Arrays in validating MNV predictions, 
is not considered particularly accurate due to the non-linear response of radiographic film to 
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a fluorescent signal (Gassmann et al., 2009).  However, it was used in this work as it was the 
method recommended by the array manufacturer. 
Section 4.4.2 – Potential Future Work 
Both the literature examined during the construction of the viral models and the simulation 
results indicate that viral infection can potentially affect the global metabolic flux 
distributions.  This motivates future work which is aimed at utilising the full capabilities of 
the QSSPN software to integrate the signalling network model with a GSMN.  Chapter 5 – 
Integration of the Translational Control Model with a Genome Scale Metabolic Network of 
a RAW 264.7 Cell describes the first version of such an integrated model.  However, given 
the low predictive power of the integrated model, when evaluated against the Metabolic 
Benchmark dataset, more work is needed before this model can be used to generate 
hypotheses directing experimental work.  However, examining the effects of viral infection 
upon the cellular metabolic network would have added significant value to this section of 
the project.  Future use of this type of model and in this way should involve working 
towards understanding the impact of viral infection upon the cellular metabolic network.  
This would be achievable with this type of model if the predictive power were raised 
considerably.   
Furthermore, experimental works looking at predictions generated by the MNV model are 
needed.  Given that a number of these predictions involve looking at the post-translational 
modification, particularly phosphorylation, of well-recognized signalling components (such 
as MK2 and MSK1), it should be possible to use immunoblotting for many.  A possibility also 
exists to examine the effects of the increases to transcription factor activity, such as CREB 
and ATF-2, through the use of the Polymerase Chain Reaction (PCR) technique targeting 
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genes under the control of these transcription factors.  Conducting these works would give a 
broader understanding to the effects MNV infection has upon the cell. 
Developing a method for quantifying the predictive power of the model should also be 
considered if modelling of this type is to be used when looking at host-pathogen 
interactions.  Despite the difficulties noted in Section 4.4.1 – Problems Encountered & 
Troubleshooting, a method based upon the one used throughout this project may be viable.  
For this to be the case, increasing the number of data points used in the calculation of the 
MCC value must be achieved.  The increasing availability of transcriptomics and proteomics 
datasets looking at viral infection, such as those generated by Aevermann et al. (2014), will 
hopefully begin to provide access to large-scale datasets that would be necessary for a 
quantitative measure of the predictive power of the model. 
Section 4.4.3 – Concluding Remarks 
The incorporation of the various effects viral infection can induce, in both the cellular 
signalling network and to the translational machinery, was carried out.  Moreover all three 
viruses represent understudied, important human pathogens, or in the case of MNV, a 
surrogate of one.  Whilst it is not being suggested that the viruses used here all infect RAW 
264.7 cells, the three viruses chosen in this work were selected as they produce different 
effects to the cellular signalling network and the translational apparatus.  With this in mind, 
the number of effectors monitored during simulations was substantially increased so as to 
be able to detect more widespread effects.   
The work presented here differs from other published works looking at viral infection from a 
systems biology perspective.  The model to which the viral effects were added was a large-
scale reconstruction of the signalling network that surrounds and regulates translation 
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initiation in mammals.  Other models, such as the work of Jensen and co-workers (2013), 
were very limited in scope.  Whilst the approach of Jensen et al. (2013) does lead to 
experimentally validated findings, it does limit the future uses of the model.  The main 
benefit of using a literature-based reconstruction model is that the model can be adapted 
with relative ease to simulate new viral or, more generally, pathological effects.  Moreover, 
the qualitative nature of the model means that kinetics of viral perturbations are not 
necessary and do not require proper integration with the kinetic parameters of the host.  
Furthermore, the scope of this model means that it is possible to monitor the potential 
impact of infection upon a wider range of cellular effectors and consequently lead to the 
generation of more testable behaviours. 
The model of JUNV infection demonstrates that large-scale aberrations to the cellular 
signalling network are possible even when only a few initial alterations are made.  This 
demonstrates the high degree of cross-talk between signalling pathways, and the effects 
that this has upon the functionality of the model as a whole.  Consequently, this highlights 
just how viral infection can be thought of as a ‘systems-level perturbation’ (Garmaroudi et 
al., 2010) to the host.  The results of this set of simulations are suggestive of JUNV 
producing effects to numerous signalling pathways adjacent to ERK1/2 and PI3K, such as 
MSK1.  Furthermore, these simulations suggest that the increase in ERK1/2 activity 
promotes alterations to the metabolic network through mTORC1.   
Of the three viruses selected, perhaps the most disappointing model was that of ANDV 
infection.  Both Gavrilovskaya et al. (2013) and McNulty et al. (2013) demonstrate mTORC1 
activation and Cimica and co-workers (2014) have shown that Interferon signalling is 
affected by ANDV infection.  Despite these findings, little else is known as to the cellular 
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effects of ANDV infection.   It was hoped that this model would shed light on additional 
pathways activated by ANDV.  However, the predictions generated were both few in 
number and for the most part, directly downstream of mTORC1.  The reduction of eIF4G 
phosphorylation was also noted.  This finding is suggestive of a reduction of mTORC2 
activity, possibly as a result of the increase in S6K1 activity (Julien et al., 2010).  However, 
with no reduction in either AKT1 or PKCα phosphorylation, which are both mTORC2 
substrates in the model, it is not possible to state this with any certainty.   This being said, 
this model had the fewest number of well documented perturbations to input into the 
model.  However, the effectors with altered levels of activity are suggestive of cellular 
metabolic reprogramming.  The implication of this model yielding only few predictions is 
redolent of both the need for more research into ANDV infection and to ensure that models 
are as expanded as possible to make certain that important events can be properly placed 
into context.   
Given safety considerations, it is difficult to undertake work to validate hypotheses 
generated about either JUNV or ANDV infection.  However, work with MNV is possible and 
may give valuable insight into the molecular biology of the important human pathogen, 
HuNV.  As already stated in Section 4.4.2 – Potential Future Work, the effectors altered 
during MNV infection may lead to vast changes to the cell.  Alterations to the level of 
activity of transcription factors may produce large shifts in gene expression.  Both CREB 
(Zhang et al., 2005) and ATF-2 (Bailey & Europe-Finner, 2005) can regulate genes involved in 
a diverse array of important cellular processes.  To date, with the exception of Royall et al. 
(2015), very little work has been embarked upon to examine the effects members of the 
Norovirus genus can induce in the cellular signalling network.   
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The work with a model of MNV infection has revealed that the virus may affect a large 
number of important signalling pathways.  Whilst the findings that ERK1/2 and p38 were 
activated was expected (Royall et al., 2015), the activation of downstream effectors of these 
pathways, notably Elk-1, MK2 and MKP-7, is a novel hypothesis.    PKCα activity has been 
linked positively, in the case of Respiratory Syncytial Virus entry (San-Juan-Vergara et al., 
2004), or negatively, in the case of Vesicular Stomatitis Virus replication (Zhu et al., 2011), to 
the regulation of viral infection.  However, to date, the involvement of PKCα activity has not 
been investigated in MNV infection.  This work suggests that PKCα activity is not altered by 
MNV infection.   
The ability to experimentally validate findings of the model was a significant milestone for 
this section of the project.   The predicted increase in CREB phosphorylation, as shown in 
Section 4.3.2 – Simulations of the Murine Norovirus Models, in response to MNV infection 
was experimentally verified.  The unpublished work by N. Doyle and E. Royall with Human 
Phospho-MAPK Arrays indicated that CREB phosphorylation was increased during MNV 
infection at 12hpi (as shown in Section 4.3.2.1 – Experimental Validation of the Hypotheses 
Resulting from Simulations of the Murine Norovirus Model).  As detailed in Royall et al. 
(2015), RAW 264.7 cells were infected with MNV at an MOI of 10.  Following 2hpi or 12hpi, 
the cells were harvested and the lysates used in Human Phospho-MAPK Arrays.  Given that 
CREB phosphorylation was not specifically targeted for perturbation when the viral effects 
were added to the MNV model, this can be viewed as experimental validation of one of the 
predicted behaviours.  This is true despite the behaviour of CREB not being unexpected 
given the position of this transcription factor downstream of both ERK1/2 (Impey et al., 
 Page 225 
 
1998; Xing et al., 1998; Ying et al., 2002) and p38 (Di Petro et al., 2007; Di Giacomo et al., 
2009).   
Although no work has investigated the effect of the MNV-induced increase in CREB 
phosphorylation, as noted in Section 4.4.2 – Potential Future Work, this could possibly be 
achieved through the use of PCR aimed at investigating if CREB target genes exhibit 
expression changes as a result of this.  An increase in CREB phosphorylation on the Ser-133 
site is not unique to MNV infection.  Both Human Immunodeficiency Virus 1 (Gibellini et al., 
1998) and Human T-Cell Leukaemia Virus (HTLV-1) (Kim et al., 2007b) are known to induce 
CREB phosphorylation on the Ser-133 residue.  HTLV-1 appears to require this 
phosphorylation of CREB, through the viral protein Tax, so as to enhance transcription of the 
viral genome (Geiger et al., 2008) and maybe functions to regulate apoptosis (Trevisan et al., 
2004; Trevisan et al., 2006 (as cited by Geiger et al., 2008)).  Given that MNV (Bok et al., 
2009), and FCV (Roberts et al., 2003; Sosnovtsev et al., 2003), have been shown to induce 
apoptosis, any anti-apoptotic roles for phosphorylated CREB seem questionable but it 
remains to be seen if CREB is required for viral transcription.  Bok and co-workers (2009) 
noted that viral RNA achieves a maximal level at 8hpi with the level being maintained at 
12hpi.  This is in keeping with the work presented here in which an increase in CREB 
phosphorylation was noted between 2hpi and 12hpi.  
The factor resulting in an increase in p38 activity during MNV infection is not known.  The 
results presented here and in the array data showing that neither MKK3 nor MKK6 exhibit a 
concomitant increase in phosphorylation, suggest that a viral protein maybe responsible for 
this increase.  Many other viruses, including JUNV (Rodríguez et al., 2014) and members of 
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the Flavivirus genus (Lin et al., 2006; Werme et al., 2008; Laurent-Rolle et al., 2010), use 
viral factors to alter the activation of cellular signalling pathways.  
The behaviour of the other model components, GSK3, MKK3 and MKK6, were also 
experimentally validated.  In all three cases, no significant increase in phosphorylation was 
predicted.  The Human Phospho-MAPK Array data confirmed this behaviour.  Whilst the 
model failed to predict that MSK2 phosphorylation would be unaffected by MNV infection, 
the validation of four predicted behaviours so far indicates that the MNV model has an 80% 
success rate and, whilst not directly comparable, is indicative of a positive MCC value.  
The models presented in this chapter reveal that it is possible to mimic viral infection and 
predict additional behaviours.  As has been shown here, a systems approach is capable of 
identifying cellular targets involved in viral infection which may not have been immediately 
obvious targets of study.  On the whole, all viruses examined here produce a wide variety of 
cellular affects and in all cases generate findings that are not readily explainable, which is 
indicative of complex, non-trivial behaviour.  As such the work presented here can be seen 
as providing a new method for modelling the complex network of host-pathogen 
interactions that accompany infection.  Whilst many of the predicted behaviours are not yet 
experimentally validated, the background model of cellular translation has been validated 
(as shown in Chapter 3 – Experimental Validation of Model Predictions) and demonstrated 
as having a significant degree of predictive power (as shown in Chapter 2 – Model Creation 
& Refining).  To conclude, the simulations presented here generated plausible hypotheses 
that can be used to direct future experimental research on the interactions of viruses with 
the host translational machinery and signalling network.   
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Section 5.1 – Introduction 
This chapter covers the work aimed at linking the model of the regulation of translation to a 
GSMN, Flux Balanced Analysis model of a RAW 264.7 cell.  This model was developed by 
Bordbar et al. (2012) and is based upon transcriptomic, proteomic and metabolomic data.  
There is a growing body of literature that highlights the pronounced effects the host-
pathogen interactions have upon the metabolic network of the cell (Wang et al., 2008b; 
Saric et al., 2010; Coelho et al., 2015; Milner et al., 2015), or of the pathogen (Raghunathan 
et al., 2010).  This motivates the integration of the translational control model with the 
GSMN to study whether translation initiation is co-regulated with the biosynthesis of 
metabolic precursors of protein synthesis. 
In previous chapters, the level of predictive power of the model was raised to an MCC = 
0.4558 and several model behaviours have been validated.  From here, attention was 
turned to carrying out preliminary work of investigating the dual regulation of translation 
and metabolism.  Additionally, as the method of simulating the model detailed in Chapter 2 
– Model Creation & Refining is computationally demanding, several attempts in this 
chapter, were made at developing a method for running less computationally demanding 
simulations, which yield results of comparable predictive power to the existing method.   
Section 5.1.1 – Linking mTORC1 via S6K1 to the Regulation of Metabolism 
An emerging role for mTORC1 is being discovered in the regulation of metabolism.  mTORC1 
regulates anabolic metabolism by promoting the synthesis of new proteins, nucleotides and 
lipids while at the same time inhibiting the cellular process of autophagy (Shimobayashi & 
Hall, 2014).  This regulation of anabolic metabolism occurs via either a regulation of 
transcription or post-translational modification of transcription factors or enzymes central 
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to a particular metabolic pathway.  As shown in Figure 5.1.1a, the majority of these effects 
have been shown to be dependent on the mTORC1 substrate, S6K1.   
One of the core metabolic pathways regulated by mTORC1 is the glycolytic pathway.  This 
regulation has also been shown to be required for carrying out normal cellular functions and 
immune regulation (Donnelly et al., 2014).  The ability to regulate glycolysis is mediated by 
the transcription factors, c-Myc and Hypoxia Inducible Factor-1α (HIF-1α) (Düvel et al., 
2010).  Both of these transcription factors are capable of regulating multiple enzymes in the 
glycolytic pathway (Ibid).  Moreover, despite being capable of regulating the expression of 
distinct enzymes, both c-Myc and HIF-1α can bind to similar nucleic acid sequences and, 
despite sometimes acting in an antagonistic fashion (Mazure et al., 2002; Koshiji et al., 
2004), function to enhance the expression of many of the same glycolytic enzymes, such as 
Phosphofructokinase, Hexokinase and Triose Phosphate Isomerase (Gordan et al., 2007).  
Additionally, mTORC1 activity has been shown to not only up-regulate Glucose Transporter 
1 expression but also promotes membrane localization of the glucose transporter 
(Makinoshima et al., 2015). 
S6K1 mediates HIF-1α and c-Myc transcription and translation through the phosphorylation 
of Signal Transducer and Activator of Transcription 3 (STAT3) (Kim et al., 2009a; Thiem et al., 
2013; Dodd et al., 2014; Li et al., 2014; Rad et al., 2015) and eIF4B (Tandon et al., 2011; Csibi 
et al., 2014; Dodd et al., 2014).  Regulation of pyrimidine synthesis occurs through S6K1-
mediated phosphorylation of the rate-limiting enzyme Carbamoyl-Phosphate Synthetase 2, 
Aspartate Transcarbamylase and Dihydroorotase (CAD) (Lindsey-Boltz et al., 2004; Ben-Sahra 
et al., 2013; Robitaille et al., 2013).  The final pathway canonically regulated by mTORC1 is 
lipid and sterol biosynthesis.  The transcription factors, Sterol-Regulatory Element Binding 
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Proteins (SREBP) 1 and 2, are regulated at the level of expression by the mTORC1 substrate, 
Retinoid X Receptor (Norrmén et al., 2014) whilst proteolytic activation of these 
transcription factors is mediated by S6K1 (Düvel et al., 2010).  
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Figure 5.1.1a – Overview of the Role Played by S6K1 in Regulating Multiple Metabolic 
Pathways.  The mTORC1 substrate S6K1 is responsible for carrying out many of the regulatory 
roles ascribed to mTORC1 in the regulation of metabolism.  In the phosphorylated form, S6K1 
can bring about changes in gene expression, by either increasing the level of phosphorylated 
eukaryotic Initiation Factor 4B (eIF4B), mediating the proteolytic processing of the Sterol-
Regulatory Element Binding Proteins (SREBP) 1/2 (SREBP1/2c), or by directly phosphorylating 
Carbamoyl-Phosphate Synthetase 2, Aspartate Transcarbamylase and Dihydroorotase (CAD).   
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Section 5.2 – Methods 
Section 5.2.1 – Proposed New Approaches 
The asynchronous stochastic method outlined in Chapter 2 – Model Creation & Refining 
uses a Monte Carlo method to analyse sequences of feasible molecular interactions, given 
the connectivity of the model.  As described in Section 2.1.4.2 – Evaluation of the Predictive 
Power of the Model, the 1,000 trajectories sampled for the Wild Type and inhibitor models 
were interrogated using Reachfq and 99.99% Binomial Confidence Intervals calculated and 
regions of significant difference were identified.  A benchmark dataset (the Metabolic 
Benchmark dataset) detailing published effects of each inhibitor, on the selected model 
components, was used to validate the behaviour of the model and, quantitatively, analyse 
the predictive power of the model.  Both the MCC (Matthews, 1975) and the AC (Burset & 
Guigó, 1996) were again used to convert the qualitative measures of predictive power, given 
by the comparison of simulation behaviours to the benchmark datasets, to a quantitative 
measure.  The equations used to calculate these measures of predictive power are given in 
Section 2.1.4.2 – Evaluation of the Predictive Power of the Model. 
The asynchronous simulation is computationally more demanding, as large numbers of 
molecular interactions firing need to be generated and saved to disk space for further 
analysis.  This creates a challenge for QSSPN simulations integrating GSMN models.  In every 
instance where a Constraint Place state change, the FBA of the entire GSMN needs to be run 
multiple times to update the states of objective nodes.  Since FBA is the most time 
consuming operation in the QSSPN algorithm, this increases the computational cost when 
compared with the un-integrated signalling network alone.   
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In order to attempt to reduce the computational demands of the simulations, additional 
method were employed.  The synchronous execution of at least some molecular 
interactions would lead to a reduction in the number of iterations and thus, diminish the 
number of times the FBA would need to be performed.  Consequently, the simulation 
output files would be smaller.   
The first alternative method proposed was aimed at interpreting the model as a series of 
ODEs (as discussed in Section 2.1.4.3.1 – Case Study Identifying Differences in the 
Asynchronous Simulation Approach & the Synchronous Methods).  This deterministic 
approach was selected to apply to the full model, due the computational benefits this 
method has over the asynchronous stochastic method. In this approach, the reaction kinetic 
parameters are set equal to one.  If a molecular species is present, the species 
concentration variable becomes one and the reaction is enabled.  Inhibitor concentrations 
are seen as taking a value of one if it is absent, and so enabling the molecular interaction, or 
zero if the species is marked with a molecular activity level.  This would have the effect of 
reducing the solution to that particular ODE to zero.  A further synchronous simulation 
approach was tested, in which all enabled molecular interactions to fire in each time-step.  
However, due to the deficiencies discussed in Section 2.1.4.3 – Synchronous Simulation 
Methods and Section 2.1.4.3.1 – Case Study Identifying Differences in the Asynchronous 
Simulation Approach & the Synchronous Methods this method was tested only with 
Rapamycin incorporated into the model to establish if this approach could produce the 
expected model predictions. 
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Both the asynchronous stochastic and ODE methods were implemented using version 3.0 of 
the software QSSPN and developed by A. Kierzek (as part of the QSSPN formalism).  These 
methods were run using an identical model so as to ensure the results were comparable.   
The QSSPN software was used here, as it allowed the integration of a qualitative model of 
the regulation of translation initiation with a GSMN of a RAW 264.7 murine macrophage.  
This GSMN has been shown to be capable of reproducing experimentally derived data 
(Bordbar et al., 2012), and is constraint-based.  The integration is achieved by identifying 
transcription factors regulated by mTORC1 and linking these transcription factors to genes 
found within the GSMN.    As noted by Fisher and colleagues (2013), the activation of the 
constraint-based GSMN is achieved only if the activation thresholds are reached in the 
qualitative model.  23 metabolic genes, from a range of metabolic pathways including the 
pentose phosphate pathway, glycolysis and lipid and sterol biosynthesis, were linked to 
mTORC1 activation in this way.  The functioning of the integrated model was confirmed by 
the production of Biomass.  Biomass, as a ‘metabolite’ within the flux balanced analysis 
model, is the sum of all the external metabolites produced by the model, as such Biomass 
production was viewed as being required for translation to occur. 
Section 5.3 - Results 
Section 5.3.1 – Current, Asynchronous, QSSPN Simulation Method 
Initial integration of the models was aimed at linking the mTORC1 signalling pathway to the 
regulation of metabolic pathways found in the RAW 264.7 cell GSMN.  This integration 
resulted in 23 genes required for multiple metabolic pathways, including glycolysis, the 
pentose phosphate pathway and lipid/sterol biosynthesis, being placed under the control of 
mTORC1.  In order to incorporate the expression of 23 new metabolic genes and the effects 
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of the mTORC1 substrate, S6K1 on these genes, it was necessary to add 197 novel molecular 
interactions.  The expression of these 23 genes required the addition of multiple new 
molecular species including several transcription factors and the stages of expressing these 
genes.  In total, including the repetition of molecular species to account for involvement in 
multiple molecular interactions, 188 new Petri Net compentents, to model these species, 
were incorporated into the model. 
Before the two new methods could be tested, a point of comparison was necessary.  This 
point of comparison was obtained by running simulations using the method detailed in 
Chapter 2 – Model Creation & Refining.  The novel methods required version 3.0 of QSSPN.  
Since the implementation of the synchronous approach altered the main simulation loop in 
the QSSPN code, validation of the new code was necessary.  Accordingly, version 1.0 of 
QSSPN was also included in this new round of simulations to ensure that functionality of 
QSSPN had been conserved through to version 3.0.    The dataset against which the model 
integrated with the RAW 264.7 cell GSMN was tested is shown in Supplementary 
Information 3. This dataset was termed the Metabolic Benchmark, composed of 186 
literature articles, concerned the effects of chemical inhibitors on key model effectors.  The 
bibliographic information concerning this Benchmark can be found in Supplementary 
Information 1a.  Simulations show that the results obtained with the asynchronous method 
implemented in version 3.0 of the QSSPN software are identical to the results obtained with 
version 1.0.   
The simulations run in this section were done using the method presented and used 
elsewhere in this project.  These results were obtained using version 3.0 of QSSPN.  These 
results (shown in Supplementary Information E7 – Frequency Data Generated by Reachfq 
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with Associated 99.99% Binomial Confidence Intervals (sheet entitled Asynchronous Method 
Results)) were then to be used as a benchmark against which the other two, alternative 
methods would be tested.  The upper and lower 99.99% Binomial Confidence Intervals, 
calculated in the software R, were then calculated for each identified key model effector. 
As Rapamycin has been shown to affect eIF4E phosphorylation via MNK2, elsewhere in this 
project, it is worth noting that the integration of the Petri Net model with the RAW 264.7 
cell GSMN did not eliminate this prediction.  The frequency of trajectories resulting in eIF4E 
phosphorylation was reduced when Rapamcyin was introduced to the model (0.472 in the 
Wild Type model versus 0.007 in the Rapamycin model).  Moreover, the frequency of 
trajectories leading to MNK2 phosphorylation was also altered, with an increase from 0.502 
in the Wild Type model to 0.845, in the Rapamycin model. 
The summary of the Confusion Matrices, shown in Figure 5.3.1ai, describe the comparison 
of the results of simulations with QSSPN version 3.0, with the literature-based Metabolic 
Benchmark dataset.  For each inhibitor model, a summary of the predictive power is given.  
The overall measure of predictive power, given in Figure 5.3.1aii, contains the pooled results 
of all the matrices.  This then provides enough information to make a reasonable 
assessment of the overall predictive power of the model.  The results of individual models 
are of interest when looking at where model improvements are needed. 
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i.   
  Confusion Matrix Values  
Model TP TN FP FN MCC Value 
BIX02189 1 7 0 3 0.4183 
CGP57380 3 6 0 1 0.8081 
GSK2334470 2 11 1 2 0.4623 
LY294002 4 3 1 9 0.0537 
PD184352 6 1 0 7 0.2402 
PD98059 11 3 0 3 0.6268 
Rapamycin 9 3 1 4 0.3812 
SB203580 5 2 4 8 -0.2630 
SP600125 11 3 1 4 0.7100 
XMD8-92 2 2 0 1 0.6667 
 
ii. 
       
 Confusion Matrix Values 
 
Measures of Predictive Power 
 TP TN FP FN MCC Value AC Value α-Value 
 
Overall 54 41 8 42 0.3789 0.3762 4.4x10-7 
        
Figure 5.3.1a – Predictive Power of the Model of Translational Regulation Integrated with a GSMN 
of RAW 264.7 Cell Metabolism and Simulated with the Current, Asynchronous Method.  (i) 
Following the simulation and interrogation of the model with QSSPN (Version 3.0) and Reachfq, the 
frequency of trajectories resulting in the activation of each model effector, were calculated for the 
Wild Type and inhibitor models.  By calculating the 99.99% Binomial Confidence Intervals for each 
effector, and comparing the Wild Type and inhibitor models, it was possible to identify regions of 
significant difference.  Comparing the behaviour of the model to the Metabolic Benchmark dataset 
allowed the construction of Confusion Matrices with behaviour being characterised as being either 
True Positive (TP), True Negative (TN), False Positive (FP) or False Negative (FN).  Calculating the 
Matthews’ Correlation Coefficient (MCC) converted this qualitative measure of predictive power to a 
quantitative one.  (ii)  The overall predictive power of the model was calculated by pooling the 
variables in the Confusion Matrices of the individual inhibitors.  The Approximate Coefficient (AC) 
was also calculated.  By conducting a Chi Square Test, using the resulting α-Value, it was possible to 
confirm that the predictive power of the model was significantly different from random. 
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In order to ensure the continued functioning of QSSPN, it was necessary to ensure 
agreement between versions 1.0 and 3.0.  The data shown in Supplementary Information E7 
– Frequency Data Generated by Reachfq with Associated 99.99% Binomial Confidence 
Intervals details the values obtained with version 3.0.  Although the data is not shown here, 
those values are identical to those obtained with version 1.0 and so demonstrates that 
functionality of the QSSPN software is conserved.   Integration of the model is known to be 
functioning as Biomass was produced in the Wild Type model, albeit at a low level with the 
frequency of trajectories reaching Biomass production being 0.044.  Such a low frequency is 
not unexpected given the experimentally derived lower bound of the Biomass reaction 
within the RAW 264.7 cell GSMN model was set to 0.0281/h (Bordbar et al., 2012). This may 
be indicative of a need for a more comprehensive integration of the GSMN with the 
signalling pathways.   
During this evaluation of the functioning of the model, the alteration to the level of 
phosphorylated eIF4E and a reduction to phosphorylated AKT1 during Rapamycin 
incorporation were maintained.  This suggests that the functioning of the model was 
maintained during the integration with the RAW 264.7 cell GSMN.  Despite the two 
experimentally validated predictions being maintained through the integration process, the 
MCC value is markedly, but not significantly (as determined by a Chi Square Test, α = 0.305), 
lower than it was prior to the integration with the GSMN (MCC = 0.3759 versus MCC = 
0.4558 (as calculated in Section 2.2.4 – Evaluation of the Predictive Power of the Final 
Model)).  Given this reduction in predictive power was quite substantial, albeit not 
significant, it was decided that the method that produced the smallest decrease in MCC 
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value would be the best method to take forward, even if this means simulations are 
relatively expensive in a computational sense. 
Section 5.3.2 – Proposed New Methods 
Section 5.3.2.1 – Ordinary Differential Equation Method 
The first proposed method was deterministic and treated the model as a series of ODEs.  
Consequently, only one trajectory was necessary.  While ODEs are usually used to express 
quantitative models, they were applied here to a qualitative model.  All continuous variables 
were allowed to vary between zero and one.  All kinetic parameters are set equal to one.  If 
a molecular species is not marked with any discrete activity levels, then this parameter is 
multiplied by zero.  Conversely, if molecular species are marked with discrete activity levels, 
then this is multiplied by one.     
Attempts with this method revealed that the predicted behaviours of alterations to the level 
of eIF4E phosphorylation and a reduction in AKT1 phosphorylation, were shown to occur, as 
shown in Figure 5.3.2.1a. 
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Figure 5.3.2.1a – Summary of the Results of the Ordinary Differential Equation Simulation Method.  This method evaluates the model as a series of ODEs in which the kinetic 
parameters are set equal to one and are multiplied by one if the molecular species are marked with discrete activity levels.  This subjective, yet deterministic, method is evaluated in 
an equally qualitative manner by comparing the Wild Type model and an Inhibitor model.  If an increase of more than 10% in the amount of each effector is observed in the 
simulation a ‘↑’ is given.  Conversely, for a decrease of more than 10% a ‘↓’ designation is listed.  Where no change occurs, the result is given by ‘-‘.  For marginal increases or 
decreases (less than 10%), combinations of these are given. 
  BIX02189 CGP57380 GSK2334470 LY294002 PD184352 PD98059 Rapamycin SB203580 SP600125 XMD8-92 
ppMEK1 - - - ↓ ↓ ↓ ↓ - - - 
ppMEK2 - - - ↓ ↓ ↓ ↓ - - - 
ppERK1 - - - ↓ ↓ ↓ ↓ - - - 
ppERK2 - - - ↓ ↓ ↓ ↓ - - - 
pRSK1 - - - - - - - - - - 
rpS6-Pi - - - - - - - - - - 
pMNK1 - ↓ ↑/- ↑ ↓ ↓ ↑ ↓ ↓ - 
pMNK2 - ↓ ↑/- ↑ ↓ ↓ ↑ ↓ ↓ - 
eIF4E-Pi - ↓ ↑/- ↑ ↓ ↓ ↓ ↓ ↓ - 
pJNK1 - - - ↑ - - ↑ - ↓ - 
cJun-Pi - - - - - - - ↓ ↓ - 
ppp38a - - - ↑ - - ↑ ↓ - - 
pERK5 ↓ - - ↑ ↑ ↓ ↑ - - ↓ 
PI3K-Act - - - ↓ - - - - - - 
PIP3 - - - ↓ - - - - - - 
PDK1-Act - - ↓ ↓ - - - - - - 
pPKCz - - ↓ ↓ - - ↓ ↑ - - 
ppAKT1 - - - ↓ - - ↓ - - - 
ppS6K1 ↓/- ↓ ↓ ↑ ↓ ↓ ↓ ↓ ↓ ↓/- 
eIF4B-Pi - - - ↓ ↑/- ↑/- ↑ ↓ ↑/- - 
p4E-BP1 - - - - ↓ ↓ ↓ - - - 
mTORC1-Act - - - - ↓ ↓ ↓ - - - 
pTSC2 - - - - - - - - - - 
c-Myc - - - - ↓ ↓ ↓ - - - 
HIF-1a - - - - ↓ ↓ ↓ - - - 
SCD1 - ↓ ↓ ↑ ↓ ↓ ↓ ↓ ↓ ↓/- 
PFK - - - - ↓ ↓ ↓ - - - 
BIOMASS - ↓ ↑ - - - ↓ - ↓ - 
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It is worth noting that the use of the word ‘subjective’, in Figure 5.3.2.1a, to describe the 
results of the ODE method refers only to the fact that as rates are multiplied by one if 
discrete acitivty levels are present in the molecular species serving as reactants for a 
particular molecular interaction.  As a consequence of this use of pseudo-kinetic parameters 
the traces of molecular amounts must be regarded as subjective.  Had kinetic parameters 
been available concerning the concentration of particular species and the rate constants for 
model reactions, the output of the ODE model would be absolute with the presence of large 
molecule numbers minimising deviations from the mean (Kleinstein & Singh, 2001). 
The ODE method is a deterministic method that has the potential to greatly improve the 
existing methodologies of systems biology but also suffers from significant drawbacks.  This 
method is attractive in terms of the contribution it makes towards the aim of making 
simulations computationally less costly.  The need for only one trajectory both speeds up 
the running of simulations and reduces the computational power required.  However, the 
deterministic properties of this method, whilst attractive, suffer greatly from a lack of 
realistic kinetic parameters.  The results of this simulation suffer from a lack of sensitivity, as 
shown in Figure 5.3.2.1a.  In this Figure, no observed change in the trajectory was denoted 
by ‘-‘, a marginal increase or decrease (of less than 10%) is denoted by ‘↑/-‘ or ‘↓/-‘, 
respectively and larger increases or decreases, of greater than 10%, are given by ‘↑’ and 
‘↓’, respectively.  Only gross changes are visible using this method.  The summary of the 
Confusion Matrices shown below, Figure 5.3.2.1b, demonstrate this in the marked reduction 
in the predictive power. 
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i.   
  Confusion Matrix Values  
Model TP TN FP FN MCC Value 
BIX02189 1 7 0 3 0.4183 
CGP57380 3 5 1 1 0.5833 
GSK2334470 2 11 1 2 0.4623 
LY294002 5 1 3 8 -0.3110 
PD184352 8 0 1 5 -0.2070 
PD98059 10 3 2 3 0.3508 
Rapamycin 11 0 3 3 -0.2141 
SB203580 6 4 2 7 0.1207 
SP600125 6 4 0 9 0.3508 
XMD8-92 1 2 0 2 0.4082 
 
ii. 
       
 Confusion Matrix Values 
 
Measures of Predictive Power 
 TP TN FP FN MCC Value AC Value α-Value 
 
Overall 53 37 12 43 0.2922 0.2926 1.38x10-5 
        
Figure 5.3.2.1b – Overview of the Predictive Power of the Model when Simulated with the 
Ordinary Differential Equation Method.  (i) The interactions in the Petri Net model were converted 
to a series of Ordinary Differential Equations.  The tool to do this was developed by A. Kierzek as part 
of the QSSPN project.  By comparing the traces of each effector in the Wild Type model to those in 
each inhibitor model, it was possible to identify regions of difference.  This behaviour of the 
inhibitors in the model were then compared to the Metabolic Benchmark dataset.  This behaviour 
was characterised as either being a True Positive (TP), True Negative (TN), False Positive (FP) or a 
False Negative (FN).  These Confusion Matrix variables were then converted to a quantitative 
measure of predictive power in the form of the Matthews’ Correlation Coefficient (MCC).  (ii) By 
pooling these variables for each inhibitor, it was possible to calculate an overall MCC value.  This 
overall measure of predictive power was confirmed by calculating the Approximate Coefficient (AC).  
Moreover, to demonstrate that the level of predictive power was significantly different from 
random, the α-Value of a Chi Square Test was calculated. 
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This marked reduction in the MCC values between the current, asynchronous method (MCC 
= 0.3759) and this ODE method (MCC = 0.2922), whilst appearing to be non-significant (as 
determined by a Chi Square Test, α = 0.492), was of great importance in deciding which 
method was to be taken forward for use in later simulations. 
Section 5.3.2.2 – Synchronous Method 
Although synchronous simulations demonstrated that Rapamycin was able to alter the level 
of phosphorylated eIF4E and reduce AKT1 phosphorylation, it did produce some rather 
questionable results from the model of translational regulation integrated with the GSMN.  
As expected from Section 2.1.4.3.1 – Case Study Identifying Differences in the 
Asynchronous Simulation Approach & the Synchronous Methods, MNK2 phosphorylation 
was abolished by this method.   
Signalling pathways require a highly coordinated response to a signal in order for signal 
transduction to occur.  Each interaction must occur in a tightly temporally regulated fashion 
(Kholodenko et al., 2010).  The synchronous approach assumes that all molecular 
interactions proceed with the same velocity.  While it is easy to understand how the 
temporal nature of a tiered signalling pathway is essential, it may be less clear for cross-talk 
between signalling pathways.  In a MAPK cascade for example, in order for the next kinase 
to be phosphorylated the upstream kinase must be activated (Ibid).  Similarly, the temporal 
nature of feedback mechanisms are clear.  During negative feedback, a downstream effector 
acts to inhibit the pathway and thus prevents further transduction.  This allows oscillatory 
behaviour to be observed (Kholodenko, 2006).  However, in order to understand how cross-
talk between signalling pathways is temporally regulated, it is necessary to note that the 
nature of cross-talk is complex and may only occur if sustained activation of a pathway is 
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achieved (Housden & Perrimon, 2014).  Moreover, even within a particular pathway the 
efficacy of the interaction between the kinase and differing downstream targets is not 
uniform (Loog & Morgan, 2005 (as cited by Jin et al., 2008b)).   
To relate this back to the synchronous approach, if AKT1 has in excess of 70 known cellular 
targets (Martelli et al., 2012) it is likely that AKT1 is able to interact with some with greater 
efficiency than others.  Consequently, these substrates will be phosphorylated in a much 
shorter timescale than others.  The synchronous approach does not take this into account 
when firing all enabled molecular interaction.   
While the asynchronous approach does not include exact reaction rates, it does allow for 
some molecular interactions to occur before others.  Gillespie algorithm simulations are 
used to create an ensemble of 1,000 individual trajectories, in which different orders of the 
firing of molecular interactions are tested.  In this ensemble, there are examples of 
trajectories in which reactions occur in the correct order for biological behaviour to be 
feasible.  In this way, non-parametric, qualitative simulations with the Gillespie algorithm 
are capable of generating biological behaviour of interest in signalling cascades.  The 
qualitative synchronous approach is not capable of doing this.  The only way to simulate 
signalling networks in a synchronous way would be to fully parameterise the model and run 
ODE simulations.  Thus, examples in this dissertation show that the asynchronous 
simulations with the Gillespie algorithm can be used to qualitatively model signalling 
networks, while a synchronous approach is not. 
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Section 5.4 – Discussion  
Section 5.4.1 – Potential Future Work 
Given the reduction in predictive power that accompanied the integration of the RAW 264.7 
cell GSMN, it would seem logical to attempt to increase the predictive power of the model 
through considerable increases in the level of cross-talk between the signalling pathways.  A 
more detailed understanding of the nature of the interaction between signalling pathways, 
other than mTORC1, and the regulation of metabolism would also be of benefit.  As noted in 
Chapter 4 – Modelling the Effects of Viral Infection, the preliminary work presented in this 
chapter is of importance as it provides a model which, when the predictive power is suitably 
raised, will allow the effects of viral infection upon metabolism to be modelled. 
Section 5.4.2 – Concluding Remarks 
Section 5.4.2.1 – Proposed Novel Modelling Strategies 
Swanson and colleagues (2003) noted that one of the key requirements in mathematical 
modelling is the need for as complete an understanding as possible of the biological system 
in question.  The ODE method, whilst initially promising, failed to meet this requirement. 
Even with a seemingly complete knowledge of the reaction kinetic parameters required to 
accurately model a biological system, the fundamental problems of failing to take into 
account all variables and not having parameters that translate well to other systems are 
always present.  When referring to the models proposed by Tracqui et al. (1995) and 
Swanson et al. (2002) of gliomas, Hatzikirou and co-workers (2005) remark that the 
parameters used are only likely to refer explicitly to one system and may not be 
representative of all glioma systems.  This example serves to illustrate that even with truly 
mathematical models it is difficult to represent a biological system in a way that is both 
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realistic and meaningful.  The treatment of the qualitative, stochastic translational control 
model as an ODE model resulted in an obvious, albeit non-significant, decrease in predictive 
power.  The ODE method used in this study resulted in a considerable decrease in 
computational cost but was only brought about at the expense of accuracy and 
verisimilitude.  This being said, of the new ODE and synchronous methods, only the ODE 
method was worthy of carrying forward for a complete examination of the model. 
Section 5.4.2.2 – Integration of the GSMN with the Translational Regulation 
Model 
In addition to the trial of new modelling approaches, the integration of a GSMN with the 
model of the regulation of translation initiation represented a new direction for the project.  
Given that protein synthesis requires around one third of the total ATP produced by 
oxidative phosphorylation (Buttgereit & Brand, 1995), the ability to model both allowed the 
dynamic relationship between the two processes to be simulated.  The work shown here 
establishes the plausibility of connecting a GSMN to a stochastic model.  Although a 
significant reduction in the predictive power of the translation model was noted, the 
predictive power did remain positive.  A possible explanation for this is that additional 
signalling pathways must be linked to the expression of genes found within the Bordbar et 
al. (2012) GSMN.  As shown in Figure 5.3.1a in Section 5.3.1 – Current, Asynchronous, 
QSSPN Simulation Method, there is low correlation between the majority of the inhibitor 
models and model effectors involved in the linking of the translational regulation model and 
the GSMN. 
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Section 6.1 – Introduction 
This chapter summarises the findings of the project as a whole and describes future uses of 
the model presented here.  More detailed information on the findings can be found in the 
individual chapters. 
The process of synthesising nascent polypeptides is a major energetic burden to the cell, 
requiring around 30% of all ATP produced (Buttgereit & Brand, 1995).  The understanding of 
translation in mammalian cells is far from complete with much information being inferred 
from work with yeast.  This being said, whilst the process in both systems is analogous there 
are differences.  An illustration of the differences can be seen in the structure and size of 
the yeast and mammalian ribosomes (Morgan et al., 2000).  Moreover, translation is 
involved in the pathophysiology of a number of significant human and veterinary diseases.  
Graff and co-workers (2008) even posit that the targeting of specific initiation factors may 
offer therapeutic approaches for diseases, such as cancer.   
The signalling pathways that regulate translation are complex.  The interactions that exist 
between such pathways add a further level of complexity to the cellular environment.  Siso-
Nadal and co-workers (2009) noted that in order for signals to be transduced in concert, the 
signalling pathways must form an interconnected network.  Indeed, the connectivity within 
this network is the source of the robust nature of many of the dynamic behaviours that cells 
exhibit (Ibid) and functions to allow the integration of multiple signals (Hartwell et al., 1999).  
A consequence of this integration is to allow cells to demonstrate complex and coordinated 
patterns of behaviour (Ibid).  With this in mind, any attempt to model a process, such as 
translation, which affects the functioning and indeed, viability of the cell must take into 
account the interconnected nature of the signalling pathways. 
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In Section 1.5.1 – Aims & Objectives, the aims of the project were listed.  In all cases, these 
aims were achieved with various degrees of success and work investigating them was 
carried out.  The main aim of this project was not to just computationally simulate the 
regulation of mammalian translation initiation by a large-scale reconstruction of a signalling 
network, but also to carry out these simulations alongside experimental validation of the 
behaviour of the model.   In keeping with this view, it was possible to experimentally 
validate six predicted behaviours.   
The overarching aim of this work was to produce a stochastic, qualitative model of the 
regulation of translation initiation by a signalling network.  Over the course of this project, 
several accomplishments were necessary in order to achieve this aim: 
 Analyse available literature of over 1,100 articles on translational 
regulation and construct large-scale molecular interactions network 
model 
 Develop a literature-based benchmark dataset and a method to 
quantitatively analyse the predictive power of the model 
 Experimental validation of the prediction involving an increase in the 
phosphorylation of eIF4E in response to Rapamycin 
 Experimental validation of the prediction involving a decrease in the 
phosphorylation AKT1 in response to Rapamycin 
 Provide a mechanism to explain the increase in eIF4E phosphorylation 
 Incorporate the effects of viral infection into this model 
 Experimental validation of the prediction involving an increase in CREB 
phosphorylation during MNV infection and three other behaviours 
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 Quantification of the model through the incorporation of a model of 
ERK1/2 activation 
 Attempt to link metabolism to the regulation of translation 
Section 6.2 – Model Construction & Predictive Power 
Evaluation 
In order to construct the model it was necessary to collate information published in over 
1,158 peer-reviewed articles.  This model was then converted to the binary model 
formalism, which represents the activation conditions of each molecular interaction, 
without introducing unrealistic oscillations.  The final model accounted for 584 interactions 
between 511 molecular species.  This model differs from currently existing ones, such as 
that of Firczuk et al. (2013), in several regards.  The yeast model presented by Firczuk and 
co-workers (2013) is considerably smaller than the one created here and does not include 
the regulatory network controlling translation initiation.  This difference is important as it 
means that the model of regulating translation covers a much larger range of pathways.  
Consequently, this model has a much wider range of future implications. 
The future development of this model should focus upon linking translational regulation to 
important and emerging pathways and processes.  Furthermore, any continuation of this 
work should also look to incorporate new pathways that are found to regulate translation, 
for example the phosphorylation of eIF4B by Pim kinases (Yang et al., 2013b; Cen et al., 
2014).   
Given that cellular stress, and the formation of Stress Granules, have been shown to bring 
about considerable alterations to the levels of translation (Hoffman et al., 2012; Ruggieri et 
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al., 2012), it seems that the incorporation of the process of forming Stress Granules should 
be considered.  If the translational control model were to incorporate Stress Granule 
formation, it would better allow the phosphorylation of eIF2α to be modelled.  This point of 
translational regulation has been one of the hardest to model as the exact nature of the 
input signal was hard to define and the upstream signalling pathways are very complex and 
not necessarily directly linked to the regulation of translation.  Moreover, the biological 
relevance of eIF2α phosphorylation in RAW 264.7 cells is hard to define.  Overexpression of 
Monocyte Chemotactic Protein-Induced Protein 1 has been shown to attenuate the 
phosphorylation of this initiation factor (Qi et al., 2011).  Similarly, given the model is 
amenable to the simulation of viral infection, it would be necessary to also model strategies 
used by RNA viruses to limit the activation of PKR and the interferon response (Överby et 
al., 2010; Uchida et al., 2014). 
The cell cycle represents the second process that would be of interest to link to translation.  
The process of translation has been noted to be a key regulatory point in the progression of 
the cell cycle in yeast (Daga & Jimenez, 1999), human (Göpfert et al., 2003) and Xenopus 
(Groisman et al., 2002) cells.   
A further application for extending this work may come from combining the model of the 
regulation of translation initiation with models of elongation.  Attempts at this may prove 
difficult given the qualitative nature of the model presented in this work.  However, the 
stochastic framework used in the implementation of the Totally Asymmetric Exclusion 
Process models of elongation, such as that of Reuveni and co-workers (2011), may lead to a 
better understanding of how translation is regulated by a combination of extrinsic (in the 
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case of the signalling pathways) and intrinsic (for example at the level of the ribosome) 
factors. 
The conversion to the binary model formalism eliminated the random fluctuations between 
the on and off states of effectors, such as kinases, in the model.  Moreover, a binary model, 
in which effectors are either active or inactive, removes the pseudo-kinetic parameters that 
marking molecular species with multiple discrete activity levels introduces and, therefore, 
the model is governed solely by the known connectivity of the molecular network.  
Furthermore, the functionality of the model is reduced to simulating the conversion of 
sufficient model effectors that would bring about a biological effect.  This binary model 
formalism represents a powerful, novel method of simulating large-scale biological systems. 
One of the major outcomes of this work was the creation of a benchmark dataset and a 
method for measuring the predictive power of the model.  This method concerns a 
comparison of the behaviour of the model with known effects.  Existing literature has been 
examined to compile data on the effect of 12 chemical inhibitors on 23 molecular effectors.  
Using the Human Phospho-MAPK Arrays, it was possible to examine how 13 of these 
effectors respond to Rapamycin in RAW 264.7 cells.  From this it was possible to provide a 
quantitative measure of predictive power by way of the MCC and the AC.  Beck and co-
workers (1997) argued that model validity is a determination as to whether the system can 
carry out a particular function in a consistent manner with the number of adverse outcomes 
being minimised.  To this end, this model validation approach used here provides insight 
into how well existing data can be reproduced by the model and gives an indication as to 
how predictive the behaviour of the model is.  
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Based on the findings of this work that the MCC value is sensitive to small changes in the 
model, it is recommended that this method should be taken forward.  However, this in silico 
predictive power analysis has a potential shortcoming.  The method is only amenable to 
large systems or systems where sufficient data about model components is available.  For 
such models, the number of data points is limited and therefore the resulting MCC value is 
susceptible to large changes being introduced after relatively small changes to model 
connectivity.  It was shown in Section 2.2.1.1 – Updated Benchmark Dataset that the use of 
data only relating to small data subsets, such as specific cell types, can also lead to a marked 
reduction in data points.  For this reason, the inclusion of data from all cell types was used.  
Although it could be argued that this would serve to reduce the overall value of the dataset 
against which to compare the model, the large size of this dataset means that variations are 
potentially reduced.  
Although Fisher and co-workers (2013) employed the use of MCC values to measure the 
predictive power of the hepatocyte model, the use of this correlation coefficient in this 
project is novel in one key regard.  In order to evaluate the functioning of the translational 
regulation model, no dataset against which to compare model behaviour was available.  
Fisher et al. (2013) were able to compare the behaviour of the hepatocyte model to the 
work of Song et al. (2009).  Here 134 literature articles have been used to create a 
benchmark dataset of the effects of 12 chemical inhibitors on 23 model effectors.  Apart 
from being applied for model validation, this dataset constitutes a comprehensive literature 
review that can be used by researchers when planning future work on the effects various 
inhibitors have upon key model signalling effectors. 
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The standardisation of nomenclature used in the model, with links to databases through the 
assignment of identifiers, adds to the quality of the project by providing an open and 
transparent development process.  One of the major obstacles within the field of systems 
biology is the arbitrary naming of molecular species.  This prevents the integration of 
models developed by different groups.  Whilst the Systems Biology Markup Language has 
helped to standardise biochemical models (Hucka et al., 2003 (as cited by Bornstein et al., 
2008)), the links to established databases, such as Uniprot and Entrez, will help to make the 
model more accessible to those outside of systems biology. 
Section 6.3 – Experimental Validation 
In an oversimplified way, systems biology aims to reconstruct biological systems and, using 
these models, to generate predictions (Ideker et al., 2001).  The usefulness of the model 
constructed here was, therefore, demonstrated by the ability to generate seven predicted 
behaviours that were linked to translational machinery directly and also the regulatory 
signalling pathways.  Furthermore, these behaviours were amenable to experimental 
validation.  Moreover, as stated above, the model not only consistently reproduced the 
behaviour of inhibitors in multiple cell types but also displayed good agreement with 
experimental data collected in RAW 264.7 cells treated with Rapamycin using the Human 
Phospho-MAPK Arrays.  Indeed this ability ‘to bring the theoretical predictions and 
experimental data into close apposition’ is one of the fundamental principles of systems 
biology (Ideker et al., 2001).  Consequently, the experimental validation of six of the seven 
predicted behaviours overcame a major obstacle for this work.   
The ability to demonstrate that six in silico behaviours occur in a cell line adds significant 
value to the model as a whole.  The work undertaken in this project has produced a model 
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of cellular translation that it has been experimentally validated.  However, in regard to the 
behaviour of the MNV model, despite several predicted behaviours being experimentally 
validated, it was not possible to validate the behaviour of MSK2, in this model.  This 
indicates that further refinement of the model upstream of MSK2 is required.  
Consequently, of the seven predicted behaviours that were experimentally tested, over the 
course of this project, it was possible to confirm six of these.  This corresponds to a success 
rate of 85.7%. 
The exact nature of eIF4E phosphorylation has only recently become known.  Herdy et al. 
(2012) noted that eIF4E phosphorylation allows for a change in gene expression.  This view 
is in keeping with the work presented here.  Experimentally, Rapamycin-mediated mTORC1 
inhibition was shown in Chapter 3 – Experimental Validation of Model Predictions, to cause 
an increase in eIF4E phosphorylation.  Given the role of mTORC1 in mediating cell growth 
(Dowling et al., 2010) and the finding that cellular stress signalling is inhibited by the 
mTORC1 substrate, S6K1 (Shin et al., 2013), it seems plausible that mTORC1 inhibition 
should bring about a stressed state in the cell and necessitate a change in gene expression.   
Whilst it is a little harder to conclusively state the effect Rapamycin has upon the 
phosphorylation of AKT1, the work presented here does indicate that inhibition of this 
protein kinase occurs, possibly through mTORC2 inhibition, following one hour of treatment 
of cells with this macrolide.  The work presented in Chapter 3 – Experimental Validation of 
Model Predictions, using Human Phospho-MAPK Arrays, clearly demonstrates that the level 
of phosphorylated AKT Pan is significantly reduced.  This is in keeping with the work of Chen 
and co-workers (2010).  These authors observed that high concentrations of Rapamycin 
served to reduce the phosphorylation of AKT1.   Only with respect to treatment length does 
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the work demonstrated here offer some disagreement with Sarbassov et al. (2006).  Both of 
these studies use treatment lengths of 24 hours.  However, Sarbassov and co-workers 
(2006) noted that the effect of diminishing AKT1 phosphorylation was cell type specific.  This 
specific effect correlates well with the work by Schreiber et al. (2015) in which the ratio of 
FKBP12 and FKBP51 was found to be important for determining the extent of Rapamycin-
mediated inhibition of mTORC2.  As noted in Chapter 3 – Experimental Validation of Model 
Predictions, determining this ratio in RAW 264.7 cells may prove useful.  Despite the fact 
that immunoblotting with lysates of cells treated with Rapamycin for three hours failed to 
demonstrate that AKT1 phosphorylation was reduced, it is still possible to argue that this 
hypothesis has been, to some extent, experimentally demonstrated.  Possible reasons for 
the inability to corroborate the Human Phospho-MAPK Array result is given in Section 3.4.2 
– Validation of the AKT1 Phosphorylation Prediction.   
Section 6.4 – Mechanism for Rapamycin-Induced Increases 
in eIF4E Phosphorylation 
Whilst experimentally, Rapamycin has been shown to increase the level of eIF4E 
phosphorylation, the first version of the binary model predicted a decrease (as noted in 
Section 2.2.2 – Re-Evaluation of the Binary Model).  This discrepancy motivated further 
work that has led to the improvement of the model and a better understanding of the 
nature of the relationship between mTORC1 and eIF4E.  In order to identify a potential 
mechanism by which eIF4E phosphorylation can be increased by Rapamycin, a small model 
was created.  This model only concerned the molecular interactions directly linked to 
mTORC1 activation and eIF4E phosphorylation.  Interrogation of this small model revealed 
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the three points which would allow mTORC1 inhibition to positively affect eIF4E 
phosphorylation.  These points, as noted in Section 2.2.3 – Mechanism by Which mTORC1 
Inhibition Affects eIF4E Phosphorylation, detail factors which when taken together all 
contribute to eIF4E phosphorylation.  These involve the relative levels of eIF4E and 4E-BP1, 
an alternative kinase for PKCα and potentially alterations to the activity of a protein 
phosphatase.  Work to correct the direction of change in eIF4E phosphorylation was able to 
provide in silico evidence for two of these points.  In the model eIF4G phosphorylation was 
disconnected from eIF4E phosphorylation and 4E-BP1 was maintained at a level lower than 
that of eIF4E.  Together both changes permitted an increase in eIF4E phosphorylation that 
was dependent upon MNK2 and independent of MNK1.  This is in agreement with the work 
by Stead and Proud (2013) in which MNK2 was implicated in mediating a Rapamycin-
induced increase in eIF4E phosphorylation.  Moreover, the simulations presented here 
suggest that this increase is not dependent upon either ERK1/2 or p38, again in agreement 
with earlier work (Stead & Proud, 2013; Eckerdt et al., 2014).  Although numerous other 
studies have also noted that Rapamycin is capable of increasing eIF4E phosphorylation (Sun 
et al., 2005; Wang et al., 2007c; Grosso et al., 2011; Marzec et al., 2011), no real consensus 
was found between these studies as to how mTORC1 is related to the post-translational 
modification of this initiation factor. 
Section 6.5 – Models of Viral Infection 
In order to demonstrate the potential of the translational control model, perturbations 
normally associated with viral infection were implemented into the model.  Additionally, to 
show the flexibility of the modelling approach, a range of viral effects were chosen.  Two of 
the viruses (JUNV and ANDV) are severe, emerging human pathogens about which little is 
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known.  The third virus, MNV, is a surrogate of the medically important HuNV.  Although not 
permissive in RAW 264.7 cells, ANDV and JUNV are capable of inducing changes in the 
activation of different cellular signalling pathways.  The changes that were made to the 
three models were all taken from existing literature or, in the case of MNV, from 
experimental data generated in-house.   
QSSPN simulations and Reachfq analysis revealed that MNV infection induces considerable 
changes to the signalling network of the cell.  As shown in Figure 6.5a, the outcome of these 
simulations led to the conclusion that MNV not only mediates changes in gene expression 
through the promotion of eIF4E phosphorylation (Royall et al., 2015), but this also occurs 
through alterations to the phosphorylation states of the transcription factors, CREB, ATF-2 
and Elk-1.  The experimental increase in CREB phosphorylation correlates well to the 
increase seen in the simulations presented in Chapter 4 – Modelling the Effects of Viral 
Infection.  Despite this increase not being an unexpected finding, seeing as it is downstream 
of both p38 (Di Petro et al., 2007; Di Giacomo et al., 2009) and ERK1/2 (Impey et al., 1998; 
Xing et al., 1998), it was not a perturbation that was specifically induced in the model and 
thus, represents the experimental validation of one viral prediction.     
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Figure 6.5a – Schematic of the Effects of MNV-Induced ERK1/2 and p38 Activation.  MNV induces 
the activation of ERK1/2 and p38α.  Both the model and Human Phospho-MAPK Array data 
suggest that p38α activation is independent of MKK3 and MKK6.  The work of Royall et al. (2015) 
noted that the increase in eIF4E phosphorylation is dependent upon p38α and MNK1.  
Experimentally, an increase in the phosphorylation of CREB has been demonstrated. Given that no 
significant change in MSK2 phosphorylation was noted in the array data., it is likely that the 
increase in CREB phosphorylation requires ERK1/2- (Deak et al., 1998; Sindreu et al., 2007; Brami-
Cherrier et al., 2009) or p38α- (Aggeli et al., 2006; McCoy et al., 2007) dependent MSK1 
phosphorylation (Ananieva et al., 2008).  The stability of AU-Rich Element-containing mRNA is also 
hypothesised as being affected during MNV infection with TTP phosphorylation being increased in 
a MK2-dependent manner.  Hypothesised links are denoted by broken blue arrows.  The solid blue 
arrow is the proposed mechanism by which the increase in CREB phosphorylation may occur 
during MNV infection.  Red arrows denote links where the model and array data are not in 
agreement or, in the case of broken, faded red arrows,  where link are found in the literature but 
not believed to be important based upon the array data.  Green arrows represent those reactions 
perturbed in the model. 
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In terms of the other viral models, the effects being simulated are of considerable 
importance to public health in South America as the pathogens triggering them cause 
severe and often fatal human infection.  The incorporation of JUNV infection into the model 
produced considerable effects to the cellular signalling network.  The cause of which 
appears to be connected to the feedback loops linking ERK1/2 to JNK1.  Despite knowing 
that ERK1/2 activation is required for JUNV replication (Rodríguez et al., 2014), it is unclear 
whether this feedback loop is of importance during JUNV infection.   
Whilst the model of ANDV infection produced only limited testable predictions, the results 
do indicate that metabolic reprogramming of the cell could occur through mTORC1 
activation, as indicated by the increase in HIF-1α expression (shown in Section 4.3.3 – 
Simulation of the Andes Virus Models).  The model presented here indicates that S6K1 and 
4E-BP1 phosphorylation occurs during ANDV infection.  This is in contrast with the work of 
McNulty et al. (2013) but somewhat in agreement with Gavrilovskaya et al. (2013).  It is 
worth noting, however, that the latter publication used cells under hypoxic conditions but 
does show that S6K1 phosphorylation accompanies ANDV infection.  The use of 
metabolomics approaches during ANDV infection may help to elucidate whether the 
activation of mTORC1 is linked to metabolism. 
The work presented in Chapter 4 – Modelling the Effects of Viral Infection clearly 
demonstrates that the translational regulation model is amenable to modelling other 
systems.  Further work must be undertaken to improve the functioning of the model 
integrated with the metabolic network.  This is of considerable importance given the 
growing body of literature identifying the metabolic network as a target for viral infection 
(Vastag et al., 2011; Grady et al., 2013).   
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Despite the successful modelling of viral infection, this section of work suffers from a lack of 
suitable methods to quantify the predictive power, as noted in Section 4.4.1 – Problems 
Encountered & Troubleshooting.  The method used in this work concerned validation of 
effects by comparing expected behaviours to the reality of simulations.  Given the small 
number of known effects for these viruses, the use of the method used elsewhere in this 
project was not deemed appropriate.  Future work looking at viral infection with such 
models should be aimed at developing a method, perhaps using the MCC values, for the 
quantification of predictive power.  This method will become appropriate as more data is 
collected and particularly so if more data concerning the effects chemical inhibitors can 
have on the infection process. 
Section 6.6 – Integration of the Translational Regulation 
Model with a GSMN 
Whilst the complete integration of the ERK1/2 model did not provide any additional benefit 
to the model, linking mTORC1 signalling to the regulation of metabolism was tested.  The 
use of FBA models is recognised as allowing the experimentally suggested alterations in 
metabolism to be recognised (Quek et al., 2014).  Moreover, QSSPN permits the integration 
of such models of metabolism with Petri Net models (Fisher et al., 2013).  Given the 
intimate relationship between cell growth and anabolic metabolism, linking mTORC1 to the 
control of metabolic gene expression seemed a logical way to bring about this integration.  
Several models of metabolism, derived from both the human (Thiele et al., 2013) and mouse 
(Sigurdsson et al., 2010) genomes, are available.  Whilst of value, neither of these models 
was specific enough to use in a model that would ultimately be tested in RAW 264.7 cells.  
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23 genes found in the Bordbar et al. (2012) GSMN of a RAW 264.7 cell were placed, based 
upon existing literature, under to control of mTORC1.     
The linking of the GSMN of a RAW 264.7 cell allowed the relationship between translation 
and metabolism to be modelled.  The production of Biomass in this GSMN was seen as a 
requirement for protein synthesis.  Although the frequency of Biomass production was low, 
the lower bound of the Biomass reaction, as detailed in Bordbar et al. (2012), was set to the 
low value of 0.0281/h.  Although this reaction rate is not directly comparable with the 
Reachfq analysis, this low frequency of Biomass production in the Wild Type model (with a 
value of 0.044) can in a way be seen as in keeping with the published data.  Despite the 
integration being accomplished successfully, the result of this incorporation was a marked, 
albeit not significant, reduction in predictive power (MCC = 0.3376 versus MCC = 0.4558).  
Whilst no definitive reason can be given for this reduction, it could be argued that a more 
comprehensive integration of the Petri Net model, through additional signalling pathways, 
with the GSMN could serve to correct this.  This argument is valid, as the comparison 
between the literature dataset and the simulation results demonstrated a somewhat less 
than ideal correlation for those effectors involved in linking of mTORC1 to the GSMN.  This 
first attempt at linking metabolism to the control of translation highlighted the need for a 
more complete understanding of the dual regulation of translation and metabolism by the 
cellular signalling network. 
Section 6.7 – Novel Modelling Strategies 
The main aim of the work linking metabolism to the translational regulation model was to 
improve the overall quality of the model by allowing the interplay between metabolism and 
translation to be modelled.  However a second aspect to the work involved the testing of 
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two novel modelling strategies.  As detailed in Section 5.2.1 – Proposed New Approaches, 
these approaches aimed to reduce the computational cost of running simulations with little 
or no detrimental effects on predictive power.  These methods, termed the synchronous 
simulation and the Ordinary Differential Equation Methods, were run in parallel with the 
asynchronous simulation method (outlined in Chapter 2 – Model Creation & Refining).  The 
performance of the two novel methods further validated the method that had been used 
throughout the project and led to a better understanding of the need for the use of exact 
stochastic simulation methods when modelling biological systems. 
An initial test of these approaches was carried out to ensure that the two experimentally 
tested behaviours of the model were conserved.  The synchronous method was unable to 
model the Rapamycin-mediated increase in eIF4E phosphorylation.  It was discovered that 
this approach introduces the false assumption that within a cell, all biochemical reactions 
that can occur will occur, in the same time interval.  The removal of this temporal control of 
reactions, as noted in Section 5.3.2.2 – Synchronous Method, limits any further use of this 
method.  It highlights the importance of the process of selecting the next reaction, which is 
based on probability and the Propensity Function (as discussed in Section 1.4.1 – Exact 
Stochastic Simulation with the Gillespie Algorithm).   
The other method, the Ordinary Differential Equation Method, relies on converting the 
model to a series of qualitative ODEs, in which reaction kinetics are equal to one.  Although 
it was possible to quantitatively analyse the predictive power of the model using the MCC 
and AC formulae, this method produced results that were entirely subjective and, 
consequently, the identification of regions of difference was open to observer bias.  Perhaps 
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because of this subjective nature, the predictive power of the model analysed in this way 
was significantly reduced from MCC = 0.3376 to MCC = 0.2785.   
Section 6.8 – General Conclusion 
In summary, the overall aim of this project was to create a model simulating the regulation 
of mammalian translation initiation by the network of cellular signalling pathways.  This 
work has produced such a model and validated the predictive power of this model against a 
unique benchmark dataset based on a comprehensive review of published literature.  
Statistically significant predictive power has been achieved and the model has produced 
experimentally testable hypotheses.  Experimental work directed by these findings provided 
mechanistic insight into cross-talk between the mTORC1 and eIF4E phosphorylation.  
Moreover, this mechanism has provided some insight into the cellular stoichiometry of 
eIF4E and the interacting partner, 4E-BP1.  This model of cellular translation has also been 
linked to the GSMN of a RAW 264.7 cell and given much needed insight into how such 
integration, with a large-scale model, can be achieved.  Finally, the overall potential for 
future uses of this model has been demonstrated by successfully modelling the effects 
several medically important viruses can have upon the cellular signalling network and the 
translational machinery.  Although much future work has been suggested throughout, the 
main output of this project has been to produce a model that can function within other 
larger models.  The potential applications for this model are not limited to just viral 
infections.  Areas such as cancer or cardiovascular biology may also benefit from a model of 
translation which, with adjustment, could be used to help guide research in these fields. 
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The follow Supplementary Information is provided: 
Supplementary Information 1 - References for the Construction of the Literature Datasets 
This information was used when evaluating the effect of inhibitors within the model.  This 
dataset was used throughout this work (Chapter 2 – Model Creation & Refining and 
Chapter 5 – Integration of the Translational Control Model with a Genome Scale Metabolic 
Network of a RAW 264.7 Cell) 
Supplementary Information 2 - Dataset against Which the Binary Model was Tested (Final 
Benchmark Dataset) 
The information contained within this table should be used in conjunction with the 
information contained with Supplementary Information 1.  The information contained 
within this dataset was used to analyse the final version of the binary model. 
Supplementary Information 3 - Dataset Against Which the Model Integrated with 
Metabolism was Tested (Metabolic Benchmark Dataset) 
The information contained within this table should be used in conjunction with the 
information contained with Supplementary Information 1.  The overall dataset is similar to 
that presented in Supplementary Information 3.  To prevent repetition, only the effects 
linked to the extra effectors are shown. 
Supplementary Information 4 – Ingredients List for Solutions Produced In-House 
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The Following Can be Found on the Enclosed USB Drive 
Supplementary Information E1 – Standardization of the Nomenclature of Model 
Components 
This files works to standardize the naming of model components by linking all proteins, 
genes and miRNAs within the model to the established databases, Uniprot, Entrez and 
miRBase, respectively.   
Supplementary Information E2 - List of Model Transitions & References in the Binary 
Model 
This provides complete documentation of all model reactions with associated references. 
Supplementary Information E3 – Final Version of the Binary Model 
The .spept (E3a) and .xml (E3b) files of the Final version of the model.  This model 
represents the Wild Type model against which the behaviour is tested.  The predictive 
power of this model is given in Section 2.2.4 – Evaluation of the Predictive Power of the 
Final Model. 
Supplementary Information E4 – MNV Model 
The .spept (E4a) and .xml (E4b) files contain the model used as the mock infected MNV 
model against which the effects of MNV infection were tested.  The results of this model are 
given in Section 4.3.2 – Simulation of the Murine Norovirus Models. 
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Supplementary Information E5 – LPS Benchmark Dataset 
This .xlsx file contains the information relating to the LPS Benchmark and the effect of cell 
type on the level of predictive power. 
Supplementary Information E6 – Revised Original Benchmark Dataset 
This .xlsx file contains an updated version of the Initial Benchmark.  The references 
contained within this benchmark do not use LPS stimulation. 
Supplementary Information E7 – Frequency Data Generated by Reachfq with Associated 
99.99% Binomial Confidence Intervals 
This .xlsx file contains all frequency data generated by Reachfq and the associated 99.99% 
Binomial Confidence Intervals for model refinement and predictive power analysis. 
The supplementary information E1-E7 can be found on the flash drive that accompanies this 
work.  To open the .spept files for Supplementary Information E3 and E4, please ensure that 
Snoopy is installed on your computer.  To download Snoopy, copy the following into your 
internet browser: 
http://www-dssz.informatik.tu-cottbus.de/DSSZ/Software/Snoopy#downloads 
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Supplementary Information 1a - Benchmark Dataset 
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Supplementary Information 1b - Benchmark Dataset 
References for the Binary Model with Lipopolysaccharide 
(LPS Benchmark) 
The references shown below were used in the construction of the benchmark dataset concerning the effects each inhibitor 
has on Lipopolysaccharide stimulated cells.   
Note: Those that are faded denote studies conducted with Macrophage cell lines.  These are used in Section 2.2.2.1 – 
Updated Benchmark Dataset as the basis of the benchmark dataset 
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BIX02189 
ppMEK1 No Effect (PMID: 18834865) 
ppMEK2 No Effect (PMID: 18834865) 
ppERK1 Partial Inhibition with Cadmium Chloride (PMID: 22521884); No Effect (PMID: 18834865) 
ppERK2 Partial Inhibition with Cadmium Chloride (PMID: 22521884); No Effect (PMID: 18834865) 
RSK-Pi Decrease for RSK3 (PMID: 22997248) & RSK2 & RSK4 (PMID: 18834865) 
rpS6-Pi Reduction Implied But Not Directly Shown 
pMNK1 Partial Inhibition (PMID: 18834865) 
pMNK2 No Effect (PMID: 18834865) 
eIF4E-Pi Not Tested 
pJNK1 No Effect (PMID: 18834865) 
cJun-Pi Not Tested But Potential Indirect Inhibition (PMID: 20075332; PMID: 12574153) 
ppp38a Partial Inhibition (PMID: 18834865) 
pERK5 Inhibition Demonstrated (PMID: 18834865; PMID: 22254155; PMID: 24491810) 
PI3K-Act Not Tested 
PIP3 Not Tested 
PDK1-Act No Effect (PMID: 18834865) 
pPKCz Not Tested 
ppAKT Partial Inhibition (PMID: 18834865) 
ppS6K Partial Increase (PMID: 18834865) 
eIF4B-Pi Not Tested 
p4E-BP1 Not Tested 
mTORC1-Act Not Tested 
pTSC2 Not Tested 
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CGP57380 
ppMEK1 Not Tested 
ppMEK2 Not Tested 
ppERK1 No Effect (PMID: 11463832) - Disputed (Partial Increase) (PMID: 18694961) 
ppERK2 No Effect (PMID: 11463832) - Disputed (Partial Increase) (PMID: 18694961) 
RSK-Pi Possible Inhibition (PMID: 18694961) - Maybe Specific to CML 
rpS6-Pi Possible Inhibition (PMID: 18694961) - Disputed (PMID: 20664001) 
pMNK1 Inhibition Demonstrated (PMID: 23269249) 
pMNK2 Inhibition Demonstrated (PMID: 23269249) 
eIF4E-Pi Inhibition Demonstrated (PMID: 23269249; PMID: 18081851) 
pJNK1 No Effect (PMID: 11463832) 
cJun-Pi Not Tested 
ppp38a No Effect (PMID: 11463832) 
pERK5 Not Tested 
PI3K-Act Not Tested 
PIP3 Not Tested 
PDK1-Act Not Tested 
pPKCz Not Tested 
ppAKT Not Tested 
ppS6K No Effect (PMID: 20664001) 
eIF4B-Pi Not Tested 
p4E-BP1 Partial Inhibition (PMID: 18694961) 
mTORC1-Act No Effect (PMID: 18694961) 
pTSC2 Not Tested 
 
 
 399 
 
 
 GSK2334470 
ppERK1 No Effect (PMID: 21087210) 
ppERK2 No Effect (PMID: 21087210) 
ppMEK1 No Effect (PMID: 21087210) 
ppMEK2 No Effect (PMID: 21087210) 
pRSK1 Partial Inhibition (PMID: 21087210) 
rpS6-Pi Inhibition Demonstrated (PMID: 21087210) 
pMNK1 No Effect (PMID: 21087210) 
pMNK2 No Effect (PMID: 21087210) 
eIF4E-Pi Not Tested 
pJNK1 No Effect (JNK1 & JNK3); Partial Activation (JNK2) (PMID: 21087210) 
cJun-Pi Not Tested 
ppp38a No Effect (PMID: 21087210) 
pERK5 Not Tested 
PI3K-Act No Effect (PMID: 21087210) 
PIP3 No Effect (PMID: 21087210) 
pPDK1 Inhibition Demonstrated (PMID: 21087210) 
pPKCz Partial Inhibition (PMID: 21087210) 
ppAKT No Effect (PMID: 21087210) 
ppS6K1 No Effect (PMID: 21087210) 
eIF4B-Pi Not Tested 
p4E-BP1 Not Tested 
mTORC1-Act Not Tested 
pTSC2 Not Tested 
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 LY294002 
ppMEK1 Partial Inhibition (PMID: 17850214) 
ppMEK2 Partial Inhibition (PMID: 17850214) 
ppERK1 Partial Inhibition (PMID: 17850214; PMID: 11157888); Disputed (No Effect) (PMID: 10480882; PMID: 12242656) 
ppERK2 Partial Inhibition (PMID: 17850214; PMID: 11157888); Disputed (No Effect) (PMID: 10480882; PMID: 12242656) 
pRSK1 No Effect (PMID: 17850214) 
rpS6-Pi Inhibition Demonstrated (PMID: 8895571; PMID: 11713299) 
pMNK1 Partial Inhibition (PMID: 17850214) 
pMNK2 Not Tested 
eIF4E-Pi Blocks Rapamycin Induced Increase (PMID: 16103051) 
pJNK1 No Effect (JNK1 & JNK2) Partial Inhibition (JNK3) (PMID: 17850214) 
cJun-Pi Not Tested 
ppp38a No Effect (PMID: 11040049; PMID: 11367542; PMID: 17850214) 
pERK5 No Effect Implied (PMID: 14670836) 
PI3K-Act Inhibition Demonstrated (PMID: 8106507) 
PIP3 Inhibition Implied (PMID: 8106507) 
PDK1-Act Inhibition Demonstrated (PMID: 17850214; PMID: 9748166) 
pPKCz Inhibition Demonstrated (PMID: 9748166) Disputed (Activation) (PMID: 17850214) 
ppAKT Inhibition Demonstrated (PMID: 11801244; PMID: 16551362; PMID: 11755539) 
ppS6K Inhibition Demonstrated (PMID: 15677443; PMID: 10480882; PMID: 11755539; PMID: 11145615; PMID: 12242656; PMID: 9287347)  
eIF4B-Pi Not Tested 
p4E-BP1 Inhibition Demonstrated (PMID: 11231341) 
mTORC1-Act Inhibition Demonstrated (PMID: 8895571; PMID: 19346248) 
pTSC2 Not Tested 
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 PD184352 
ppMEK1 Inhibition Demonstrated (PMID: 10998351; PMID: 17850214; PMID: 12534346) 
ppMEK2 Inhibition Demonstrated (PMID: 10998351; PMID: 17850214; PMID: 12534346) 
ppERK1 Partial Inhibition (PMID: 12069688; PMID: 17850214) 
ppERK2 Partial Inhibition (PMID: 12069688; PMID: 17850214) 
pRSK1 Not Tested 
rpS6-Pi Partial Inhibition (PMID: 19376132) 
pMNK1 Not Tested But Implied (PMID: 9155017) 
pMNK2 Not Tested But Implied (PMID: 9155017) 
eIF4E-Pi Not Tested But Implied (PMID: 9155017) 
pJNK1 Increase Demonstrated (PMID: 18347148) 
cJun-Pi Not Tested 
ppp38a No Effect (PMID: 22076433) But Disputed (PMID: 11431348) - Activation Reported (PMID: 18347148) 
pERK5 No Effect (PMID: 12069688; PMID: 18358237) 
PI3K-Act Not Tested 
PIP3 Not Tested 
PDK1-Act Partial Inhibition (PMID: 10998351) 
pPKCz Not Tested 
ppAKT Partial Activation (PMID: 19147570; PMID: 22668349) 
ppS6K Partial Inhibition (PMID: 11431469) 
eIF4B-Pi Not Tested 
p4E-BP1 Inhibition Demonstrated (PMID: 11799119) 
mTORC1-Act Inhibition Demonstrated (PMID: 21071439) 
pTSC2 Partial Inhibition (PMID: 15292274) 
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 PD98059 
ppMEK1 Partial Inhibition (PMID: 9395471; PMID: 9315666; PMID: 11043572; PMID: 10998351) 
ppMEK2 Partial Inhibition (PMID: 9395471; PMID: 9315666; PMID: 11043572; PMID: 10998351) 
ppERK1 Partial Inhibition (PMID: 7499206; PMID: 12704121; PMID: 16342118; PMID: 21655705; PMID: 10998351; PMID: 23615277) 
ppERK2 Partial Inhibition (PMID: 7499206; PMID: 12704121; PMID: 16342118; PMID: 21655705; PMID: 10998351; PMID: 23615277) 
pRSK1 Inhibition Demonstrated (PMID: 21619683)  
rpS6-Pi Inhibition Demonstrated (PMID: 21233202) But Disputed (PMID: 19176818) 
pMNK1 Inhibition Demonstrated (PMID: 9155017) 
pMNK2 Inhibition Demonstrated (PMID: 9155017) 
eIF4E-Pi Inhibition Demonstrated (PMID: 11154262; PMID: 9211946) 
pJNK1 Activation Demonstrated (PMID: 11353829; PMID: 11408609) 
cJun-Pi Partial Inhibition (PMID:11435459) 
ppp38a No Effect (PMID: 12663671; PMID: 23615277) 
pERK5 Inhibition Demonstrated (PMID: 10473620; PMID: 18358237) 
PI3K-Act Not Tested 
PIP3 Not Tested 
PDK1-Act No Effect (PMID: 10998351) 
pPKCz Not Tested 
ppAKT No Effect (PMID: 12481421; PMID: 23615277) 
ppS6K S6K2 Inhibited (PMID: 11431469) Degree Disputed (PMID: 12489846) - No Effect (PMID: 10998351) 
eIF4B-Pi Not Tested 
p4E-BP1 Inhibition Demonstrated (PMID: 11799119) 
mTORC1-Act No Effect (PMID: 20439490) 
pTSC2 Not Tested 
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Rapamycin 
ppERK1 
Inhibition at Higher Doses (Activation at Lower Doses (PMID: 19151764)) (PMID: 20512842 ); No Effect (PMID: 23437362; PMID: 16160607; 
PMID: 11567647; PMID: 15767555; PMID: 12820963; PMID: 22343118) 
ppERK2 
Inhibition at Higher Doses (Activation at Lower Doses (PMID: 19151764)) (PMID: 20512842 ); No Effect (PMID: 23437362; PMID: 16160607; 
PMID: 11567647; PMID: 15767555; PMID: 12820963; PMID: 22343118) 
ppMEK1 No Effect (PMID: 15767555) 
ppMEK2 No Effect (PMID: 15767555) 
pRSK1 Activation at Low Doses (PMID: 19151764) 
rpS6-Pi Inhibition Demonstrated (PMID: 23437362; PMID: 21075311; PMID: 16763566) 
pMNK1 No Effect Indicated (PMID: 21406405) 
pMNK2 Increase Demonstrated (PMID: 23831578) 
eIF4E-Pi Increase Demonstrated (PMID: 23831578; PMID: 16103051) 
pJNK1 Activation Demonstrated (PMID: 21324487; PMID: 15767555); Inhibition Demonstrated (PMID: 9016789; PMID: 16160607) 
cJun-Pi Activation Demonstrated (PMID: 12820963) 
ppp38a Inhibition Demonstrated (PMID: 16160607; PMID: 11567647); No Effect (PMID: 12820963; PMID: 9933636) 
pERK5 Not Tested 
PI3K-Act No Effect on the Expression (PMID: 12766174) 
PIP3 Not Tested 
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 Rapamycin 
pPDK1 No Effect Indicated (PMID: 16377759) - Any Affect May be Substrate-Dependent (PMID: 21075311) 
pPKCz Not Tested Directly (PMID: 10339425) 
ppAKT 
Inhibition at Higher Doses (PMID: 20512842 ); Activation Possible at Lower Doses (PMID: 16103051; PMID: 23437362; PMID: 17698586; PMID: 
21075311) 
ppS6K1 Inhibition Demonstrated (PMID: 23437362; PMID: 21114628; PMID: 11567647; PMID: 15030312; PMID: 16763566; PMID: 15833867) 
eIF4B-Pi Increase Demonstrated at Lower Dose (PMID: 21075852); Prolonged Exposure - Inhibition Demonstrated (PMID: 16763566) 
p4E-BP1 Partial Inhibition Demonstrated (PMID: 19402821; PMID: 17425689; PMID: 11799119) 
mTORC1
-Act 
Inhibition Demonstrated (PMID: 15899889); No Effect Possible (PMID: 16103051) 
pTSC2 Not Tested 
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 SB203580 
ppMEK1 No Effect (PMID: 10998351) 
ppMEK2 No Effect (PMID: 10998351) 
ppERK1 Activation Demonstrated (PMID: 10960075; PMID: 11297530; PMID: 16111636) Disputed (PMID: 17850214; PMID: 10998351) 
ppERK2 Activation Demonstrated (PMID: 10960075; PMID: 11297530; PMID: 16111636) Disputed (PMID: 17850214; PMID: 10998351) 
pRSK1 Partial Inhibition Demonstrated (PMID: 17906627) 
rpS6-Pi Partial Inhibition Demonstrated (PMID: 23315073) 
pMNK1 Not Tested 
pMNK2 No Effect (PMID: 11154262) 
eIF4E-Pi Partial Inhibition Demonstrated (PMID: 9545260; PMID: 12781867; PMID: 15075293) 
pJNK1 Activation Demonstrated (PMID: 10960075) But Disputed (PMID: 9598985) 
cJun-Pi Activation Demonstrated (PMID: 10960075) But Disputed (PMID: 9598985) 
ppp38a Inhibition Demonstrated (PMID: 9753474; PMID: 18502741; PMID: 21903942) 
pERK5 Not Tested 
PI3K-Act No Effect (PMID: 11367542) 
PIP3 No Effect (PMID: 11367542) 
PDK1-Act Inhibition Demonstrated (PMID: 10702313) 
pPKCz Activation Demonstrated (PMID: 15665819) 
ppAKT Inhibition Demonstrated (PMID: 10702313; PMID: 11042204) 
ppS6K Partial Inhibition Demonstrated (PMID: 10455142; PMID: 9299480) 
eIF4B-Pi No Effect (PMID: 16763566) 
p4E-BP1 Partial Inhibition Demonstrated (PMID: 23315073) 
mTORC1-Act Inhibition Demonstrated (PMID: 23315073) 
pTSC2 Increase Demonstrated (PMID: 23315073) 
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SP600125 
ppMEK1 Partial Inhibition (PMID: 17850214) 
ppMEK2 Partial Inhibition (PMID: 17850214) 
ppERK1 Partial Inhibition - Disputed (PMID: 15454338; PMID: 20868664; PMID: 12603281; PMID: 12697808)  
ppERK2 Partial Inhibition - Disputed (PMID: 15454338; PMID: 20868664; PMID: 12603281; PMID: 12697808)  
pRSK1 Partial Increase (PMID: 16449644) Disputed (PMID: 12603281) 
rpS6-Pi Partial Inhibition (PMID: 21320501) 
pMNK1 Partial Inhibition (PMID: 17850214) 
pMNK2 Partial Inhibition (PMID: 17850214) 
eIF4E-Pi Partial Inhibition (PMID: 20359850; PMID: 20359507) 
pJNK1 Inhibition Demonstrated (PMID: 17850214) 
cJun-Pi Inhibition Demonstrated (PMID: 20868664; PMID: 16449644; PMID: 16176902; PMID: 19305497) 
ppp38a 
No Effect (PMID: 16449644; PMID: 12603281; PMID: 17850214; PMID: 18359001); Very Early Increase Demonstrated (PMID: 12878189; 
PMID: 18359001) 
pERK5 Partial Inhibition (PMID: 20643107) 
PI3K-Act Not Tested BUT Inhibition of δ Isoform of p110 Subunit - Subunit Specific (PMID: 19106158; PMID: 21558088) 
PIP3 Not Tested 
PDK1-Act Partial Inhibition (PMID: 17850214) 
pPKCz No Effect (PMID: 17850214) 
ppAKT No Effect (PMID: 17850214) 
ppS6K Partial Inhibition (PMID: 17850214; PMID: 16099428) 
eIF4B-Pi Partial Inhibition (PMID: 17850214; PMID: 21263197) 
p4E-BP1 Partial Inhibition (PMID: 17850214 & PMID: 21263197) 
mTORC1-Act Inhibition Demonstrated (PMID: 21320501; PMID: 22493283) 
pTSC2 Not Tested 
 
 407 
 
 XMD8-92 
ppMEK1 Not Tested 
ppMEK2 Not Tested 
ppERK1 No Effect (PMID: 20832753) 
ppERK2 No Effect (PMID: 20832753) 
pRSK1 Partial Inhibition (PMID: 20832753) 
rpS6-Pi Not Tested 
pMNK1 Not Tested 
pMNK2 Not Tested 
eIF4E-Pi Not Tested 
pJNK1 Not Tested 
cJun-Pi Not Tested 
ppp38a Not Tested 
pERK5 Inhibition Demonstrated (PMID: 20832753; PMID: 23428871) 
PI3K-Act Not Tested 
PIP3 Not Tested 
PDK1-Act Not Tested 
pPKCz Not Tested 
ppAKT Not Tested 
ppS6K Not Tested 
eIF4B-Pi Not Tested 
p4E-BP1 Not Tested 
mTORC1-Act Not Tested 
pTSC2 Not Tested 
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Note the details of the effects of Ku0063794 are included as Ku0063794 was used in the initial model 
 
Ku0063794  
ppMEK1 No Effect (PMID: 19402821) 
ppMEK2 No Effect (PMID: 19402821) 
ppERK1 No Effect (PMID: 19402821) 
ppERK2 No Effect (PMID: 19402821) 
pRSK1 No Effect (PMID: 19402821) 
rpS6-Pi Partial Inhibition (PMID: 19402821) 
pMNK1 Partial Activation (PMID: 19402821) 
MNK1/2-Pi Partial Inhibition (PMID: 19402821) 
eIF4E-Pi Not Tested 
pJNK No Effect (JNK2α2) Partial Inhibition (JNK1α1) (PMID: 19402821) 
cJun-Pi Not Tested 
ppp38a No Effect (α-isoform) (PMID: 19402821) 
pERK5 Not Tested 
PI3K-Act No Effect (PMID: 19402821) 
PIP3 No Effect - Implied (PMID: 19402821) 
PDK1-Act Partial Inhibition (PMID: 19402821) 
pPKCz Partial Inhibition (PMID: 19402821) 
ppAKT No Effect (PMID: 19402821) 
ppS6K No Effect (PMID: 19402821) 
eIF4B-Pi Not Tested 
P4E-BP1 Inhibition Demonstrated (PMID: 19402821) 
mTORC1-Act Inhibition Demonstrated (PMID: 19402821) 
pTSC2 Not Tested 
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Torin-1, whilst not used in this project, is included as the list of effects is a tool that can be used for other works. 
 
Torin-1 
ppERK1 Activation Demonstrated (PMID: 21508335; PMID: 21278786) - No Effect (PMID: 22343943; PMID: 21592956) 
ppERK2 Activation Demonstrated (PMID: 21508335; PMID: 21278786) - No Effect (PMID: 22343943; PMID: 21592956) 
ppMEK1 Not Tested 
ppMEK2 Not Tested 
pRSK1 Inhibition Demonstrated (At Higher Concentrations) (PMID: 22223645) 
rpS6-Pi 
Inhibition Demonstrated (PMID: 24424027; PMID: 22552098; PMID: 24008870; PMID: 21908613; PMID: 22065737; PMID: 23415771; PMID: 
21576368; PMID: 23319332) 
pMNK1 No Effect (PMID: 22223645) 
pMNK2 No Effect (PMID: 22223645) 
eIF4E-Pi Inhibition Demonstrated (PMID: 20679199) 
pJNK1 No Effect (PMID: 22223645) 
cJun-Pi Activation Demonstrated (PMID: 21508335) 
ppp38a No Effect (PMID: 21592956) 
pERK5 Not Tested 
PI3K-Act No Effect (PMID: 22015718; PMID: 23436801) - But Activation Maybe Possible (PMID: 22015718) 
PIP3 Not Tested 
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Torin-1 
pPDK1 Not Tested 
pPKCz Inhibition Demonstrated (PMID: 24375676) - No Effect (PMID: 22223645) 
ppAKT 
Inhibition Demonstrated (PMID: 21508335; PMID: 21659604; PMID: 22223645; PMID: 22733130; PMID: 20089925; PMID: 23142081; PMID: 
24311379; PMID: 20735411; PMID: 22006022; PMID: 24043828) 
ppS6K1 
Inhibition Demonstrated (PMID: 22552098; PMID: 21508335; PMID: 21659604; PMID: 22343943; PMID: 22223645; PMID: 21858812; PMID: 
23707523; PMID: 23524850; PMID: 23888043) 
eIF4B-Pi Not Tested 
p4E-BP1 
Inhibition Demonstrated (PMID: 21508335; PMID: 21659604; PMID: 23547259; PMID: 23077579; PMID: 21858812; PMID: 23707523; PMID: 
21841310; PMID: 21307192) 
mTORC1
-Act 
Inhibition Demonstrated (PMID: 19150980; PMID: 23934889; PMID: 23401004; PMID: 22053105; PMID: 21576368; PMID: 23963679) 
pTSC2 Not Tested 
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BIX02189 
c-Myc Not Tested 
HIF-1α Not Tested with the Inhibitor - ERK5 Maybe Important though (PMID: 16735500) 
Scd1 Not Tested 
PFK Not Tested 
 
 
CGP57380 
c-Myc No Effect (PMID: 22370634) 
HIF-1α No Effect (PMID: 25115400) 
Scd1 Not Tested 
PFK Not Tested 
 
 GSK2334470 
c-Myc Not Tested 
HIF-1α Not Tested 
Scd1 Not Tested 
PFK Not Tested 
 
 LY294002 
c-Myc Inhibition Demonstrated (PMID: 22546857; PMID: 15467756; PMID: 25636967) 
HIF-1α 
Inhibition Demonstrated (PMID: 16849522; PMID: 12032158; PMID: 10749120; PMID: 14982927; PMID: 12070140; PMID: 11457733; PMID: 
20194722; PMID: 15714461; PMID: 22787058) 
Scd1 Inhibition Demonstrated (PMID: 20876744) 
PFK 
Inhibition Demonstrated (PMID: 16051672) - No Effect  on Level (PMID: 20958264) - Activity May be Inhibited (PMID: 17302559; PMID: 
20958264) 
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 PD184352 
c-Myc 
No Effect on mRNA Level (PMID: 15286700) - Inhibition Demonstrated (Inhibitor Not Used Alone) (PMID: 
18497825) 
HIF-1a Inhibition Demonstrated (PMID: 17213817) - No Effect (PMID: 18199551) 
SCD1 Not Tested 
PFK Not Tested 
 
 Rapamycin 
c-Myc Inhibition Demonstrated (PMID: 14576155; PMID: 18621930; PMID: 23612979; PMID: 15634685; PMID: 10993886; PMID: 25636967) 
HIF-1α 
Inhibition Demonstrated (PMID: 20670887; PMID: 21567203; PMID: 18781596; PMID: 17968710; PMID: 17502379; PMID: 12032158; PMID: 
12242281; PMID: 10749120; PMID: 22900063) - No Effect (PMID: 16849522; PMID: 12149254;  PMID: 20194722; PMID: 22787058) 
Scd1 Inhibition Demonstrated (PMID: 20670887; PMID: 20876744) 
PFK Inhibition Demonstrated (PMID: 20670887) 
 
 SB203580 
c-Myc 
Inhibition Demonstrated (PMID: 20212154; PMID: 16365184; PMID: 10648601; PMID: 12080469; PMID: 
11563982) 
HIF-1a Inhibition Demonstrated (PMID: 20194722; PMID: 11978547; PMID: 12482858) - No Effect (PMID: 15714461) 
SCD1 No Effect (with 5-Fluorouracil Pretreatment) (PMID: 24135379) 
PFK Not Tested 
 
 SP600125 
c-Myc Inhibition Demonstrated (PMID: 15890690; PMID: 20335523; PMID: 21525782; PMID: 25486532; PMID: 19418558; PMID: 24104553; PMID: 19996270) 
HIF-1a No Effect (PMID: 20194722) 
SCD1 Increase Demonstrated (in Trans-10, cis-12 conjugated linoleic acid Cotreatment) (PMID: 21744278) 
PFK Not Tested 
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 XMD8-92 
c-Myc Inhibition Demonstrated (PMID: 24880079) 
HIF-1α Not Tested 
Scd1 Not Tested 
PFK Not Tested 
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Supplementary Information 4 – 
Ingredients List for Solutions 
Produced In-House 
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Running Buffer 
14.4gm Glycine (Thermo Fisher Scientific Inc., Rockford, IL (USA)) 
3.0gm Tris-Base (Thermo Fisher Scientific Inc., Rockford, IL (USA)) 
5ml 20% SDS (Thermo Fisher Scientific Inc., Rockford, IL (USA)) 
Made up to 1l with MIlli-Q® Ultrapure (EMD Millipore Corp., Merck KGaA, Darmstadt (DE)) 
 
 
Transfer Buffer 
14.4gm Glycine (Thermo Fisher Scientific Inc., Rockford, IL (USA)) 
3.0gm Tris-Base (Thermo Fisher Scientific Inc., Rockford, IL (USA)) 
200ml Methanol (Sigma-Aldrich Co. LLC, St. Louis, MO (USA)) 
Made up to 1l with MIlli-Q® Ultrapure (EMD Millipore Corp., Merck KGaA, Darmstadt (DE)) 
 
 
1x PBS-Tween Solution 
10 Dulbecco A/PBS Tablets (Oxoid Ltd., Thermo Fisher Scientific Inc., Rockford, IL (USA)) 
1ml Tween-20 (Sigma-Aldrich Co. LLC, St. Louis, MO (USA)) 
Made up to 1l with MIlli-Q® Ultrapure (EMD Millipore Corp., Merck KGaA, Darmstadt (DE)) 
 
 
 
 
 
 
 
 
